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Summary 
 
Kiss-1 and its receptor (Kiss-1R) are suggested as a novel pair of metastasis suppressors 
for several human solid tumours. However, the role of Kiss-1 and Kiss-1R in colorectal 
cancer remains largely unknown. Therefore, the aim of this study was to investigate the 
role and signal transduction of Kiss-1 and its receptor in colorectal cancer. 
Colorectal cancer cell lines (HT115, HRT18, RKO and Caco-2) were screened for the 
mRNA expression levels of Kiss-1 and Kiss-1R. Sublines of cancer cells with 
differential expression of Kiss-1 and Kiss-1R were created, using ribozyme transgenes 
to knock down the expression of Kiss-1 and Kiss-1R, respectively. The stabilized 
transfected cells were used to study the influence of Kiss-1 and Kiss-1R on the function 
of colorectal cancer cells using by in vitro function assays (growth, adhesion, wounding 
and invasion assays) and ECIS assay. The influence of Kiss-1 on tumour growth was 
also tested using an in vivo tumour model. To further explore the receptor activation 
and signalling pathways downstream of Kiss-1, Kisspeptin-10 was also used in HT115 
Kiss-1 knockdown cells. Phosphorylation of Kiss-1 and the effect of Kiss-1 on MMP-9 
and MMP-2 were detected using immunoprecipitation and zymography, respectively. The 
study also investigated Kiss-1 and Kiss-1R expression and their correlation to the 
clinical outcome in human colorectal cancer, using real-time PCR and 
immunohistochemistry.  
Kiss-1 and Kiss-1R played a suppressive role in the invasion and migration of 
colorectal cancer cells, in that knocking down both Kiss-1 resulted in increased 
cell-matrix invasion and cellular migration as demonstrated by a series of cell models. 
Exogenous Kiss-1 (Kisspeptin-10) decreased cellular migration of colorectal cancer 
cells and required ERK signalling as shown during the ECIS based analyses. The 
inhibitory influence of Kiss-1 on the motility of cancer cells was via the reduction of 
MMP-9, shown by zymography. In the in vivo tumour model, tumour growth rate of 
Kiss-1 knockdown colorectal cancer cells was significantly faster than the control cells. 
In human colorectal cancer tissues, levels of message expression of Kiss-1 had a 
negative correlation with Dukes staging, TNM staging, tumour size and lymph node 
involvement. Kiss-1R expression was significantly decreased in tumour tissues 
compared with adjacent normal tissues. The present study has demonstrated that Kiss-1 
and Kiss-1R play a pivotal tumour suppressor role in colorectal cancer. The inhibitory 
effect on cancer cells involves the regulation of MMPs and the ERK signaling pathway. 
The molecule pair is candidate prognostic indicator in patients with colorectal cancer. 
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Chapter 1 
 
General Introduction 
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1.1 Colorectal cancer 
 
1.1.1 Introduction 
 
Colorectal cancer (CRC) is the second most commonly diagnosed cancer [1] and is a 
major cause for mortality and morbidity globally. Worldwide, colorectal cancer is the 
fourth and third most common cancer in men and women respectively [2]. There are 
approximately 142, 000 new diagnoses and 50,000 deaths reported annually in the 
United States, [3-4]. In Australia, 1 in 17 men and 1 in 26 women will be diagnosed 
with colorectal cancer within their lifetime [5]. In the UK, colorectal cancer accounts 
for about 13% of all new cancer cases and in 2009, more than 41,000 new cases were 
diagnosed [6].  
 
1.1.2 Epidemiology and risk factors 
 
Incidence and Mortality 
Nearly 1,200,000 new colorectal cancer cases are believed to occur globally, annually, 
and accounting for approximately 10% of all cancers, and resulting in 609,000deaths. 
In addition, around 40,700 people in the UK were diagnosed with colorectal cancer 
and there were approximate 15,800 deaths from colorectal cancer in the UK[7]. In 
2010 it was estimated that there were 141,570 new cases of colorectal cancer and 
3 
 
51,370 deaths, accounting for nearly 10% of deaths from cancer in the United States 
[3]. Of these cases, there is a 0.5% to 2.0% probability of invasive colorectal cancer, 
1.0% to 1.6% probability of carcinoma in situ, 7% to 10% probability of a large (1 cm 
or larger) adenoma, and 25% to 40% chance of an adenoma of any size in unscreened 
individuals age 50 years or older [8].  
Increasing age is more strongly associated with colorectal cancer incidence than any 
other demographic factor. Consequently, the incidence of colorectal cancer increases 
dramatically above the age of 45 to 50 years for both men and women. In most 
countries, age-standardized incidence rates are lower for women than for men. 
Interestingly, colorectal cancer incidence has been steadily decreasing in the United 
States and Canada; whilst incidence in Asia is markedly increasing (Japan, Korea and 
China) [7]. Between 2002 and 2006, the age-standardized rate per 100,000 people 
was 59.0 for men and 43.6 for women in the United States for all ethnic groups 
combined[3]. It has been observed that there has been a reduction in both 
age-standardized colorectal cancer incidence and mortality in the United States over 
the past 10 years. It may benefit from the advance diagnosis and early screening 
measures. 
 
Geographic Variation 
In general, higher incidence and mortality of colorectal cancer are more commonly 
seen in the developed Western nations [7, 9]. On the other hand, the incidence rate in 
4 
 
Alaskan Natives exceeds 70 per 100,000 [10]. This is in clear contrast to rates in 
Gambia and Algeria which are less than 2 per 100,000 [9]. The aforementioned 
decrease in colorectal cancer incidence in the United States may be due to the 
advanced application of colonoscopy with polypectomy, although alterations in 
lifestyle factors (e.g. dietary change and smoking cessation) and the utilization of 
chemoprevention have also been suggested as the potential reasons [11].  
 
 
 
Figure 1.1.Demographic difference in the incidence of colorectal cancer worldwide 
[6] 
(http://www.cancerresearchuk.org/cancer-info/cancerstats/types/bowel/incidence/uk-b
owel-cancer-incidence-statistics) 
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Figure 1.2.Demographic difference in the incidence of colorectal cancer in European 
countries [6] 
(http://www.cancerresearchuk.org/cancer-info/cancerstats/types/bowel/incidence/uk-b
owel-cancer-incidence-statistics) 
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Socioeconomic Factors 
Generally speaking, rates of cancer incidence and mortality are higher in 
economically advantaged countries. This may be related to dietary factors (such as the 
consumption of a high fat, high sugar, high red meat or low-fibre diet), lack of 
physical activity and increasing incidence of obesity. 
 
1.1.3 Family history of colorectal cancer 
 
Hereditary Nonpolyposis Colorectal Cancer 
Hereditary nonpolyposis colorectal cancer (HNPCC), also known as Lynch Syndrome, 
is a genetic condition predisposing to colorectal cancer and accounts for about 3% of 
all colorectal cancers. It is associated with the development of up to 100 colonic 
polyps, usually in the right colon [12]. The most common HNPCC subtypes are type I 
and type II. HNPCC type I is distinguished by an increased rate of progression to 
colorectal cancer in polyps which may lead to the onset of colorectal cancer by the 
age of 40 years. HNPCC type II is associated with the development of extra colonic 
tumours, which originate in the skin, bile duct, liver, stomach, small intestine, renal 
pelvis, bladder, ureter or urethra, uterus or ovary, and pancreas. The lifetime risk of 
colorectal cancer in HNPCC is 80%, with a 40% increase in the risk of endometrial 
cancer and a less than 10% increase in the risk of developing all other cancers [13]. 
The modified Amsterdam criteria classification of HNPCC is shown in Table 1.1 
below. The modified Amsterdam criteria classification of HNPCC is shown in Table 
1.1 below. 
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Familial Adenomatous Polyposis 
Familial Adenomatous Polyposis (FAP) accounts for 1% of colorectal cancer. The 
key feature of FAP is the presence of thousands of colonic polyps which usually 
increase with age. There is a predisposition to colorectal cancer in patients when they 
are in their 50s or 60s [14].Surgical treatment is preferred at an early stage as most 
patients with FAP develop colorectal cancer if the colon is not removed as a 
prophylactic procedure. Other clinical manifestations of FAP include incipient 
congenital hypertrophy of the retinal pigment epithelium, mandibular osteomas, 
supernumerary teeth, epidermal cysts, adrenal cortical adenomas and desmoid 
tumours in addition to and malignant conditions such as thyroid tumours, a 5% to 10% 
risk of duodenal adenocarcinoma and brain tumours 
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Table 1.1 Amsterdam criteria classification of HNPCC 
Amsterdam I Criteria 
>or equal to three relatives with colorectal cancer 
>or equal to one case in a first degree relative 
>or equal to two successive generations should be affected 
>or equal to one tumour should be diagnosed before the age of 50 years 
FAP should be excluded 
Tumors should be confirmed with histology 
Amsterdam II Criteria 
>or equal to three relatives with HNPCC-associated cancer (colorectal, endometrial, 
small bowel, ureter, or renal pelvis) or with an HNPCC associated cancer 
>or equal to two successive generations should be affected 
>or equal to one case before age 50 
FAP should be excluded 
Tumors should be confirmed with histology 
Bethesda Criteria (diagnosis of HNPCC is made if any of the following criteria are 
fulfilled) 
Cancer in families that meet Amsterdam criteria 
Two HNPCC-related cancers, including colorectal or extracolonic 
Patients with colorectal cancer has first degree relative with colorectal cancer or 
HNPCC related cancer; one of the cancers diagnosed before age 45, and the adenoma 
diagnosed before age 40 
Colorectal cancer or endometrial cancer before age 45 
Right-sided undifferentiated (solid or cribiform) colorectal cancer  on histopathology 
before age 45 
Signet-ring cell type colorectal cancer before age 45 
Colonic adenomas before age 40 
Dr Frank Gaillard et al. Radiopaedia.org/articles/Amsterdam-criteria-for-HNPCC 
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1.1.4 Anatomy of the Colon 
 
Sections of the colon 
Defined as the lower segment of intestine from the ileocecal valve to the anus, the 
large bowel is approximately 150 cm in length. It is divided into three segments 
defined by different morphology and location (extraperitoneal and retroperitoneal 
location): the caecum, the colon (the ascending colon, the transverse colon, the 
descending colon and the sigmoid colon), and the rectum. The large intestine, which 
can be distinguished from the small intestine by its increased diameter, has a muscular 
wall. The muscular wall includes taenia coli, haustra coli and appendices epiploicae. 
The taenia coli consists of three longitudinal muscles along the longitudinal axis of 
the colon starting near the base of the appendix and ending in the ends of sigmoid 
colon. The length of taenia coli is 30cm shorter than the bowel it is attached to, and 
the enlarged pouch formed by the shrinkage of colonic wall is called haustracoli. 
Appendices epiploicae are accumulations of subserosal fat tissue along the external 
surface of the colon. 
The right colon is made up of the caecum (with appendix) and ascending colon. It is 
anterior to the right kidney and the duodenum.  
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Blood supply to the colon 
The vascular supply to the caecum and ascending colon arises from branches of the 
superior mesenteric artery (SMA), which divides into the inferior 
pancreaticoduodenal artery, the middle colic artery, the right colic artery and the 
ileocolic artery. The middle colic artery immediately forms two large arcades in the 
transverse mesocolon, which connects with the SMA and ileocolic arterial branches. 
The ileocolic artery splits towards a right colic artery to the upper ascending colon, 
which starts with the right border of the superior mesenteric artery and forms two 
branches at the caecum (the colic branch and the ileal branch). The colic branch forms 
an anastomosis with descending branches from the right colic artery. The ileal branch 
forms branches to the distal small bowel and caecum and anastomoses with the ends 
of superior mesenteric artery. The right colon is a retroperitoneal structure. 
The transverse colon is supplied by branches of the middle colic artery. It is the first 
portion of the colon considered to be intraperitoneal, and its length is around 20cm to 
50cm. Its boundaries are defined from the hepatic flexure on the right to the splenic 
flexure on the left. Both of these points are fixed by the transverse mesocolon. The 
length of transverse mesocolon fixed both hepatic flexure and splenic flexure is 
shorter than the rest of the transverse colon section, hence the shape of transverse 
colon is described as arched prolapsed. The hepatic flexure abuts the gallbladder fossa, 
while the splenic flexure lies anterior to the tail of the pancreas.  
The descending colon is defined as the segment of colon from the splenic flexure to 
the sigmoid colon, where the colon becomes a retroperitoneal structure and its length 
is about 25-30cm. The vascular supply of descending colon is supplied by the inferior 
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mesenteric artery (IMA). The IMA arises from the aorta and ends at the upper part of 
rectum. It gives off the left colic artery and three to four sigmoidal arteries, which 
supply the intraperitoneal sigmoid colon. The arterial arcade between the ileocecum 
and the trial of sigmoid flexure, which belongs to the part of vessels anastomose 
between mesenteric artery and its adjacent branches is known as the marginal artery 
of Drummond. The arcade, which effectively connects the left and right circulations, 
is defined as the arc of Riolan. 
 
Venous and lymphatic drainage of the colon 
The venous and lymphatic drainage of the colon parallels the arterial supply, and all 
three vessels (superior mesenteric vein, inferior mesenteric vein and splenic vein) 
course and divide within the colonic mesocolon, which belong to the hepatic portal 
system. The mesocolon therefore contains the regional lymph nodes for the segment 
of colon it supplies and drains. The different lymphatic channels pass from the 
submucosa to the intramuscular and subserosal plexus of the bowel to the first tier of 
lymph nodes lying adjacent to the large intestine and known as epicolic nodes 
[15].Paracolic nodes lie on the marginal vessels along the mesenteric side of the colon 
and are frequently involved in metastases. Intermediate nodes are found along the 
major arterial branches of the SMA and IMA in the mesocolon. The principal nodes 
are found around the origin of these vessels from the aorta, and they drain into 
retroperitoneal nodes. The drainage of the superior and inferior mesenteric veins, 
which drain the ascending, transverse, descending, and sigmoid colon, is via the 
portal vein. The rectum is drained by rectal tributaries to the vena cava. 
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The extent of resection of the colon is defined by the vascular supply and by the 
lymph nodes belonging to the mesentery [16-17]. Therefore, the whole bowel 
supplied by related vascular should be resected thereby ensuring that all related lymph 
nodes from the root of the mesentery vascular are removed. 
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Figure 1.3.The anatomy of the colon with the vascular supply 
Source: DeVita VT, Lawrence TS, Rosenberg SA: DeVita, Hellman, and Rosenberg’s 
Cancer: Principles & Practice of Oncology, 9
th
 Edition, 2011. By Lippincott 
Williams &Wikins. 
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Anatomy of the rectum 
In the upper portion of the rectum there are changes both in the musculature of the 
large bowel and in the relationship to the peritoneal covering. In the lower portion of 
the rectum, the mucosal changes occur at roughly the same location as the anal 
sphincter. The lower rectum is the area approximately from 3 to 6 cm from the anal 
verge. The midrectum goes from 5 to 6, to 8 to 10 cm, and the upper rectum extends 
approximately from 8 to 10, to 12 to 15 cm from the anal verge, although the 
retroperitoneal portion of the large bowel often reaches its upper limit approximately 
12 cm from the anal verge. In some patients, especially elderly women, the 
peritonealised portion of the large bowel can be located much lower than these 
definitions. The determination of the location of the boundary between rectum and 
sigmoid colon is important in defining adjuvant therapy, with the rectum usually 
being operationally defined as that area of the large bowel that is at least partially 
retroperitoneal. 
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Figure 1.4.Rectal anatomy.Source: Shrieve DC, Loeffler JS: Human Radiation Injury. 
2011. By Lippincott Williams &Wikins. 
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1.1.5 Staging and Prognosis of Colorectal cancer 
The Dukes classification and its modifications 
In 1932 Cuthbert E. Dukes, who was a Scottish pathologist working predominantly on 
a classification scheme for rectal cancer at St. Mark’s hospital, developed the 
classification system that has borne his name after investigating more than 2,000 
samples of colorectal cancer resections. The system and the several modifications 
made to it by Dukes and others, realized the important role played by lymphatic 
metastasis and tumourous local invasion in the progression of colorectal cancer. This 
classification supplies a modern pathological foundation for predicting the prognosis 
of patients with colorectal cancer. In 1936 Dukes had modified the C stage on the 
basis of the different levels of para-rectal lymphatic spread from superior rectal artery 
to inferior mesenteric artery. What is more, an adaptation further divided stages B and 
C in 1954 by the Americans Astler and Coller (Table 1.2). 
 
Tumor, Nodeand Metastasis Classification 
In 1954, Pierre Denoix proposed the Tumor, Node and Metastasis Classification 
(TNM) based on local invasion and lymphatic metastasis. Based on the AJCC Cancer 
Staging Manual, the 7
th
 edition of TNM staging system had been modified in 2010. 
This classification system for colorectal cancer is now the only classification system 
that is accepted [18]. The TNM system classifies colorectal tumours based on three 
categories. “T” (tumour) denotes the degree of invasion of the bowel wall, “N” (node) 
denotes the degree of lymphatic node involvement, and “M” (Metastasis) denotes the 
degree of metastasis. TNM classification reasonably describes and records the 
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anatomic extent of cancer (Table 1.3). Anatomic stage/ prognostic groups (TNM and 
Duke classifications) is described in Table 1.4. 
 
Table 1.2.Modified Dukes classification of colorectal cancer 
Stage Feature 
A 
B1 
 
B2 
C1 
 
C2 
D 
Limited to mucosa 
Extending into muscularis propria but not penetrating through it; nodes 
not involved 
Penetrating through muscularis propria; nodes not involved 
Extending into muscularis propria but not penetrating through it. 
Nodes involved 
Penetrating through muscularis propria. Nodes involved 
Distant metastatic spread 
Astler VB, Coller FA: The prognostic significance of direct extension of carcinoma of 
the colon and rectum. Ann Surg 139:846, 1954 
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Table 1.3.TNM classification of colorectal cancer 
Category Staging 
T stage Tx: primary tumourcannot be valued 
T0: no signs of tumour 
Tis: tumourin situ 
T1: tumour invades submucosa 
T2: tumour invades muscularispropria 
T3: tumour invades subserosa or beyond (without other organs) 
T4a: tumour penetrates to the surface od the visceral peritoneum 
T4b: tumour directly invades or is adherent to other organs or 
structures 
N stage Nx: lymph nodes cannot be valued 
N0: tumour cells absent from regional lymph nodes 
N1: 1 to 3 lymph nodes close to the bowel contain cancer cells 
N2: there are cancer cells in more than 3 lymph nodes that are further 
than 3cm away from the main tumour in the bowel or there are 
cancer cells in lymph nodes connected to the main blood vessels 
around the bowel 
N2a: metastasis in 4-6 regional lymph nodes 
N2b: metastasis in 7 or more regional lymph nodes 
M stage Mx: distant metastasis cannot be evaluated 
M0: no distant metastasis 
M1: metastasis to distant organs (beyond regional lymph nodes) 
M1a: metastasis confined to one organ or site (e.g. liver, lung, ovary,    
nonregional node) 
M1b: metastases in more than one organ/ site or the peritoneum 
Source: www.cancerstaging.org/staging/index.html 
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Table 1.4. Anatomic stage/ Prognostic groups 
Stage T N M Duke
1 
0 Tis N0 M0 - 
Ⅰ T1 N0 M0 A 
T2 N0 M0 A 
ⅡA T3 N0 M0 B 
ⅡB T4a N0 M0 B 
ⅡC T4b N0 M0 B 
ⅢA T1-T2 N1/N1c M0 C 
T1 N2a M0 C 
ⅢB T3-T4a N1/N1c M0 C 
T2-T3 N2a M0 C 
T1-T2 N2b M0 C 
ⅢC T4a N2a M0 C 
T3-T4a N2b M0 C 
T4b N1-N2 M0 C 
ⅣA Any T Any N M1a - 
ⅣB Any T Any N M1b - 
1: Duke B is a composite of better (T3 N0 M0) and Worse (T4 N0 M0) prognostic 
groups, as is Dukes C (any TN1 M0 and Any T N2 M0). 
Source: www.cancerstaging.org/staging/index.html 
 
1.1.6 Diagnosis of Colorectal Cancer 
Although diagnosis of colorectal cancer is no longer a significant challenge due to 
modern technologies, early diagnosis remains a challenge. 
Specific symptoms are too insidious to be detected at early-stage colorectal cancer. 
On average 60% of patients with colorectal cancer, do not have a definite diagnosis 
until 6 months after the appearance of symptoms. The main reason for this delay in 
diagnosis is arguably the lack of specific symptoms of colorectal cancer. Abdominal 
mass, change in bowel habit and abdominal pain are the most common symptoms of 
colorectal cancer, yet these symptoms are also commonly seen in functional 
gastrointestinal disorders and inflammatory bowel diseases.  
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Symptoms associated with colorectal cancer include change in bowel habit 
hematochezia, abdominal pain, abdominal mass, lower gastrointestinal bleeding, 
weight loss, change in appetite and anaemia. Bowel obstructive symptoms area 
particularly alarming sign and are seen in about 8%-29% of patients with colorectal 
cancer and usually indicate a well progressed tumour [19]. However, other symptoms 
other than obstructive symptoms do not necessarily correlation with a particular stage 
of disease [20]. In 1974 Welch reported the correlation between clinical symptoms 
and tumour location (Table 1.5). There are not any obvious symptoms at the earlier 
stage of rectal cancer, especially cancer in situ located in mucous layer. Unexplained 
blood and mucus in stool, altered bowel habit and urethral stimulation symptoms 
caused by prostate invasion by rectal cancer are classified as the symptoms associated 
with rectal cancer. 
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Table 1.5.The correlation between clinical symptoms and tumour location 
 Hemoproctia 
(%) 
Change in 
bowel habit 
(%) 
Abdominal 
Pain (%) 
Obstruction 
(%) 
Right colon 20 24.7 44.7 7.9 
Transverse 
colon 
21.1 23.2 40.1 16.2 
Descending 
colon 
27.6 26.3 35.5 23.7 
Sigmoid colon 43.1 39.7 26.6 15.1 
Rectum 60 50.8 19.2 6.9 
 Weight loss 
(%) 
Abdominal 
Mass (%) 
Anemia (%) Other (%) 
Right colon 19.4 6.3 13.8 17.4 
Transverse 
colon 
18.3 3.5 8.4 7.7 
Descending 
colon 
11.8 1.3 3.9 6.6 
Sigmoid colon 12.8 1.7 2.3 6.6 
Rectum 17.7 1.7 0 69 
 
A palpable mass, melena (right-sided colon cancers), bright blood per rectum (usually 
left-sided colon cancers or rectal cancer) or abdominal tenderness may be detected by 
physical examination. Digital rectal examination is an essential part of the physical 
examination. Obstructions caused by colon cancer, which results in abdominal 
distention and constipation is usually in the sigmoid or left colon. In contrast, the 
symptoms of right-sided colon cancers are possibly more insidious most of the time. 
Adenopathy, hepatomegaly, jaundice, or even pulmonary signs (dry cough, 
haemoptysis and thoracalgia) may be present with metastatic disease. Complications 
of colorectal cancer include intestinal perforation, acute gastrointestinal bleeding, 
acute obstruction, and functional impairment secondary to distant metastases. 
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1.1.7 Screening for Colorectal Cancer 
Evaluation should include complete history, family history, physical examination, and 
laboratory tests, colonoscopy, and pan-body computed tomography (CT) scan [21]. 
Upon completion of the diagnosis and staging (endoscopic ultrasound should be an 
integral part of staging of rectal cancer), incorporation of expertise from medical, 
radiation, and surgical oncologists is required to formulate and implement a treatment 
plan. 
 
Laboratory examination 
Routine blood analysis may detect iron-deficiency anemia, electrolyte derangements, 
and liver function abnormalities. Carcino-embryonic antigen (CEA) is one of the most 
helpful tumour markers that is monitored post-operatively to detect recurrence disease 
and may herald liver metastases [22]. Despite this, CEA is hardly a useful tool in 
early detection of colorectal cancer, and CEA rises may also occur due to tumours of 
non-colonic origin and non-cancer conditions. The normal level of CEA is also a 
challenging issue, due to different standards adopted by different laboratories in 
different countries. Based on the observation of sensitivity and specificity valued by 
different standard, Youden’s index and predicted value demonstrated the highest 
value when the concentration of CEA was 5ng/ml (Table 1.6) (Zhang et al. 1993). 
With the advance of molecular biological techniques, attention has been drawn to 
stool-based tools and new blood-based tests. Technologies now exist to extract 
genomic DNA or protein from stool and assay for evidence of genetic alterations [23]. 
Large-scale validation studies are in progress. One particularly attractive pathway for 
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stool-based diagnostics would be able to stratify patients as high, moderate, or low 
risk for colorectal cancer and thus influence modality and frequency of screening. In a 
complementary fashion, functional genomics are being applied to pair-wise 
comparisons of normal colon and colorectal cancers. This may allow screening of the 
entire human genome of nearly 30,000 genes and discovery of those genes, known 
and novel, that may be up-regulated or down-regulated and possibly linked to 
detection, prognosis, and therapy. 
 
Table 1.6.Evaluation of level of CEA (ng/ml) 
CEA 
(ng/ml) 
Sensitivity Specificity Positive 
predictive value 
Negative 
predictive value 
Youden's 
index 
>3 73 62 57 77 0.35 
>5 59 84 72 75 0.43 
>10 45 96 89 72 0.41 
>15 36 99 96 69 0.35 
(http://mall.cnki.net/magazine/Article/ZHWK405.017.htm) 
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Colonoscopy 
The best approaches for screening will take into consideration multiple factors 
including benefit to risk ratio, speed, sensitivity, specificity, cost-effectiveness and 
other social and economic factors. To this end, colonoscopy is currently most likely to 
offer the most effective approach when one considers all of these factors [24]. 
A patient at an average-risk of having colorectal cancer is defined as a man or woman 
above the age of 50, without personal or family history of adenomatous polyps or 
colorectal cancer and absence of any occult or acute GI bleeding.  
Optical colonoscopy is currently thought to be the most sensitive method for 
screening. The use of a colonofibroscope is suggested as a vital development of 
colorectal cancer diagnosis [25]. Advantages of using optical colonoscopy include 
direct visualization, polyp resection (although limited by the size and anatomic 
location of the polyps) and to obtain biopsies. The morbidity of colon cancer can 
decrease by approximately 76%-90% after the colorectal carcinoma resection by 
colonoscopy [26]. As with other examination method, optical colonoscopy has its 
associated side effects, such as bowel perforation, Flexible sigmoidoscopy typically 
allows visualization of the rectum, sigmoid colon, and descending colon up to the 
splenic flexure without the requirement of conscious sedation and hemodynamic 
monitoring but is limited in its reach compared with the colonoscopy. 
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Barium enema 
Flexible sigmoidoscopy should not be considered as a single screening measure but 
requires coupling with barium enema. Barium enema allows visualization of the 
entire colon, and affords advantages of ease of preparation, lack of conscious sedation 
and haemodynamic monitoring, and ability to visualize polyps and masses. However, 
an obvious disadvantage is its sensitivity in which small polyps may be missed.  
 
Other examinations 
New noninvasive technologies are evolving, although most of the new methods are 
still under investigation. These new technologies, for example ultrasonic examination, 
CT scan and Magnetic Resonance (MR)-colonography, may provide some initial data 
demonstrating efficacy. The advantage of CT scans is that the test allows imaging of 
adjacent mucosa and metastasis with lymph nodes or distant organs, hence it benefits 
the clinical staging. According to the CT staging criteria of EC suggested by Moss et 
al in 1981, the accuracy of staging on CT was 85.7% (Table 1.7) [27]. CT virtual 
colonoscopy, which is specially applied by the diagnosis of prominent colorectal 
lesions (>5cm) is a new CT assisted diagnostic technique [28-30]. A recent study has 
shown that the finding from CT virtual colonoscopy is consistent with optical 
colonoscopy, although large-scale population studies are still needed [31].  
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Table 1.7.CT staging by Moss et al [27]. 
Stage  
Ⅰ The thickness of bowel wall is normal (approximate 5cm), polypoid 
disease shows protrusions toward cavities. 
Ⅱ Local bowel wall is thickening; adjacent tissues have been invaded; no 
distant metastasis 
Ⅲ Local bowel wall is thickening; adjacent tissues have been invaded 
with involvement of local lymph nodes; no distant metastasis 
Ⅳ Distant metastasis (e.g. liver, lung, distant lymph nodes) 
 
1.1.8 Pathology of Colorectal cancer 
Colorectal cancer derived from the mucosa, namely adenocarcinomas, account for 
more than 90% of colorectal tumours [32]. Other histological types include squamous 
cell carcinoma, carcinoid, leiomyosarcoma, and lymphoma. Most grading systems 
classify adenocarcinoma into well, moderately or poorly differentiated tumours. 
Large bowel tumours may invade from mucosa through the entire bowel wall and 
beyond. Lymphatic metastasis which involves lymphatic vessels and lymph nodes are 
common. Haematogenous spread to the lung and liver are the most frequently seen 
distant metastases from colorectal cancer. There is little propensity for colon cancer to 
spread longitudinally within the bowel wall, in contrast to esophageal or gastric 
cancers. In 2000, colorectal cancer had been designated as a malignant epithelial 
tumour in colon or rectum and the malignancy is defined as observation of tumour 
penetrating the lamina muscularis into the submucosa [33]. The WHO histology 
classification of colorectal cancer is shown in Table 1.8 
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1.1.9 Therapy of colorectal cancer 
 
Surgery 
As the primary treatment of patients with colonic tumours, surgery with curative 
intent is possible in around 75% of patients [34]. Surgery of primary colorectal cancer 
is on the basis of the anatomy and mechanisms by which this disease spreads. 
Colorectal adenocarcinomas may grow rapidly and invade into the lymphatics of the 
submucosa and bowel wall. For the assurance of the curative resection, sufficient 
lengths of bowel need to be resected distal and proximal to the tumour. One approach 
of lymphatic metastasis is to extend through the serosa into mesenteric lymphatics at 
the root of the mesentery, and removal of the main lymphatic drainage system of the 
mesentery must be operated. Right hemicolectomy, transverse colectomy, left 
hemicolectomy and sigmoid resection are the usual procedure in colonic surgery, 
whilst those in rectal surgery include Dixon-operation, Parks-operation and 
Bacon-operation. All the operations must be performed by adherence to surgical 
oncologic principles (la principe aseptique, to avoid subsidiary-injury, minimal 
invasion, radical resection and non-neoplasia surgical operation) without major 
sacrifice of bowel function.  
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Table 1.8.WHO histology classification of colorectal cancer[33] 
Epithelial tumour 
Adenoma 
Villiform adenoma 
Tubulose adenoma 
Tubulovillous adenoma 
Serrated adenoma 
carcinoma 
Adenocarcinoma 
Mucinous adenocarcinoma 
Signet-ring cell carcinoma 
Small cell carcinoma 
Epidermoid carcinoma 
Adenosquamous carcinoma 
Medullary carcinoma 
Undifferentiated carcinoma 
Carcinoid 
EC cell, secreted serotonin carcinoma 
L cell, secreted glucagon peptide and PP/PYY carcinoma 
Anaplastic carcinoma 
Non-epithelial tumour 
Lipoma 
Leiomyoma 
Gastrointestinal stromal tumour 
Leiomyosarcoma 
Hemangiosarcoma 
Kaposi sarcoma 
Malignant melanoma 
Malignant lymphoma 
MALT marginal zone Bcelllymphom 
Mantle cell lymphoma 
Diffuse large B-cell lymphoma 
Secondary tumour 
Polyp 
Hyperplastic polyp 
Peutz-Jeghers 
Juvenile peutz-Jeghers 
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Chemotherapy 
Moertel et al. reported that the addition of 5- fluorouacil (5FU) and leucovorin 
improved survival rates of patients with resected colorectal carcinoma [35]. What is 
more, as an oral 5-FU prodrug, Capecitabine has showed similar overall and disease 
free survival rates with 5-FU in patients with resected colorectal cancer[36]. More 
recently, Oxaliplatin has been investigated as one of the adjuvant therapy of resected 
colorectal cancer. By contrast with 5-FU/ leucovorin, the improved disease-free 
survival was demonstrated in patients treated with Oxaliplatin [37].New standard 
chemotherapeutic regimens may be established based on 5FU/leucovorin/Oxaliplatin 
through the investigation of these data above. 
 
Radiotherapy 
Although surgery is commonly suggested as the main therapy of colorectal cancer, 
local recurrence and distant metastasis was the main cause of treatment failure after 
the resection of colorectal cancer [38]. In addition, the local invasion and disease 
progression occur at the advanced diseases [39]. Hence, adjuvant therapy was 
necessary to adopt in the therapy of resected colorectal cancer. Colorectal cancer, 
especially rectum cancer, was radiosensitive and controlled locally by the adjuvant 
radiotherapy, even if the profit of survival has been not verified completely after the 
radiotherapy [40]. 
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Gene Therapy 
Several aspects of colorectal cancer make the disease a reasonable potential target for 
gene therapy approaches [41]. Because colorectal cancer may progress within a 
confined space, such as the peritoneal cavity, or within a solitary organ, such as the 
liver, regional administration of a gene vector may be practical. Multiple trials of 
different gene therapy approaches, including virus directed enzyme pro-drug therapy, 
immunogenic manipulation, gene correction, and viral therapy, have all been initiated. 
These approaches are still at testing stages, and the therapeutic benefits from gene 
therapy in colorectal cancer have yet to be confirmed in clinical trials. 
 
1.1.10 Molecular Predictive Markers 
With the availability of a number of active agents, the ability to prospectively select a 
particular drug or drug combination that would have a likelihood of increasing 
efficacy or a likelihood of decreasing toxicity would be clinically useful. This method 
is highly desirable, but does not as yet exist. The past decade has seen some intensive 
research looking for potential markers. 
For example, one particular avenue of investigation is to elucidate markers of 
resistance to fluorouracil, based on knowledge of its metabolic pathways. Recent 
studies have indicated that high levels of either TS, DPD, [42] or thymidine 
phosphorylase (TP) in a tumour sample as measured by RT-PCR, may predict failure 
rate in response to an infusional 5-FU regimen [43-45]. These observations are 
intriguing but presently insufficient to exclude the use of 5-FU in a particular patient 
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Large-scale prospective trials are highly desirable before being applied to routine 
practice. There is, at the present time, no role for the use of these markers in standard 
practice. Others have investigated genomic analysis as an indicator of response or 
toxicity [46-47]. Although these approaches appear promising, they are yet to be 
validated and should not be considered as part of standard care. 
The following are some biomarkers extensively investigated in human colorectal 
cancer. 
 
1.1.11 Tumor suppressor genes in colorectal cancer 
The accumulation of intracellular gene mutation results in neoplastic transformation. 
Normal or abnormal phenotype of a cell is dependent on cell genotype and/or 
intracellular epigenetic alternation. Gene mutations, which include oncogene (e.g. 
K-ras, C-myc and src), tumour suppressor gene and DNA mismatch repair gene, are 
the basis of cancerization [48-50]. 
Tumour suppressor gene maintains cell stability by regulating cell proliferation and 
differentiation. Therefore, uncontrollable cell proliferation and the formation of 
tumour may be a result of inactivated tumour suppressor genes caused by somatic 
mutation or heredity. The APC (Adenomatous polyposis coli) [51] located at 
chromosome 5q.22.2 and P53 gene located at chromosome 17p are the most 
thoroughly investigated tumour suppressor genes in colorectal cancer. 
32 
 
 
 
Figure 1.5.Flow chart demonstrates these gene mutations are consistent with the 
order of cancer progression (from adenoma to carcinoma). 1988. By Bert Vogelstein. 
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APC (Adenomatous Polyposis Coli) Tumour Suppressor gene 
The APC protein, coded by the APC gene, controls many cellular functions of 
intestinal cells (e.g. proliferation, differentiation, migration and polarity)[52]. Many 
cases of colorectal cancer have been discovered primarily by loss or mutation of 
adenomatous polyposis coli [51]. APC was suggested as a negative regulator of Wnt 
signaling in tumour suppression [52]. A destruction complex is formed by APC with 
Axin and two kinases (casein kinase 1, CK1 and glycogen syntase kinase 3β, GSK3β) 
in the absence of Wnt signaling, which can phosphorylate the transcriptional 
co-activator β-catenin, thereby, to make β-catenin to be degraded proteasomally [53]. 
When the Wnt signalling is active, Wnt proteins will activate its receptor, Frizzled 
and subsequently dishevelled proteins, which prevent the phosphorylation of CK1 and 
GSK3β. This subsequently inhibits the formation of destruction protein and leads to 
stablisation of β–catenin protein. As a consequence, β–catenin protein is accumulated 
in the cytosol. The excess β–catenin protein subsequently translocates to the nucleus 
where it binds to the transcription factor TCF4 in the nucleus and activates target 
genes (e.g. c-myc and cyclin D1) [53]. Hence, the stabilised β-catenin caused by the 
mutation in APC protein triggers the downstream events of Wnt signaling. Consistent 
with this model, an abundance of mutation in the APC gene has been detected in 
adenoma formation in transgenic mice and has correlation with 7% of sporadic colon 
cancer [54-56]. 
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p53 Tumour Suppressor 
p53, or P53, TRP53, BCC7, is one of the best charaterised tumour suppressor genes. 
The p53 gene is localised in chromosome 17p13.1 and encodes the p53 protein, a 
transcription factor that is involved in the regulation of cell cycle, apoptosis, cellular 
senescence (McBride et al 1985, Benchinol et al 1985, Rowley 1986). Abnormalities 
of the p53 gene, transcript and protein expression have been widely reported in 
human cancers including colorectal cancer. 
Allelic loss of chromosome 17p is observed in three of four colorectal carcinomas but 
fewer than 10% of adenomatous polyps [57]. The remaining p53 allele is inactivated 
in most tumours with 17p loss of heterozygosity [58], most often at codons 175, 245, 
248, 273, or 282 [59]. LOH of 17p and mutations in p53 thus appear to arise during 
the transition from adenoma to carcinoma, perhaps facilitating progression. When 
faced with stress from DNA damage, hypoxia, reduced nutrient access, and 
aneuploidy, cells with intact p53 function undergo cell cycle arrest and apoptosis. The 
loss of p53 may allow cells to overcome such barriers to tumour growth and 
progression. 
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Another protein complex that may have tumour and tumour metastasis suppressing 
functions is Kiss-1 and Kiss-1 receptor. 
 
1.2 Kiss-1 and Kiss-1 receptor 
Discovered by Danny Welch in Pennsylvania in 1994 (Welch et al 1994), Kiss-1 (also 
known as metastin and kisspeptin-1) is a protein demonstrated to have some 
hallmarks of a tumour suppressor in some tumour types.  
 
1.2.1 Regulation of Kiss-1: 
Lee and colleagues (Lee et al 1996) introduced the full length of chromosome 6 into 
the human metastatic melanoma cell line C8161 using a microcell-mediated 
transferring technique and then found the introduction of chromosome 6 suppressed 
metastasis without impacting tumourigenicity and tumour invasion [60]. Two years 
later, the human Kiss-1 gene was isolated and identified from the melanoma cells by 
Lee et al [61-62].The premature coding products of the Kiss-1 gene is a protein with 
145-amino-acids. The protein is subsequently cleaved into a family of Kisspeptins, 
including Kisspeptin-10, Kisspeptin-13, Kisspeptin-14, Kisspeptin-54 respectively 
[48, 63-64]. Coincidently, the Kiss-1gene mapped to chromosome 1q32, which was 
identified as a human melanoma metastasis suppressor gene through the analysis of 
subtractive hybridization in highly metastatic cell lines as compared with 
non-metastatic cell lines [60]. These early findings suggested that there was a 
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regulatory gene existing on chromosome 6, which regulates the expression of Kiss-1 
gene. Subsequent research revealed that the regulatory region of Kiss-1 was in a locus 
of a 40-cM region between 6q16.3 and q23 of chromosome 6 [65]. Complementary 
studies of 51 melanoma patients by Shirasaki and co-workers showed that a loss of 
6q16.3- q23 was observed in 14 melanoma patients (51%), which had significant 
correlation (p=0.03) with a loss of Kiss-1 expression (44%) [66]. In addition, 
Goldberg et al. found the high expression of thioredoxin interacting protein (TXNIP, 
also known as vitamin D up-regulated protein 1, thioredoxin binding protein 2 or 
VDUP1) in non-metastatic melanomas, which was mapped to chromosome 1q and 
also expressed in the neo6/C8161 melanoma cell line [67]. In the subsequent studies, 
the author detected ascended TXNIP expression inhibited metastasis of melanoma 
cells via an up-regulation of Kiss-1. Moreover, PCR karyotyping revealed that the 
expression of both Kiss-1 and TXNIP were up-regulated in the cells transfected with 
CRSP3 (vitamin D receptor interacting protein) which was mapped to chromosome 6 
and led to a suppression of metastasis [67]. Meanwhile, decreased Kiss-1 expression 
and increased metastasis were evident to correlate with a loss of CRSP3 [67]. 
These findings indicate that CRSP3 mapped to chromosome 6 is an upstream 
regulator of TXNIP, which subsequently regulates the expression of Kiss-1. In other 
words, a loss of CRSP3 expression, which is caused by structural abnormality of 
chromosome 6 impairs the appropriate expression of Kiss-1 and TXNIP. 
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1.2.2 Kiss-1 receptor: Discovery and structure: 
Kiss-1 receptor (Kiss-1R), also known as G-protein coupled receptor 54 (GPR54), 
HOT7T175, AXOR12, Metastin receptor, was first discovered and cloned from rat 
brain in 1999 [68]. In humans it maps to chromosome 19p13.3, contains 5 exons and 
4 introns and encodes 398 amino acids (75 kDa) and shares 81% protein homology 
with the preceding cloned rat orthologue [64, 69].  
Tissue distribution of Kiss-1 and its receptor are often concordant. For example, both 
Kiss-1 and Kiss-1R are both highly expressed in placenta tissues [48, 61, 69]. 
Moreover, both Kiss-1 and its receptor are widely distributed throughout the central 
nervous system [69]. High levels of Kiss-1R have been observed in cerebral vortex, 
cerebellum, thalamus and pons-medulla [69]. In contrast, its cognate ligand precursor, 
Kiss-1, is highly expressed in hypothalamus and pituitary [64]. In addition to placenta, 
the expression of Kiss-1R is also high in pancreas, whilst it is expressed at low levels 
in adipose tissue, lymph nodes, peripheral blood lymphocytes, pituitary gland and 
spleen [48, 69].  
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1.2.3 Kiss-1, Kiss-1 receptor and downstream pathways: 
Concrete mechanism(s) by which Kiss-1 suppresses tumour metastasis are yet to be 
established. However, a few signal transduction pathways have been indicated as the 
key downstream events of Kiss-1/Kiss-1R complex.  
 
Calcium coblization through Gq activation 
Intracellular Ca+ was increased significantly in the cells transfected with Kiss-1 
receptor followed with treatment of Kiss-1 or Kisspeptins, such as B16-BL6 
melanoma [48], CHO-K1 [64], HEK293 [69]. Hence, the mobilization of calcium in 
cells, which treated with Kiss-1, manifested the important role of Kiss-1 receptor. 
Kiss-1Ris likely coupled to G-proteins of the Gαq/11 subfamily rather than to the Gi 
or Gs subfamily [69]. Through Gα q/11–mediated signaling pathway, phospholipase 
Cβ (PLCβ) is activated which consequently generates two kinds of second 
messengers in cells (Inositol triphosphate 3 and Diacylglycerol), leading to 
intracellular Ca
+ 
release and protein kinase C activation, respectively [70]. In the 
meantime, increased intracellular Ca
+ 
markedly suppresses tumour metastasis and 
induces differentiation and apoptosis in human cancer cells [70]. In addition, the 
capacity of colony formation of a breast cancer cell (MDA-MB-435) on hard agar 
medium is negatively correlated with the expression of Kiss-1 [71]. 
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Matrix metalloproteinases (MMPs) 
MMPs can degrade extracellular matrix and play dominating roles in the process of 
tumour metastasis. MMP-9, known as the most important protease related with 
tumour metastasis and is capable of degrading the primary structure of extracellular 
matrix and basement membrane (collagen, laminin, fibronectin), thereby promotes the 
tumour metastasis [72]. Yan et al. have shown that there was a marked reduction of in 
vitro invasion through Matrigel
®
-coated porous filters by HT-1080 cells which had 
reduced transcription and activity of MMP-9 following the overexpression of Kiss-1 
[73]. This reduction is credited in part to the diminished P65 and P50 NF-KB proteins 
which interact with the promoter of MMP [70]. Consequently, the reduced synthesis 
of MMP-9 brings about certain inhibitory effects on the mobility and invasion of 
cancer cells [48, 70]. In addition, activated focal adhesion kinase (FAK) and paxillin, 
which play a crucial role in the process of formation of focal adhesion, exhibit certain 
links with Kiss-1 and its receptor [74]. In ARO thyroid cancer cells transfected with 
Kiss-1R Kiss-1 treatment elicited strong and sustained phosphorylation of ERK1/2, at 
the same time as weak phosphorylation of p38 or pAKT [74]. A similar 
concentration-dependent release of arachidonic acid caused by Kisspeptin-10 was 
seen in CHO-K1/MR cells, in which Kisspeptin-10 strongly inhibited cell 
proliferation [64]. Activated ERK1/2 can significantly induce the formation of stress 
fibre, focal adhesion and activated RHO, via the phosphorylation of FAK and paxillin 
[48, 74]. 
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Figure1.6. The suggested mechanisms of neuronal depolarization by Kiss-1 and its 
receptor (Kiss-1R).Gα q/11 is activated by Kiss-1R and PLC to cleave PIP2 into IP3 
and DAG. IP3 promote intracellular Calcium ions release inducing cancer cells to 
differentiation and apoptosis, while DAG activates a signal cascade by activating 
PKC. The reduction of MMP-9 caused by the degradation of NF-κB contributes to 
suppress tumour metastasis through activating MAPK pathway. 
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1.2.4 Kiss-1 and Kiss-1R in Cancer: 
Breast cancer 
Lee and Welch (1997) hypothesized that Kiss-1 was possibly suppressed metastasis in 
other types of tumour, in addition to melanoma from which Kiss1 was discovered. 
This was on the basis of the map location of Kiss-1gene (chromosome 1 bands 
q32-41), where its 1q alternations are peculiar in breast tumour carcinomas. To test 
this hypothesis, the authors firstly transfected full-length Kiss-1 cDNA into a human 
breast cancer cell line, MDA-MB-435s, and then implanted the cells into athymic 
nude mice with paired control cells. The results demonstrated that the metastatic 
probability of transefected cells remarkably increased, although the tumourigenecity 
was suppressed [71]. To further test the hypothesis, Mitchell and colleagues (2005) 
discovered by using RT-PCR, that the loss of Kiss-1 gene expression was associated 
directly with the expression levels of activator protein-2a and specificity protein-1, 
two known transcription factors expressed in highly metastatic breast cancer cell lines 
[75]. In addition, Marot and colleagues (2007) found that the low level of Kiss-1 
mRNA was expressed in the ERα-negative MDA-MB-231 cells while the 
ERα-positive MCF7 and T47D cells exhibited higher expression of both Kiss-1 and 
its receptor. Interestingly, the data from postmenpopausal women with breast cancer 
showed an opposite relationship [76]. Also, an analysis of Kiss-1 mRNA in 
paraffin-embedded stage Ⅱor Ⅲ lymph node positive breast adenocarcinomas 
demonstrated that the Kiss-1 gene expression was silenced. These observations also 
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support the anti-metastatic potential of Kiss-1 in certain breast cancers [77]. Likewise, 
another study investigating the metastasis-suppressor gene profile of breast cancer 
using frozen tissue samples, analysed Kiss-1 expression at mRNA and protein levels, 
using RT-PCR and immunohistochemical staining respectively (2005) [78]. The study 
showed that Kiss-1 mRNA expression was suppressed in brain metastases from breast 
cancer. In contrast to the studies supporting the anti-metastatic potential of Kiss-1 in 
breast cancer, Martin et al. (2005) found that the expression of Kiss-1 was remarkably 
increased in primary tumours compared with normal mammary tissues. The increased 
expression of Kiss-1 in primary tumours was also correlated with the metastasis to 
lymph nodes. Likewise, the expression of Kiss-1 became higher with tumour grades 
and increased TMN status. In contrast, its receptor (Kiss-1R) was significantly 
decreased in patients with poor survival. Moreover, invasiveness of breast cancer cells 
was impaired by the knockdown of Kiss-1 [79].  
 
Gastric cancer 
Dhar et al. (2004) found that reduced Kiss-1 expression in gastric cancer was related 
to increased risk of distant metastases and tumour recurrence. The study analysed the 
expression of Kiss-1 in frozen tissue samples from 40 gastric adenocarcinomas using 
RNase protection assays, and had suggested that Kiss-1 was a possible independent 
predictor of patient survival compared with the conventional routine prognostic 
predictors of gastric cancer [80]. Likewise, an investigation of two metastasis 
43 
 
suppressor genes, Kiss-1 and KAI-1 in 49 gastric adenocarcinoma tissues together 
with 20 precancerous tissues showed that Kiss-1 mRNA was remarkably lower in 
cancer tissues compared with the precancerous tissues. It has again indicated a 
possible predictive value of Kiss-1 for the prognosis of patients with gastric cancer. 
Similar results were seen in a study by Yao et al (2007) which demonstrated that 
reduced Kiss-1 expression is seen in moderate-to-severe hyperplasia compared with 
normal-to-moderate hyperplasia, and also in T3/T4 tumours with lymph node 
involvement and distant metastases compared with tumours at earlier stages, i.e. T1-2 
without any metastasis [81]. 
 
Oesophagealcarcinoma 
Oesophageal squamous cell carcinoma (ESCC) is one of the malignancies that we 
have so little effective means to treat. A number of reasons may contribute to the 
difficulties in treating the tumour, including late diagnosis and advance stages at the 
time of first visit, commonly seen lymph node metastasis in most patients, the 
anatomical reasons that the organ is closely surrounded by some key organs and 
tissues and its rich lymphatic drainage. The latter is of particular interest: even 
diagnosed at an early stage of ESCC patients would already have lymphatic 
metastases or develop lymph node metastasis soon after surgery [82]. Therefore, 
lymph node metastasis is suggested as the most important predictor of prognosis in 
ESCC. Ikeguchi et al. (2004) assessed the expression levels of Kiss-1 and Kiss-1R in 
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ESCC tumours and noncancerous tissues of oesophagus of 71 patients with 
oesophageal squamous cell carcinomas. Using real-time PCR, the authors have found 
that loss of Kiss-1 and its receptor was detected in 86-100% of primary tumours with 
lymph node metastases, suggesting a relevance to the lymphatic metastasis and 
unfavorable prognosis, independent of the depth of tumour invasion [83]. 
Furthermore, loss of Kiss-1 and its receptor was seen in primary tumours with 
invasion to adventitia compared with the control groups without invasion and was 
also associated with lymph node metastasis [48]. These findings strongly show that 
the loss of expression of one or both genes (Kiss-1 and Kiss-1R) is possibly vital in 
lymph node metastasis, and they can be considered as prognostic factors in ESCC 
[48]. 
 
Hepatocellular carcinoma 
A small number of studies on the expression of Kiss-1 are available in the literature 
regarding tumour thrombus caused by invasion of hepatocellular carcinoma to the 
portal vein as the most vital prognostic factor of orthotopic liver transplantation for 
hepatocellular carcinoma (20%-70%) [84]. Hou et al. (2007) reported a relationship 
between the expression of Kiss-1 and MMP-9 in the formation of portal vein tumour 
thrombus (PVTT) in HCC by analysing 50 specimens of HCC (31 with PVTT and 19 
without PVTT). The expression of Kiss-1 was lower in HCC with PVTT than that in 
HCC without PVTT. It is noteworthy that a contrasting expression pattern of MMP-9 
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was seen in HCC with and without PVTT. Hou et al. thus suggested that Kiss-1 may 
possibly prevent PVTT by up-regulating MMP-9 expression [85]. Interestingly, and in 
a clear contrast, higher expression of Kiss-1 and Kiss-1R genes was detected in more 
advanced tumours by Ikeguchi and co-workers (2003). It indicates that the expression 
levels of Kiss-1 and its receptor genes may promote tumour progression rather than 
suppressing the metastasis [86]. Similarly, the strong positive immunoreactivity of 
Kiss-1 and Kiss-1R was also seen in HCCs which showed higher Kiss-1 expression in 
the HCC with poor prognosis [87]. 
 
Pancreatic cancer  
In pancreatic cancer, loss of 6q, 8q, 9q, 17q and 18q has been observed and the loss is 
associated with lymph node and distant metastases, suggesting that there is a vital 
suppressor gene existing in these regions for pancreatic cancer [88-89]. Due to the 
presence of the Kiss1 gene in the region, it was proposed that Kiss-1 expression may 
be down-regulated in pancreatic cancer. In a subsequent study employing a number of 
pancreatic cancer cell lines (AsPC-1, BxPC-3, Capan-2, CFPAC-1, PANC-1 and 
SUIT-2), Masui and co-workers (2004) found that Kiss-1 mRNA was reduced in 
pancreatic cancer whilst Kiss-1R mRNA expression was higher [90]. In 2007 Liang et 
al. demonstrated once again this view after detecting Kiss-1 expression of pancreatic 
cancer in the inducted Sprague-Dawley rats using in situ hybridization. Lower levels 
of Kiss-1 mRNA were observed in the pancreatic cancer tissues compared with 
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normal pancreatic tissues, suggesting Kiss-1 as a possible inhibitor of pancreatic 
cancer metastasis[91].  
 
Thyroid cancer 
Distant metastasis is also a crucial factor for the shortened survival of patients 
suffering from thyroid cancer. Patients who develop distant metastases from thyroid 
cancer have about 50% five year survival rates [92]. Recent studies have 
demonstrated the importance of certain receptors involved in metastatic capacity of 
thyroid cancer cells. Through the analysis of 36 thyroid tissue samples (13 papillary 
carcinomas, 10 follicular carcinomas, 2 benign follicular adenomas and 11 normal) 
using real-time PCR, Ringel et al. reported that higher levels of Kiss-1 and its 
receptor expression was detected in papillary and follicular cancers compared with 
normal tissue. The increased expression of both gene products were associated with 
greater possibility of developing distant metastases [74]. Furthermore, 
over-expression of Kiss-1R resulted in decreased capabilities of growth and migration 
of thyroid cancer cells following exposure to Kisspeptin-54 [93]. The authors found 
that Kisspeptin-54 was able to increase the protein levels of Myocyte-enriched 
Calcineurin Inter-acting Protein 1 (MCIP1) which is known as a calcineurin inhibitor. 
MCIP1 has been shown to be increased at the early stage of thyroid tumours and then 
was reduced or absent from lymph node metastases [93]. 
 
47 
 
Ovarian cancer 
Ovarian cancer is one of the leading female cancers globally. Recent data have shown 
that 24,400 women were newly diagnosed with ovarian cancer and almost 58% of 
them died from ovarian cancer in the United States in 2003 [94]. Berk and co-workers 
(2005) measured seven ovarian cancer cell lines using real time quantitative RT-PCR 
and reported that overexpression of Kiss-1 reduced metastatic colony formation by 
inhibiting cell migration [95]. Similar data were reported by Gao et al., who analysed, 
using immunohistochemical staining, the expression of Kiss-1 protein in 100 primary 
ovarian epithelial tumours (10 normal tissues, 20 benign adenomas, 20 borderline 
tumours and 50 malignant). The study showed that there was a significant increase of 
Kiss-1 expression levels in cancerous tissues compared with benign and normal ones 
while the increased Kiss-1 expression in cancer cell lines suppressed the expression of 
MMP-9 and NF-kB [96]. Furthermore, Hata and colleagues (2007) found that the 
lower expression of Kisspeptin-54 and Kiss-1R correlated with more deteriorative 
tumour and worse prognosis in 76 epithelial ovarian cancers [97]. 
 
Gestational trophoblast neoplasia (GTN) 
All forms of GTN secrete human chorionic gonadotrophin (hCG), which is a helpful 
marker in the diagnosis, staging and subsequent assessment of the therapeutic 
response of malignant GTN by monitoring serum levels of hCG. hCG would start to 
rise and reach a plateaus in those patients who are developing malignant changes. It is 
48 
 
important to detect the serum hCG of the patients with GTN. However, like the 
problems associated with similar assays, issues exist regarding false positives caused 
by heterophile antibodies in commercial available tests [98], the research community 
remains highly interested searching for new biomarker for the tumour type. On the 
strength of the studies by Horikoshi et al. which showed that there was a dramatic 
increase in the concentration of plasma Kiss-1 receptor (Kisspeptin-54) in pregnancy 
[99], Dhillo and co-workers assessed the levels of Kisspeptin-54 in GTN by 
determining plasma Kisspeptin-immunoreactive (Kisspeptin IR) using 
chromatographic analysis. They found that there was a fluctuation of plasma 
Kisspeptin-54 following chemotherapy. Moreover, they continued to determine the 
concentration of plasma kisspeptin IR in female volunteers. Together with hCG, 
progesterone and estradiol were determined in11 healthy females without pregnancy, 
5 healthy females who had previously been pregnant, 13 healthy women in the first 
trimester of pregnancy, 38 volunteers at 38 weeks of pregnancy and the same females 
15 days postpartum, and 11 women diagnosed with invasive GTN using 
radioimmunoassays and Chemiluminescent Microparticle Immunoassays [100]. The 
result showed that there was a significant positive correlation between plasma 
kisspeptin IR and circulating levels of progesterone and estradiol. It suggests that 
plasma kisspeptin can be considered as a tumour marker in patients with malignant 
GTN [101]. 
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Bladder cancer 
As the fourth most common malignancy among men, bladder cancer can be classified 
based on the depth of invasion. Non-muscle-invasion (pTis, pTa and pT1) occupied 
75% of transitional cell carcinomas (TCCs), muscle infiltration (pT2-pT4) are 20%, 
and the rest are metastatic at the time of diagnosis [102]. Five year survival rate is 
more than 90% for patients presenting with localized TCC, whilst it is only 50 and 10% 
for patients diagnosed with regional and distant metastatic disease spread respectively 
[102]. Similar to the effect of suppressing cancer metastasis by Kiss-1 observed in 
other solid tumours, loss of Kiss-1 was seen in the advanced bladder tumours [49]. 
Moreover, low levels of Kiss-1 expression were associated with increased 
histopahtological stage, poor tumour cell differentiation and poor survival rate [49, 
103].  
 
Prostate cancer 
Prostate cancer is the most common malignancy and the second leading cause of 
cancer mortality among men whose age are older than 40 years. There are no curative 
therapies for advanced prostate cancer (PCa) [104]. Even if patients have experienced 
successful surgical resection, recurrence locally or distant metastases which are 
responsible for majority of PCa-related deaths would has a great opportunity to occur 
months or years later [105-106]. Because of the lack of timeliness of the analysis of 
the primary tumour size and histology, the information provided by identification and 
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characterization of molecular signatures is particularly crucial for the diagnosis of 
PCa [106]. Down-regulation of Kiss-1 has been shown to be correlated with 
decreased Kiss-1R expression which is inversely associated with the clinical stage 
and tumour grade. Forced expression of Kiss-1 increased cell sensitization to anoikis 
and chemotherapeutic drugs. Kiss-1 suppresses migration and invasion of prostate 
cancer cells. Kiss-1 has been suggested therefore as a potential factor for risk 
assessment of PCa progression [50]. 
 
Endometrial cancer 
Uterine corpus cancer is the main cause of malignant gynaecological disease with 
more than 42,000 cases diagnosed, which is still stably increasing every year in the 
United States. Cancer cell invasion followed by metastasis impacts profoundly on 
patient prognosis and is considered as a vital issue to improve prognosis for females 
diagnosed with endometrial cancer [107]. Hyun Sook Kang et al. assessed Kiss-1 and 
its receptor expression in 92 adenocarcinomas of endometrial cancer using IHC 
staining and real time PCR. The result revealed the low expression of Kiss-1 and its 
receptor was significantly associated with certain wellknown poor prognostic factors 
of distant metastasis (for example invasion into lymphovascular space and deep 
myometrium) [107-108]. Furthermore, based on the study of subcutaneous xenograft 
established by inoculating Ishikawa cells into female nude mice, they reported that 
the decreased number of lymph node metastases of Kiss-1R﹢ Ishikawa cells was 
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seen in metastin-10-treated mice, while there was no significant difference in the 
tumour size between metastin treated and non-treated groups. It indicates that 
Kiss-1affects metastatic potential of cancer cells rather than directly inhibiting tumour 
growth [108]. 
 
Table 1.9.Table for functions of cancer cells treated with Kisspeptin-10 compared 
with the control cells 
Cell /tumour 
types 
Migration Invasion Proliferaiton Reference 
Breast cancer  ↓ None [48, 71] 
Pancreatic cancer ↓ None None [90] 
Ovarian cancer ↓   [95] 
Prostate cancer ↓ ↓  [50] 
Endometrial cancer ↓  None [108] 
 
Table 1.10.Expression of Kiss-1 and Kiss-1R in cancers compared with the 
corresponding normal tissues or background tissues 
Tumour type Kiss-1 Kiss-1R Reference 
Breast cancer ↓/↑ ↓/↑ [71, 79] 
Gastric cancer ↓  [80-81] 
Esophageal carcinoma ↓ ↓ [83] 
Hepatocellular 
carcinoma 
↑ ↑↑ [86] 
Pancreatic cancer ↓ ↑ [90] 
Thyroid cancer ↑ ↑ [74] 
Ovarian cancer ↓ ↑ [48] 
Gestational 
trophoblastneoplasia 
↓/↑ ↑/↓ [101, 109-110] 
Bladder cancer ↓ ↑ [49] 
Prostate cancer ↓ ↓ [50] 
Endometrial cancer  ↓ [108, 111] 
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The expression of Kiss-1 and Kiss-1R manifest relative differences compared with 
normal tissue in a variety of tumours from the data of Table 1.10. As these data were 
collected from different studies, it is difficult to analyse quantitatively the difference 
in the expression of Kiss-1 and its receptor among different cancers. However, the 
expression differences between Kiss-1 and Kiss-1R in comparison with normal 
tissues can be studied qualitatively in each group of cancers.  Up-regulation and 
down-regulation of Kiss-1 and Kiss-1R expression has been indicated in various 
malignancies. Reduced expression of both Kiss-1 and Kiss-1R has been detected in  
gastric cancer (without the data of Kiss-1R), oesophageal carcinoma, prostate cancer 
and endometrial cancer (without the data of Kiss-1). By contrast, the increased 
expression of Kiss-1 and its receptor has also been observed in certain solid tumours, 
including hepatocellular carcinoma,  thyroid cancer and gestational 
trophoblastneoplasia. Interestingly, several data presented contrary expression of 
Kiss-1 and Kiss-1R even in the same cancer from different studies (e.g. breast cancer 
and gestational trophoblastneoplasia). Additionally, the opposite expression of Kiss-1 
compared with that of Kiss-1R was reported in pancreatic cancer, ovarian cancer and 
bladder cancer. 
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1.2.5 Summary 
In summary, although it remains controversial, Kiss-1 has been demonstrated as a 
metastasis suppressor in most cancers, including gastric cancer, oesophageal 
carcinoma, pancreatic cancer, ovarian cancer, bladder cancer and prostate cancer. 
Relations between reduced expression of Kiss-1 and poor clinical outcomes have 
been evident in most malignancies that have been investigated. A possible explanation 
for the role played by Kiss-1 in cancer biology could be extrapolated from the 
correlation between Kiss-1 and matrix metalloproteinases (MMPs), especially 
MMP-9 and MMP-2, whose significance in tumour invasion and metastasis formation 
is well known [112]. Kiss-1 was reported to regulate MMP-9 expression negatively in 
ovarian tumour [96]. Takino a et al. explained that Kiss-1 protein contributed to form 
a steady complex with pro-MMP-2 and pro-MMP-9, which possibly have an 
influence on the proteolytic processing of Kiss-1 rather than the pro-MMP processing 
[96]. However, there are several reports suggesting contrasting roles may be played 
by Kiss-1 in certain cancers (e.g. hepatocellular carcinoma and breast cancer) [79, 86]. 
In these cases it is believed that the relative expression of Kiss-1 and it is receptor 
may be the determining factor. The reason why the expression of Kiss-1 and its 
receptor has a contrary effect on progression of hepatocellular carcinoma and breast 
cancer in comparison with other malignant tumours is still unknown, whereas it is 
proposed that there is a correlation between Kiss-1 expression and hormonal 
environment. Gottsch et al. reported that role played by the protein product of Kiss-1 
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and Kiss-1R was a vital part of regulation of GnRH secretion. Neurons expressed 
Kiss-1 can regulate the release of GnRH via Kiss-1R in either autocrine or paracrine 
manner, so to regulate the release of LH/FSH by effecting the pituitary, in the 
meantime, the expression of Kiss-1 would increase through a feedback regulation of 
high estrogen level [113]. Hence, patients with hepatocellular carcinoma suffering 
from liver cirrhosis, which leads to a disturbed hormal balance, generally show high 
estrogen levels, and the hyperestrogenic state would activate the ERα, which binds to 
the Kiss-1 gene promoter in turn elevating Kiss-1 expression [114]. The possible 
relationship between Kiss-1 expression and estrogen level may be also appropriate for 
the situation in breast cancer, since blocking the ER pathway is suggested as one of 
the most significant systemic therapies in breast cancer [87]. A role played by Kiss-1 
and Kiss-1R in other cancers regulated hormone has also been proposed. The 
elevating expression of Kiss-1 has been detected to suppress metastases in SKOV3 
ovarian cancer cells through the reverse effect caused by PKCα [95]. Consistently, it 
was concordant to the effect found in melanoma cells [115]. 
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1.2.6 Hypothesis and aims of the study 
 
Kiss-1 and Kiss-1R are generally considered as metastasis suppressor, yet the 
mechanism of Kiss-1 metastasis suppression remains largely unknown.  
It was hypothesised that Kiss-1 and its receptor may play a similar metastasis 
suppressor role in human colorectal cancer by way of aberrant expression and, by 
molecular and cellular mechansism(s) to be identified, linked to the disease 
progression of the patients.  
 
Thus the aims of the present study were as follows: 
 
1. To investigate the mRNA expression of Kiss-1 and Kiss-1R in human colorectal 
cancer cell lines using Q-PCR and RT-PCR; 
2. To generate cell models (sublines) from human colorectal cancer cell lines with 
differential expression of Kiss-1 and Kiss-1R (e.g. Kiss-1 or Kiss-1R knockdown); 
3. To investigate the impact of differentially expressed Kiss-1 on the function of 
colorectal cancer cells (e.g. growth, adhesion, invasion and migration) using in vitro 
function assays and ECIS assay, subsequently, to deduce the correlatively underlying 
mechanism(s) on the basis of the results of the function test.   
4. To investigate the expression of Kiss-1 and Kiss-1R in human colorectal cancer and 
deduce the potential clinical and prognostic implications using Q-PCR and IHC. 
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Chapter 2 
 
Materials and Methods 
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2.1 General materials 
 
2.1.1. Cell lines: 
In this study the following cell lines were used: 
HT-115, HRT-18, RKO and Caco-2 cancer cell lines with epithelial morphology were 
established from highly invasive human colorectal carcinoma, which express high 
amounts of the tumour marker carcinoembryonic antigen. They were obtained from 
the European collection of animal cell culture (ECACC), HECV, human endothelial 
cells were purchased from Interlab, Milan, Italy (Table 2.1). 
 
Table 2.1.Details of cell lines used in this study 
 
 HT-115 HRT-18 RKO Caco-2 
Species Human Human Human Human 
Tissue Colon Rectum Rectum Rectum 
Age 63 67 82 72 
Gender Male Male Female Male 
Morphology Epithelial Epithelial-like Epithelial Epithelial 
Growth 
Mode 
Adherent Adherent Adherent Adherent 
Karyotype 2n=46 2n=46 2n=46 2n=46 
Tumorigenic specified Yes Yes Yes 
Country UK UK UK UK 
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Table 2.2.Source of general compounds 
 
Material & Reagent Supplier 
10% foetal calf serum (FCS) PAA Laboratories, Coelbe, Germany 
A/G protein agarose beads Santa-Cruz Biotechnology, Santa-Cruz, 
CA, USA 
Acetic acid Fisher Scientific, Leicestershire, UK 
Acrylamide mix (30%) Sigma-Aldrich Co, Poole, Dorset, UK 
Agarose Melford Laboratories Ltd, Suffolk, UK 
Ammonium persulfate (APS) Sigma-Aldrich Co, Poole, Dorset, UK 
Amphotericin B Sigma-Aldrich Co, Poole, Dorset, UK 
Bio-Rad DC Protein Colourimic Assay Bio-Rad Laboratories, Hercules, CA, 
USA 
Boric acid Duchefa Biochemie, Haarlem, 
Netherlands 
Bromophenol Blue Sigma-Aldrich Co, Poole, Dorset, UK 
CaCl2 Sigma-Aldrich Co, Poole, Dorset, UK 
Chloroform Sigma-Aldrich Co, Poole, Dorset, UK 
Commasine Blue Sigma-Aldrich Co, Poole, Dorset, UK 
DEPC (Diethylpyrocarbonate) Sigma-Aldrich Co, Poole, Dorset, UK 
Dimethylsulphoxide (DMSO) Fisons Scientific Equipment, 
Loughborough, UK 
DMEM/Ham’s F12 with L-Glutamine 
medium 
PAA Laboratories, Coelbe, Germany 
EDTA (Ethylenediaminetetraacetic acid) Duchefa Biochemie, Haarlem, 
Netherlands 
Ethanol Fisher Scientific, Leicestershire, UK 
Ethidium bromide Sigma-Aldrich Co, Poole, Dorset, UK 
Glycine Melford Laboratories Ltd, Suffolk, UK 
HCL Sigma-Aldrich Co, Poole, Dorset, UK 
Isopropanol Sigma-Aldrich Co, Poole, Dorset, UK 
KCl Fisons Scientific Equipment, 
Loughborough, UK 
KH2PO4 BDH Chemicals Ltd, Poole, England, UK 
Mayers Htx Sigma-Aldrich Co, Poole, Dorset, UK 
Methanol Fisher Scientific, Leicestershire, UK 
NaCl Sigma-Aldrich Co, Poole, Dorset, UK 
Na2HPO4 BDH Chemicals Ltd., Poole, Dorset, UK 
NaN3 Sigma-Aldrich Co, Poole, Dorset, UK 
NaOH Sigma-Aldrich Co, Poole, Dorset, UK 
Nitrocellulose membrane Ammersham, Cardiff, UK 
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Penicillin Sigma-Aldrich Co, Poole, Dorset, UK 
Peroxidase conjugated goat anti-rabbit 
IgG 
Sigma-Aldrich Co, Poole, Dorset, UK 
Peroxidase conjugated rabbit anti-goat 
IgG 
Sigma-Aldrich Co, Poole, Dorset, UK 
Peroxidase conjugated rabbit anti-mouse 
IgG 
Sigma-Aldrich Co, Poole, Dorset, UK 
Precision qScriptTM RT PCR kit Primerdesign LTD, Southampton, UK 
REDTaqTM ReadyMix PCR reaction 
mix 
Sigma-Aldrich Co, Poole, Dorset, UK 
RNA extraction buffer Advanced Biotechnologies Ltd, Epsom, 
Surrey, UK 
SDS (Sodium dodecyl sulphate) Melford Laboratories Ltd, Suffolk, UK 
Serum bovine albumin Sigma-Aldrich Co, Poole, Dorset, UK 
Streptomycin 
 
Sigma-Aldrich Co, Poole, Dorset, UK 
Sucrose Fisons Scientific Equipment, 
Loughborough, UK 
SupersignalTM West Dura system Pierce Biotechnology Inc., Rockford, IL, 
USA 
TBS Automation Wash Buffer Biocare Medical, Concord, CA, USA 
Tetramethylethylenediamine (TEMED) Sigma-Aldrich Co, Poole, Dorset, UK 
TRI Reagent Sigma-Aldrich Co, Poole, Dorset, UK 
Tris-Cl Melford Laboratories Ltd, Suffolk, UK 
TRITC conjugated goat anti-rabbit IgG Sigma-Aldrich Co, Poole, Dorset, UK 
Trion Sigma-Aldrich Co, Poole, Dorset, UK 
Trypsin Sigma-Aldrich Co, Poole, Dorset, UK 
Tween 20 Melford Laboratories Ltd, Suffolk, UK 
Vectastain Universal ABC kit Vector Laboratories Inc, Burlingame, 
CA, USA 
ZnCl Sigma-Aldrich Co, Poole, Dorset, UK 
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Table 2.3.Source of general plastic consumables 
 
Hardware/Software Supplier 
0.4 μm filtration unit Sigma-Aldrich Co, Poole, Dorset, UK 
16-well chamber slide (for 
Immunohistochemistry) 
Nalge NUNC International,Rochester, 
NY 
25cm
2
 and 75cm
2
 culture flasks Cell Star, Germany 
Amplifluort detection system Intergen, England, UK 
Cytodex 2 beads Sigma-Aldrich Co, Poole, Dorset, UK 
ECIS (Electrical Cell-Substrate 
Impedance Sensing), Ztheta 
Applied BioPhysics Inc., Troy, New 
York, USA 
ECIS array 96W1E Applied BioPhysics Inc., Troy, New 
York, USA 
Electroporation cuvette Euro Gentech, Southampton, UK 
iCycler iQ system Bio Rad, Hercules, CA, USA 
Image J Public Domain 
Lecia DM IRB microscope Lecia GmbH, Bristol, UK 
Microscope heated plate Lecia GmbH, Bristol, UK 
Microsoft Excel Microsoft In., Redmond, WA, USA 
Neubauer haemocytometer counting 
chamber 
Reichert, Austria 
Nitrocellulose membrane Hybond C, Ammersham, Cardiff 
Partec CyFlow® FloMax software Partec GmbH, Munster, Germany 
Partec CyFlow® SL flow cytometer Partec GmbH, Munster, Germany 
Protein spectrophotometer BIO-TEK, Wolf Laboratories, York, UK 
RNA spectrophotometer BIO-TEK, Wolf Laboratories, York, UK 
Ultra-Turrax T8 Homogenizer IKA Labortechnik, Staufen, Germany 
UV light chamber Germix  
UVI-doc system UVITech, Inc., Cambridge, England, UK 
UVITech imager UVITech, Inc., Cambridge, England, UK 
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Table 2.4.Peptide Receptors and inhibitors 
Products Supplier Catalogue number 
Kisspeptin-10 (human) Tocris Bioscience, 
Bristol, UK 
 
No. 2570 
 
Kisspeptin-234 Tocris Bioscience, 
Bristol, UK 
No. 3881 
ERK inhibitor Ⅱ, 
FR180204 
Calbiochem, Germany 328007-1MG 
 
Table 2.5.Antibodies 
Antibody for Species Source Catalogue 
number 
Kiss-1 Mouse monoclonal 
IgG 
Santa Cruz 
Biotechnology, 
Inc. U.S.A. 
Sc-101246 
GPR54 (Kiss-1R) Goat polyclonal IgG Santa Cruz 
Biotechnology, 
Inc. U.S.A. 
Sc-48220 
Anti-Mouse-IgG Antibody produced in 
rabbit 
Sigma-Aldrich Co, 
Poole, Dorset, UK 
100M4783 
Anti-Goat-IgG Antibody produced in 
rabbit 
Sigma-Aldrich Co, 
Poole, Dorset, UK 
089K4773 
p-Tyr (PY20) Mouse monoclonal 
IgG2b 
Santa Cruz 
Biotechnology, 
Inc. U.S.A. 
Sc-508 
Protein A/G 
PLUS- Agarose 
Immunoprecipitation 
reagent 
Santa Cruz 
Biotechnology, 
Inc. U.S.A. 
Sc-2003 
 
 
  
62 
 
2.2 Preparation of Reagents, Buffers and Standard solutions 
The following solutions were routinely used throughout this study:   
 
2.21 Solutions for use in molecular biology 
 
Tris- Boric acid- EDTA (TBE) Electrophoresis Buffer 
The concentration of the stock solution of TBE (1.1M Tris; 900mM Borate; 25mM 
EDTA; pH 8.3) was prepared at 5 times concentrate. The solution was made by 
dissolving 540g Tris- Cl (Melford Laboratories Ltd, Suffolk, UK), 275g Boric acid 
and 46.5g EDTA in 10 litres dH2O.The pH was adjusted to 8.3 using NaOH and then 
stored at room temperature. A working solution was prepared by dissolving for 5 
times (200ml of stock solution in 800ml of distilled water).  
 
DEPC water 
A stock solution was prepared by dissolving 500μl of Diethyl Pyrocarbonate (DEPC) 
(Sigma-Aldrich, Inc., Poole, Dorset, England, UK) in 9500μl distilled water and 
autoclaved before use. 
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Loading buffer 
25mg of bromophenol blue (Sigma-Aldrich, Inc., Poole, Dorset, England, UK) and 4g 
sucrose (Fisons Scientific Equipment, Loughborough, UK) were dissolved in 10ml of 
distilled water and stored at 4
o
C (used for DNA electrophoresis). 
 
Preparation of Ethidium Bromide (EtBr) Staining Solution 
The working solution was prepared by dissolving 100mg Ethidium Bromide in 10ml 
of distilled water (strength: 10mg/ml). The solution was mixed well to dissolve the 
ethidium bromide powder (Sigma-Aldrich, Inc., Poole, Dorset, England, UK) and 
stored in aluminium foil out of the light.  
 
2.2.2 Solutions for use in cell culture 
 
Preparation of Complete Cell Culture Medium 
This solution was prepared by mixing50ml of heat inactive tedfoetal calf serum (FCS) 
(Sigma-Aldrich Company, LTD Irvine, Ayrshire, UK) in 500ml DMEM/F12 with 
2mM L- glutamine (Sigma-Aldrich Company, LTD Irvine, Ayrshire, UK). Five 
milliliter of antibiotics were added and the medium was then stored for up to a month 
at 4ºC. 
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Balanced Salt Solution (BSS) 
A ten litre stock solution of 1 time BSS (137mM NaCl, 2.6mM KCl, 1.7mM 
Na2HPO4 and 8mM KH2PO4) was prepared by dissolving 79.5g NaCl, 2.2g KCl, 1.1g 
Na2HPO4 and 2.1g KH2PO4 into distilled water. The pH was adjusted to 7.2 with 1M 
NaOH (Sigma-Aldrich, Inc., Poole, Dorset, England, UK) before use. 
 
Preparation of 0.05M EDTA 
A stock solution was prepared by dissolving 40g NaCl, 1g KCl (Fisons Scientific 
Equipment, Loughborough, UK), 5.72g Na2HPO4 (BDH Chemical 
Ltd., Poole, England, UK), 1g KH2PO4 (BDH Chemical Ltd., Poole, England, UK) 
and 1.4g EDTA (DuchefaBiochemie, Haarlem, The Netherlands) in 5L of dH2O. The 
pH was adjusted to 7.4 by adding Sodium Hydroxide (NaOH) and autoclaved before 
use. 
 
Trypsin (25mg / ml) 
A stock solution of trypsin was prepared by dissolving 500mg trypsin in 20ml 0.05 
EDTA and then filtered through a 0.2µm mini start filter (Sartorious, Epsom, UK). 
The preservation condition was -20ºC. The working solution was prepared by further 
dissolving 250µl of trypsin solution in 10ml of 0.05 EDTA and used to detach the 
cells. The preservation condition was 4ºC. 
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Preparation of100X Antibiotics 
Three point three grams of penicillin, 5g streptomycin and 12.5mg Amphotericin B in 
DMSO were dissolved in 0.5L of BSS and filtered. Five millitre was then added to a 
500ml bottle of DMEM Ham’s F12media. 
 
2.2.3 Solutions for use in cloning 
LB agar 
Ten grams tryptone (DuchefaBiochemie, Haarlem, The Netherlands), 5g yeast extract 
(DuchefaBiochemie, Haarlem, The Netherlands), 15g agar, and 10g NaCl were 
dissolved in 1L of distilled water. The pH value was adjusted to 7.0 and then the 
media was autoclaved and stored at room temperature until use. For making a LB 
agar dish, LB Agar was melted in a microwave. Appropriate antibiotic was added to 
LB media which was cooled down to about 65
o
C. The Agar solution was then poured 
into 10cm
2
 Petri dishes (BibbySterilinLtd., Staffs, UK). The LB Agar dishes were 
stored at 4
o
C until hardened. 
 
LB broth 
Ten gramstryptone, 10g NaCl and 5g yeast extract was dissolved in 1L of distilled 
water. After adjusting the pH7.0, the media was autoclaved. Antibiotics were added 
prior to use. 
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2.2.4 Solutions for use in protein work 
 
Preparation of Cell Lysis Buffer 
The Stock Solution was prepared by dissolving 2mM CaCl2, 0.5% Triton X-100, 
1mg/ml aprotinin, 1mg/ml leupeptin and 10mM Sodium Orthovanadate in 50ml 
distilled water. The solution was prepared as a 2× concentrate and stored at 4ºC.The 
working solution was prepared by diluting 10ml of the stock solution in 6.6ml of 
inhibitor buffer, 200µl of PMSF, 80µL 10mM CaCl, 3ml of 10%Triton X-100 made 
up to 20ml with distilled water. 
 
Ammonium Persulphate (APS) 
The 10% APS solution wasfreshly prepared, prior to use, by dissolving 1g APS in 
10ml distilled water and then stored at 4
o
C. 
 
Tris Buffered Saline (TBS) 
A ten time concentration stock solution was prepared by dissolving. 24.228g Tris-Cl 
and 80.06g NaCl in 1 litre of distilled water. This solution contains 200mM Tris and 
1.37M of NaCl. The pH value was adjusted to 7.4 using HCL and then stored at room 
temperature. 
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Running buffer (for SDS-PAGE) 
The stock solution (10X ) was prepared by dissolving 303g of Tris, 100g SDS 
(MelfordLaboratoriesLtd., Suffolk, UK) and 1.44kg of Glycine (Melford Laboratories 
Ltd., Suffolk, UK) in 10L distilled water and adjusting the pH value to 8.3 using 
NaOH. The working solution diluted to 1x running buffer with distilled water before 
use. 
 
Transfer Buffer (for Western Blot) 
A stock solution of total 5 litres was prepared by dissolving 15.15g Tris, 72g Glycine 
and 1 litre of methanol (Fisher Scientific, Leicestershire, UK) in 4L distilled water. 
 
Preparation of Fluorescamine for protein quantitation 
The working Solution was prepared fresh by dissolving 3mg of Fluorescamine in 
10ml acetone. 
 
Preparation of Inhibitor Buffer 
Two point seventy six grams sodium nitrate, 630g sodium fluoride, 5.58g EDTA, 10g 
Na2H2PO4 and 3× 10
5
 Units of aprotonin were made up to 1 L distilled water, 
prepared as a 3× concentrate and stored at 4ºC.  
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Preparation of 0.1% Comassie Blue 
One gram of Coomassie Blue, 400ml Methanol and 100ml Acetic acid were dissolved 
in distilled water with making up to 1L. It is then filtered and stored at room 
temperature. 
 
Preparation of SDS-PAGE Gel 
 
Table 2.6.Solution for preparing resolving gels for Tris-glycine SDS-plolyacrylamide 
gel electrophoresis  
Solution components Component volumes [116] per gel mold 
volume of 
 
20ml 
8% 
 
H2O 9.3 
30% acrylamide mix 5.3 
1.5 m Tris (pH 8.8) 5 
10% SDS 0.2 
10% ammonium persulfate 0.2 
TEMED 0.012 
10% 
 
H2O 7.9 
30% acrylamide mix 6.7 
1.5 m Tris (pH 8.8) 5 
10% SDS 0.2 
10% ammonium persulfate 0.2 
TEMED 0.008 
12% 
 
H2O 6.6 
30% acrylamide mix 8 
1.5 m Tris (pH 8.8) 5 
10% SDS 0.2 
10% ammonium persulfate 0.2 
TEMED 0.008 
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Table 2.7.Solution for preparing 5% stacking gels for Tris-glycine 
SDS-polyacrylamide gel electrophoresis 
Solution components Component volumes [116] per gel mold 
volume of 
 
10ml 
H2O 6.8 
30% acrylamide mix 1.7 
1.5 m Tris (pH 6.8) 1.25 
10% SDS 0.1 
10% ammonium persulfate 0.1 
TEMED 0.01 
Table 2.6 and 2.7 are modified from Harlow and Lane (1988); acrylamide mix and 
TEMED are supplied by Sigma-Aldrich, St. Louis, USA. 
 
2.3 General methods 
 
2.3.1 Cell Culture, maintenance and Storage 
Cell lines were cultured in Dulbecco’s Modified Eagle’s medium (DMEM/ Ham’s 
F-12 with L-Glutamine; Sigma-Aldrich, Inc., Poole, Dorset, England, UK), pH 7.3 
containing 2mM L-glutamine and 4.5mM NaHCO3, supplemented with 10% heat 
inactivated Foetal Bovine Serum (Sigma-Aldrich, Inc., Poole, Dorset, England, UK), 
and antibiotics. Cells were cultured in either 25cm² or 75cm² tissue culture flasks 
(Greiner Labortechnik, Germany) cultured in depending on the required application. 
Culture flasks were loosely capped allowing for gaseous exchange and then placed 
horizontally in a humidified incubator (98% humidification achieved with water tray 
in the incubator) (Sanyo Electric, Japan) at 37ºC with 5% CO2 (act as a buffer with 
the NaHCO3) in air. 
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Cell lines transfected with the pEF6/His plasmid vector were firstly cultured in 
5μg/ml blasticidin S (Melford laboratories ltd, Suffolk, UK) selection media. After 
selection, the cell lines were transferred into 0.5μg/ml blasticidin S maintenance 
media. 
Confluency of cell lines were visually measured using the light microscope. Cells 
were routinely sub-cultured after reaching 80-90% confluency. All handling of cells 
were carried out in a Class II Laminar Flow Cabinet with autoclaved and sterile 
equipment.  
 
2.3.2 Trypsinization and Counting of cell lines 
•The tissue culture flask was taken out from incubator. The waste medium was 
removed by aspiration .Following this, the flasks were rinsed briefly with 5ml of 
EDTA in Balanced Salt Solution buffer to remove remaining serum which would 
inhibit the action of trypsin. 
•Approximately, 1-2 ml of trypsin / EDTA solution (Trypsin0.01% (w/v) and EDTA 
0.05% (w/v) in HBSS buffer) was added to the flasks which were subsequently 
incubated for 5 minutes at 37ºC, to allow cell detachment.  
•Once detached, 5ml of DMEM was added to each flask to neutralise trypsin. The cell 
mixture was transferred to a new 30 ml universal container (Greiner Bio-One Ltd, 
Gloucestershire, UK). The cell pellet was collected from the cell suspension by 
centrifugation (1,780 rpm for 8 minutes). 
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•Cell pellets were re-suspended in 5mls of DMEM solution for re-culturing or for 
immediate experimental work  
•Cell counts were performed using a Neubauer haemocytometer counting chamber 
(Mod-FuchsRosenthal, Hawksley, UK) under an upright microscope (Reichert, 
Austria) at ×10 objective magnification. 
• The haemocytometer calculated the number of cells in a predetermined volume of 
fluid so to obtain the quantity of cells per millilitre. The haemocytometer chamber 
was divided into 9 squares with dimensions of 1mm × 1mm ×0.2mm. For ensuring 
the consistency of cell density and reducing the errors, four corners of 9 squared areas 
were counted. The number of cells was calculated by using the following equation: 
 
Cell number/ml= (the sum of the number of cells in four corners ÷ 8) x (1 x 10
4
)   
 
2.3.3 Storage of cell lines in liquid nitrogen and cell resuscitation 
The cell lines were stored in liquid nitrogen by re-suspending the cell pellet in 
complete medium (DMEM/HAM’s F12) with 10% dimethylsulphoxide (DMSO; 
Fisons, UK) at a cell density of 1×10
6
 cells/ml. One millilitre of cell suspension was 
transferred into pre-chilled CRYO.S
TM
 tubes (Greiner Bio-One, Germany) and then 
frozen at -80ºC for 1 day before storage in liquid nitrogen (-196ºC). 
To resuscitate the frozen cells, the CRYO.S
TM
 tube was removed from liquid nitrogen 
and thawed rapidly in a 37ºC water bath. The cell suspension was transferred into a 
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universal container containing 5ml of pre-warmed DMEM/HAM’s F12 and incubated 
at 37ºC for 10 minutes and then centrifuged at 1600 rpm for 5 minutes. The medium 
was removed by aspiration. 5ml of fresh DMEM/Ham's F12 to added to the pellet to 
resuspend the cells. The above procedure was repeated twice to remove any possible 
trace of DMSO. Finally, the cell pellet was re-suspended in 5ml of DMEM/Ham's F12 
and transferred to a 25cm² tissue culture flasks. The cells were incubated at 37ºC with 
98% humidification and 5% CO2.  
 
2.4 Methods for RNA detection 
 
2.4.1 Total RNA isolation 
Required of reagents:  
 RNA isolation reagent 
 Chloroform 
 Isopropanol 
 75% Ethanol 
 DEPC treated water 
 
Ribonucleic acid (RNA) is present within the nucleus, cytoplasm and mitochondria of 
all living eukaryotic cells. Ribosomal RNA (rRNA), transfer RNA (tRNA) and 
messenger RNA (mRNA) are the three main subtypes of RNA. mRNA isof particular 
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importance, as it carries the genetic information for subsequent protein synthesis. The 
presence of specific mRNA therefore gives a good indication of which proteins are 
being produced by the cell at the transcript level. 
The protocol of RNA isolation was carried out using the Tri Reagent kit 
(Sigma-Aldrich, Inc., Poole, Dorset, England, UK). 
• After the confluency of cells in a monolayer reached approximate 90%, the medium 
was emptied and replaced with RNA reagent (1ml / 5-10 x 10
5
 cells) tolyse the cells. 
The cell lysate was then transferred into a 1.8 ml eppendorf tube, which was further 
incubated for 5 minutes at 4
o
C 
• To the tube, 0.2ml (per 1ml of RNA reagent) chloroform (Sigma-Aldrich, Inc., Poole, 
Dorset, England, UK) was added. The tube was vigorously mixed for 15 seconds and 
incubated at 4
o
C for 5 a further minute. 
• The resulting homogenate was then centrifuged at 12,000rpm for 15 minutes at 4oC 
(Boeco, Wolf laboratories, York, UK). The spinning resulted in the separation of the 
lysate into three phases: a lower pink organic phase containing protein, an inter phase 
containing DNA, and an upper aqueous phase containing RNA in the acidic 
environment.  
• The aqueous phase containing RNA was carefully transferred into a fresh eppendorf 
tube before adding an equal volume of isopropanol (Sigma-Aldrich, Inc., Poole, 
Dorset, England, UK). The homogenate was then incubated for 10 minutes at 4
o
C. 
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After centrifuging the samples at 12,000rpm for 10 minutes at 4
o
C, it deposited a 
white pellet (RNA precipitates) on the bottom of the eppendorf tube. 
• After carefully removed the supernatant, the RNA precipitate was washed twice with 
1ml 75% ethanol in DEPC water. Each wash was carried out by adding 1ml 75% 
ethanol, vortexing, and centrifuging the samples at 7,500rpm for 5 minutes at 4
o
C. 
• The RNA pellet was briefly dried at 55oC for 5-10 minutes in a Techne, Hybridiser 
HB-1D drying oven (Wolf laboratories, York, UK), in order to evaporate the 
remaining ethanol. 
• Finally, the RNA pellet was dissolved in 50-100μl of DEPC water (Diethyl 
pyrocarbonate, Sigma). The impact of DEPC, as a histidine specific alkylating agent, 
is to inhibit the hydrolysis of RNases on RNA. 
 
2.4.2 RNA Quantification 
The concentration and purity of the resulting RNA was determined by measuring its 
absorbance at wavelength of A260nm/A280nm (WPA UV 1101, Biotech Photometer). 
A260nm/A280nm ratio gave an estimate of the purity of the RNA, through 
calculating the difference of absorbance between the RNA sample and DEPC water 
(as a blank), using a quartz cuvettes (Optiglass limited, Essex, UK).The 
spectrophotometer detected the concentration of ssRNA (ug/ul) at a wave length of 
260nm. The concentration of RNA samples were then standardised using DEPC water 
and subsequently stored at -80ºC for future use. 
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2.4.3 Reverse Transcription of RNA for production of cDNA 
Reverse transcription (RT) leads to synthesis of complementary DNA (cDNA) from 
RNA. It is followed by polymerase chain reaction (PCR) and the two processes 
together are known as RT- PCR. RT- PCR is a sensitive technique for the analysis of 
mRNA as compared with other techniques (e.g. Northern blots, RNA dot blots). Only 
a small amount of RNA is needed for this technique and it is more sensitive and rapid 
in detecting genetic sequences compared with other procedures. In this study, RT- 
PCR was performed using the iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories, 
California, USA) according to manufacturer’s instructions. Each reaction was set up 
in 200μl PCR tubes (ABgene, Surrey, UK): 
Component Volume Each reaction 
5x iScript Reaction Mix 4μl 
iScript Reverse Transcriptase 1μl 
Nuclease-free water Xμl 
RNA template (0.5μg/μl) Xμl 
Total volume 20μl 
 
The reaction was carried out in a T-Cy Thermocycler (Creacon Technologies Ltd, The 
Netherlands). The condition of the reaction is shown below: 
5 minutes at 25
o
C 
30 minutes at 42
o
C 
5 minutes at 85
o
C 
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After the completion of the reaction, the cDNA was diluted with PCR water by a 
factor of 1:4 and stored at -20
o
C for further use or used immediately as template for 
conventional PCR. 
 
2.4.4 Polymerase Chain Reaction (PCR) 
Polymerase Chain Reaction is a simple technique to amplifying DNA and produce a 
desired amount from a single target DNA molecule and was invented by Kary Mullis 
in 1983[117].  
 
Principle:  
• It relies on the principle of a chain reaction in which each target molecule is subject 
to further amplification. 
• Two short DNA sequences (oligonucleotides- Forward and Reverse primers), which 
bind to the template DNA by base pairing, are required and are complementary to a 
defined sequence on each of the two strands of the DNA. These primers are aligned 
with the 3’ ends facing each other. 
• In this study, the target gene of interest was amplified by PCR using the REDTaq™ 
Ready Mix PCR Reaction mix (Sigma-Aldrich, Inc., Poole, Dorset, England, UK). A 
reaction (16μl) was set up in PCR tubes below: 
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Components Volume 
cDNA template 2μl 
Forward primer (working concentration of 1 μM) 1μl 
Reverse primer (working concentration of 1 μM) 1μl 
2x REDTaq
TM
ReadyMix 8μl 
PCR H2O 4μl 
 
• The mixture of PCR reaction was placed in a 2720 Thermo cycler (Applied           
Biosystems).  
• A control reaction was included where PCR water was added instead of cDNA 
template (negative control). 
• The conditions of reaction were showed below: 
Steps Temperature Time Cycles 
Initial denaturation 94
o
C 5-10 minutes 1 
Denaturation 94
o
C 40 seconds 30-42 
Annealing 
 
Primer specific 
temperature 
30-40 seconds 
Extension 72
o
C 40 seconds 
Final extension 72
o
C 7-10 minutes 1 
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2.4.5 Agarose gel electrophoresis and DNA visualisation 
Agarose gel electrophoresis is the most common method of DNA separation and 
analysis. The basis of this technique is to separate the amplified DNA on the basis of 
charge and size using an electrical current. 
Depending on the size of PCR products, an appropriate agarose gel (from 0.8% to 2% 
agarose powder in TBE buffer) was chosen (Melford Chemicals, Suffolk, UK). 
Agarose gel was melted by heating (e.g. microwave). After completely melting, the 
liquid gel solution was poured into electrophoresis cassettes (Scie-Plas Ltd., 
Cambridge, UK) containing well forming combs. A low percentage agarose gel (0.8%) 
was used to separate PCR products with a high number of base pairs (>500bp) and 2% 
agarose gel to separate DNA fragments with low number of base pair (<500bp). 
Once the gel had set (30-40 minutes) TBE buffer was poured over the gels to exceed 
5mm of the gel surface. 8μl DNA ladder (1kb)(Cat No.M106R; GenScript USA Inc.) 
or 8-10μl of each sample were loaded into the wells. 
The gel was then run at a constant voltage of 100 volts (Gibco BRL Power pack 
model 250EX, Life Technologies) for 35-55 minutes or until the samples had 
migrated about two thirds down the agarose gel (depending on the PCR product size). 
The PCR product was then stained using ethidium bromide solution for around 15 
minutes with continuous agitation to ensure uniform staining. Ethidium bromide is a 
dye, which binds to double stranded DNA between the base pairs and fluoresces when 
exposed to UV light. This was sometimes followed by destaining in distilled water for 
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30-60 minutes if it was deemed necessary for removal of strong background staining 
on the agarose gel from the fluorescent dye.  
After staining the PCR products the gels were visualised using an Ultra Violet 
Transilluminator (UVP, Cambridge, UK) and photographed using the thermal printer 
or scanned for storing images electronically. 
 
2.4.6 Quantitative RT-PCR (Q-PCR) 
PCR has become a crucial technique involved in biomedical research in most 
laboratories since 1990s. The development of real-time Q-PCR, which added a new 
dimension to PCR, has significantly improved the quantification of nucleic acid 
samples. Real-time quantitative polymerase chain reaction (QPCR) was developed in 
1992, which allowed quantification of DNA, cDNA, or RNA templates as the 
products accumulates with each cycle of amplification. It had excellent sensitivity and 
specificity to detect specific gene sequences in a broad dynamic range. On the basis 
of the detection of a fluorescent reporter molecule that increases during PCR 
amplification (the level of fluorescence detected is directly proportional to the PCR 
product yield). The level of fluorescence was continuously monitored by a sensitive 
camera attached to a computer and hence the term ‘real-time’. 
The current study quantified transcript copy number of the gene transcript of interest 
using the Ampliflour™ Uniprimer™ system (Intergen company®, New York, USA). 
The ampliflour probe consisted of a 3’ region specific to the Z-sequence 
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(ACTGAACCTGACCGTACA) present on the target specific primers, and a 5’ 
hairpin structure labelled with a flurophore (FAM), described by Nazarenko et al. in 
1997 [118]. The flourophore was linked to an acceptor moiety (DABSYL), which 
acted to quench the fluorescence emitted by the flourophore, thus preventing any 
signal from being detected in this hairpin structure. 
During PCR, the probe acted as a template for DNA polymerisation in which DNA 
polymerase uses its 5’-3’ exonuclease activity to degrade and unfold the hairpin 
structure, thereby sufficient fluorescence was allowed to be emitted and detected 
through by disruption of the energy transfer between flourophore and quencher. The 
fluorescent signal emitted was directly related to the amount of DNA, which had been 
amplified during each PCR cycle. 
Each amplified reaction was set up below: 
Component Volume 
Forward primer 0.3μl (10pmol/μl) 
Reverse Z primer 0.3μl (1pmol/μl) 
Ampliflour probe 0.3μl (10pmol/μl) 
2x iQ
TM
Supermix 5μl 
cDNA and PCR H2O 4μl 
Each sample was loaded into a 96-wells plate (Applied biosystems
TM
 Life 
Technologies LTD, Paisley, UK); Standards were usually arranged in the first row 
(ranging from copy numbers of 10
1
-10
8
), covered with optically clear sticky film from 
ABI. The 96-wells plate was placed in an ABI StepOne Plus thermal cycler (Figure 
2.1A) and the reaction was detected by software designed by Applied biosystems 
(ABI) laboratories, UK, with the conditions shown in the following: 
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Steps Temperature Time Cycles 
Initial denaturation 94
o
C 5minutes 1 
Denaturation 94
o
C 10 seconds 80-90 
 
Annealing 55
o
C 35 seconds 
Extension 72
o
C 20 seconds 
The fluorescent signal was detected at the annealing stage by a camera where its 
geometric increase directly correlated with the exponential increase of product. This 
was then used to determine a threshold cycle (TC) for each reaction and the transcript 
copy number depended on when the fluorescence detection reached this specific 
threshold. 
The degree of fluorescence emitted by a range of standards of a known transcript 
copy number was then used to compare to the amount emitted by each sample, 
allowing for the transcript copy number in each sample to be accurately calculated. 
Furthermore, the transcript copy number of each sample was then normalised against 
the detection of β-actin or GAPDH copy numbers. The procedure was repeated at 
least three times. A typical example of the quantitative reaction is shown 
inFigure2.1.B. 
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Figure 2.1.A.StepOne Plus instrument used in the present study. 
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Figure 2.1.B. Qualification of transcript level. A. The levels of transcript from 10
1
 to 
10
8
 copy number of standard samples are detected using ABI's StepOne Plus, from 
ABI. B. Subsequent generation of a standard curve from these samples. 
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2.4.7TaqMan® probe based assay 
This is an alternative technique to Amplifor. TaqMan
®
 probes were used during the 
process of PCR amplification so as to detected the presence and quantify the amount 
of specific target sequences. These Probes were designed as oligonucleotides, which 
had been tagged with one fluorescent group (6-carboxyfluorescein [6-FAM]) and one 
fluorescence quenching group (6-carboxy-tetramethyl-rhodamine) at the 5’ end and 
the 3’ end respectively. These probes had a higher Tm (Melting Temperature) than the 
primers, and during the extension phase must be 100% hybridized for success of the 
assay. The close proximity of the quencher to the reporter fluorochrome prevented its 
natural fluorescence. However, as the PCR progresses the probe bound to the PCR 
products and Taq polymerase cleaved the reporter fluorochrome and the quencher 
from the probe, releasing the sequence specific fluorescent signal (reporter 
fluorochrome). The amount of fluorescence released during the amplification cycle 
was proportional to the amount of PCR product generated in each cycle. The 
operating principle of TaqMan
®
 probes is shown below (Figure 2.2.) 
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Figure 2.2.The TaqMan
®
 probe based APCR assay 
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2.5 Methods for protein detection 
 
2.5.1 Protein extraction and preparation of cell lysates 
• When cells had reached an adequate confluency, the cell monolayer was first 
washed with BSS buffer and then scrapped off using a cell scraper. The typical way to 
quantify the number of cells was to collect the cells second day after the overnight 
cultivation of the consistent number of each cell line. 
•The cell suspension was transferred into a universal tube. 
• The supernatant was removed after centrifuging (1,800 rpm) for 8 minutes. The cells 
were similarly washed in BSS twice. 
• The cell pellet was then resuspended in 200-300μl (depending on pellet size) lysis 
buffer. 
• The suspension was then transferred into a 1.8ml eppendorf tube and rotated on a 
Labinco rotating wheel (Wolf laboratories, York, UK) at room temperature for one 
hour so as to allow for cell lysis. 
• The resulting lysate was centrifuged at 13,000rpm for 15 minutes. The supernatant 
was transferred to a fresh microfuge tube. The pellet that contained insolubles and any 
unwanted cell debris was discarded.  
• The protein samples were then either quantified for SDS-PAGE as explained below, 
or stored at -20
o
C until further use. 
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2.5.2 Protein quantification and preparation of samples for SDS-PAGE 
In order to standardised the protein sample concentration for Western blotting, the 
amount of protein in each sample was quantified by following the protocol outlined in 
the Bio-Rad DC Protein Assay kit (Bio-Rad laboratories, Hemel Hampstead, UK). 
Briefly, 
• In a 96 well plate, 50mg/ml of bovine serum albumin (BSA) standard (Sigma, 
Dorset, UK) was serially diluted in the same lysis buffer, to produce a concentration 
gradient from 0.78mg/ml to 50mg/ml and used to set up a standard curve of protein 
concentration. 
• Five microlitres of either protein sample or standard was added into fresh wells, 
before 25μl of ‘working reagent A’ (prepared by adding 20μl of reagent S per 
millilitre of reagent A), and then 200μl of reagent B was added to each well. 
• After mixing the samples, the plate was left at room temperature for 30-45 minutes 
in order to allow the colorimetric reaction to take place. Once this was complete, the 
absorbance of each of the wells was measured at 620nm using the ELx800 plate 
reading spectrophotometer (Bio-Tek, Wolf laboratories, York, UK). 
• Using the absorbance of the standards to set up a standard curve, and by comparing 
standard to the absorbance of the samples, protein concentration of the test samples 
was determined. The samples were then diluted in an appropriate amount of lysis 
buffer in order to normalise them to the required final concentration of 1.0-2.0mg/ml. 
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• This was then further diluted with 2x Lamelli sample buffer concentrate 
(Sigma-Aldrich, St Louis, USA) in a ratio of 1:1 before the samples were denatured 
by boiling at 100
o
C for 5-10 minutes, and either loaded onto a SDS-PAGE gel or 
stored at -20
o
C until further use. 
 
2.5.3 Western blotting: transferring proteins from gel to nitrocellulose 
membrane 
•Once SDS-PAGE was completed, the protein samples were transferred onto a 
nitrocellulose membrane by Western blotting. The electrophoresis equipment was 
disassembled and the gel pried out from in between the two glass plates before 
discarding the stacking gel. The resolving gel was then placed on the bottom graphite 
base electrode in a SD20 SemiDry Maxi System blotting unit (SemiDRY, Wolf 
Laboratories, York, UK) on top of 3 pieces of 1x transfer buffer pre-soaked filter 
paper (Whatman International Ltd., Maidstone, UK), and 1 sheet of Hybond 
nitrocellulose membrane (Amersham Biosciences UK Ltd., Bucks, UK). 
• An additional 3 sheets of pre-soaked filter paper were placed on top of the gel to 
form a sandwich arrangement of paper: membrane: gel: paper, as shown in figure 
2.3.Electroblotting was then carried out at 15v, 500mA, and 8W for around 20 
minutes to an hour (depending on protein size).  
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Once the proteins had been sufficiently transferred, the membranes were placed in the 
Ponseau S solution, which would temporarily stain the protein band. This would 
allow visualisation of transferred protein and protein markers. 
The membrane was blocked over night at 4
o
C in 10% skimmed dry milk solution (10% 
milk powder and 0.1% polyoxyethylene (20) sorbitanmonolaurate (Tween 20) 
(Sigma-Aldrich, St Louis, USA) in 50ml TBS. This acted to block the proteins onto 
the membrane for subsequent antibody probing. 
 
 
Figure 2.3.Diagrammatic sketch of the electrophoresis equipment transferring 
proteins from gel to nitrocellulose membrane. 
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2.5.4 Protein detection using specific Immuno-probing 
•The membrane was transferred into 50ml falcon tubes (Nunc, Fisher-Scientific, 
Leicestershire, UK) ensuring that the membrane surface that had been in contact with 
the gel was facing upwards. 10% milk blocking solution was added to the membranes 
and incubated for an hour at room temperature on a roller mixer (Stuart, 
Wolf-Laboratories, York, UK). 
•Once this procedure was complete, the 10% milk solution was poured off and 
replaced with 10ml of3% milk solution (3% milk powder, 0.1% Tween 20 in TBS) for 
15 minutes. This was followed by incubation of the membranes for an hour at room 
temperature, with primary antibody diluted 1:500 in 5mls of 3% milk solution. 
• After pouring off the primary antibody solution, any remaining unbound antibody 
was washed off twice in 3% milk solution at 15 minute intervals. 
• Once washing was completed, the membranes were further incubated with 5ml of 
1:1000 HRP (horse raddish peroxidase) conjugated secondary antibody diluted in 3% 
milk. This was carried out for an hour at room temperature on a roller mixer. 
• This was followed by two 15 minute washes in 10ml of 3% milk solution, and two 
15 minute washes with Tween TBS (0.2% Tween 20 in TBS), in order to wash off any 
unbound secondary antibody. 
• A final two 15 minute washes with TBS was carried out so as to remove any residual 
detergent, before placing the membrane in weighing boats containing TBS solution, 
ready for chemiluminescent detection. 
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2.5.5 Chemiluminescent protein detection 
Chemiluminescent protein detection was carried out using the chemiluminescence 
detectionkit (Luminata, Millipore), which consisted of a highly sensitive 
chemiluminescent substrate that detected the horseradish peroxidase (HRP) used 
during the Western blot procedure. The protocol was carried out as follows: 
• One millilitre regent was added into the weighing boat containing the membrane to 
be analyzed and developed for 5 minutes at room temperature with constant agitation, 
the membrane was carefully removed from the solution using forceps. 
• Any excess solution on the membrane was then drained over a piece of tissue paper 
and transferred into a fresh weighing boat. The chemiluminescent signal was detected 
using an UVITEC Imager (UVITEC Inc., Cambridge, UK) which contains both an 
illuminator and a camera linked to a computer, which then captures and stores the 
image. 
• Each membrane was subjected to varying exposure times until the protein bands 
were sufficiently visible. These images were then captured and further analyzed with 
the UVI band software package (UVITEC, Cambridge, UK), which allowed for 
protein band quantification. 
• In this study, GAPDH was used as a housekeeping gene and run alongside any other 
proteins to be detected, so as to allow for additional normalisation of the samples, and 
to compensate for any other negligible inaccuracies which might have occurred 
during the protein quantitation and loading process. The glyceraldehyde 3-phosphate 
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dehydrogenase (GAPDH) was used due to its highly abundant and conserved nature 
within eukaryotic cells. It is one of the most widely employed and accepted internal 
controls in scientific research. 
• In order to confirm reliability of the results, each Western blot was carried out three 
times and the protein bands quantified and standardised against GAPDH, followed by 
calculation of mean values and graphical presentation of the results. 
 
2.5.6 Preparation of immunoprecipitates 
Immunoprecipitation (IP) can be used for analysing intracellular phosphorylation that 
occurs in downstream signaling cascades. The process involves adding a specific 
antibody targeted against a protein of interest within a cell lysate. This is then mixed 
with sepharose or agarose bonded staphylococcal protein A, protein G, or both, in 
order to collect the ensuing protein-antibody complexes. These complexes are then 
centrifuged to induce precipitation, run on an SDS-PAGE gel, and evaluated using 
immunoprobing.  
 
This process was carried out as follows:  
• Antibody targeted against a protein of interest was added to the cell lysate samples 
before being incubated at 4
o
C for 1 hour on a Labinco rotating wheel. 
• Following incubation, 20μl of conjugated A/G protein agarose beads (Santa Cruz 
Biotechnology, supplied by Insight Biotechnologies Inc, Surrey, England, UK) was 
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added to each sample and placed back on the wheel for another hour to allow 
antibody-protein complexes to bind to the beads. 
• Centrifuging at 8,000 rpm for 5 minutes to remove any unbound protein or excess 
antibodies present in the supernatant. The protein pellet was subsequently washed 
twice with 300μl lysis buffer before being resuspended in 40-60μl of 1x sample buffer, 
and boiled for 5-10 minutes. The resulting samples were then run on SDS-PAGE, 
transfered from gel to nitrocellulose membrane, probed by specific antibodies 
(primary antibody and secondary antibody) and imaged chemiluminescently followed 
by procedure given in sections 2.6.2- 2.6.5. 
 
2.5.7 Gelatin zymography assay 
1x10
6
 cells were counted and seeded to a tissue culture flask and incubated overnight. 
After incubation, the cells were washed once with 1x BSS followed by a wash with 
serum-free DMEM/Ham's F12 and then either incubated in serum-free DMEM 
control or treated medium for 4 hours. Following a 4 hour treatment, the medium was 
collected and mixed with a non-reducing sample buffer. Protein samples were 
separated using SDS-PAGE on gels containing 10% gelatin (Sigma-Aldrich Co, Poole, 
Dorset, UK).After SDS-PAGE, gels were renatured by washing in renaturing buffer 
twice (15 minutes for each time) at room temperature, and then soaked in developing 
buffer at 37
o
C for the incubation of 36- 40 hours. Following incubation, the gels were 
stained with 0.5% Coomassie blue in distilled de-ionized water for 1 hour and washed. 
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The gel was destained using a destaining buffer for approximate 1 hour based on the 
staining strength of gel. The gel was generally stained blue. Where there was active 
MMP-2 and/or MMP-9, the gel stain became bright due to degradation of gelatin by 
the proteases. Images from the gels were obtained. The density of the protein bands 
was quantified using a similar method given in early sections.  
 
2.6 Alteration of gene expression 
 
2.6.1 Knocking down gene expression using Ribozyme Transgenes 
In order to knockdown the expression of Kiss-1 and its receptor (Kiss-1R), it is 
targeted at the mRNA level using hammerhead ribozyme transgenes that specifically 
target and cleave the mRNA transcripts of Kiss-1 and Kiss-1R. The hammerhead 
ribozyme was first described by Forster and Symons in 1987 as a self-cleaving region 
in the RNA genome of various plant viroids and virusoids. The hammerhead motif 
was subsequently integrated into short synthetic oligonucleotides, transforming it into 
a turnover catalyst capable of cleaving various RNA targets (Uhlenbeck, 1987; 
Haseloff and Gerlach, 1988). 
Hammerhead motifs contain a conserved secondary structure that consists of three 
helical stems (I, II, and III) enclosing a junction known as the catalytic core, typified 
by various invariant nucleotides. The best codons demonstrated to be suitable for 
cleavage are GUC, AUC and UUC (Figure 2.4).  
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In order to generate a ribozyme transgene specific to Kiss-1 and Kiss-1R, primers 
were designed using Zuker’s RNA mFold programme (Zuker, 2003) according to the 
secondary structure of the gene transcripts (Figure 2.5 and 2.6). Subsequently, an 
appropriate GUC ribozyme target site was chosen from within the secondary structure 
of Kiss-1 or its receptor. The ribozyme was created to specifically bind the sequence 
adjacent to this GUC codon. This made it possible for the hammerhead catalytic 
region of the ribozyme to bind to and specifically cleave the GUC sequence within 
the target mRNA transcript. The transgenes were generated by carrying out 
touchdown PCR under the following conditions: 
 
Steps Temperature Time Cycles 
Initial denaturation 94
o
C 5 minutes 1 
Denaturation 94
o
C 10 seconds 48 
 
 Annealing 
 
70
o
C 
65
o
C 
60
o
C 
57
o
C 
54
o
C 
50
o
C 
15 seconds 
15 seconds 
15 seconds 
15 seconds 
15 seconds 
15 seconds 
Extension 72
o
C 20 seconds 
Final extension 72
o
C 7-10 minutes 1 
 
• Subsequently, the transgenes were run on a 2% agarose gel in order to verify their 
presence as well as size before being cloned into the pEF6/His plasmid as described 
in the following section. 
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Figure 2.4.Secondary structure of hammerhead ribozyme binding with substrate 
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Figure 2.5.Secondary structure of human KiSS-1, generated using the mfold 
programme (Michael Zucker& Nick Markham, © Rensselaer Polytechnic Institute 
Hosted by The RNA Institute, 1995-2012, http://mfold.rna.albany.edu/?q=mfold), 
based on human full length Kiss mRNA 
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Figure 2.6.Secondary structure of human KiSS-1R/GPF54, generated using the mfold 
programme (Michael Zucker& Nick Markham, © Rensselaer Polytechnic Institute 
Hosted by The RNA Institute, 1995- 2012, http://mfold.rna.albany.edu/?q=mfold), 
based on human full length Kiss mRNA. 
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2.6.2 TOPO TA gene cloning and generation of stable transfectants 
The TOPO TA expression system provided a highly efficient and simple one step 
cloning approach without the requirement of ligases, specific PCR primers, or any 
post PCR procedures. The process involved the direct insertion of Taqpolymerase 
amplified PCR products (which carried an A-overhang at the 3-end of the product) 
into a plasmid vector. 
This current study used the pEF6/V5-His-TOPO plasmid vector (Invitrogen Inc., 
Paisley, UK) which was provided linearised with a single 3’ Thymidine (T) overhangs 
for TA cloning, and a covalently bound Topoisomerase. Due to the activity of 
independent terminal transferase of the template, Taqpolymerase would catalyse the 
addition of a single deoxyadenosine (A) to the ends of PCR products. This allowed 
for efficient ligation of the PCR product into the plasmid vector due its 3’ T overhang 
mentioned above. 
 
2.6.3 TOPO cloning reaction 
•The following reagents were placed in a pre-labelled eppendorf tube and mixed 
gently before being incubated for 5 minutes at room temperature. 
4ul of PCR product 
1ul salt solution 
1ul TOPO vector 
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Figure 2.7.Schematic representation of the pEF6 plasmid (From pEF6/V5-His TOPO 
TA Expression Kit protocol) 
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2.6.4 Transformation of chemically competent E. coli 
• Five microlitres of the cloning reaction set up in section 2.7.1 was mixed in a vial 
with chemically competent One Shot™ TOP10 E.coli (In Vitrogen Inc., Paisley, UK) 
before being incubated on ice for 30 minutes 
• This was followed by a heat-shock at 42oC for 30 seconds in a water bath, after 
which the bacteria was immediate placed on ice for 2 minutes. 
• Two hundred and fifty microlitres of SOC medium (warmed to room temperature) 
was then added to the cell suspension and left to shake horizontally at 200rpm on an 
orbital shaker (Bibby Stuart Scientific, UK) at 37
o
C for an hour. 
•Following this incubation period, the E.coli mixture was spread onto pre-warmed 
selective LB-agar plates (with 100μg/ml ampicillin) at high and low seeding densities, 
before being incubated at 37
o
Cover night. 
•As the pEF plasmid carries antibiotic resistance genes to both ampicillin and 
blasticidin, only the cells that contained the plasmid are capable of growing on the 
agar. This was a way of selecting only the colonies positive for the plasmid containing 
your gene of interest. However, to confirm that the gene sequence had been inserted 
in the correct orientation, the colonies were further tested. 
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2.6.5 Colony selection and analysis 
•In order to confirm that a right product was inserted into the plasmid and that the 
insert was in the correction orientation, the colonies were subject to more verification. 
•This was done by carrying out PCR on around 10 discrete colonies, with three 
different sets of primers. The first reaction used a forward primer specific for the 
primer (T7F or BGHR) and a reverse primer specific for the sequence. T7F started 
around 90bp before the beginning of the insert and so if the insert was ligated in the 
correct orientation, the resulting product should be around 100bp bigger than the 
predicted product size. The second reaction contained T7F and a forward primer 
specific for the sequence. If a product was seen following amplification, then the 
insert was in the wrong orientation. If a band was seen for both reactions then the 
colonies contained a mixture of plasmids with both correctly and incorrectly inserted 
sequences. Finally, in order to verify that the full sequence had been inserted without 
degradation, a further reaction with T7F and BGHR was carried out on the colonies. 
• Individual colonies were examined by lightly touching a labelled colony with a 
pipette tip, and mixing it into each PCR reaction before specific amplification of the 
desired sequence. The thermal cycler was set to the following conditions: 
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Steps Temperature Time Cycles 
Initial denaturation 94
o
C 10 minutes 1 
Denaturation 94
o
C 20 seconds 25 
 
Annealing 55
o
C 30 seconds 
Extension 72
o
C 40 seconds 
Final extension 72
o
C 7 minutes 1 
 
2.6.6 Plasmid purification and amplification 
•Following colony analysis, the ones deemed to have the insert in the correct 
orientation were picked up from the plate and inoculated in 10ml of LB broth with 
100μg/ml ampicillin and then being incubated at 37oC over night with constant 
agitation. 
•The amplified E.coli were then pelleted by centrifugation at 4oC for 15 minutes at 
6,000rpm, and then used for plasmid extraction. This was carried out using the Sigma 
GenElute Plasmid Mini Prep Kit (Sigma-Aldrich, USA), according to the protocol 
provided by the manufacture. 
•The bacterial pellet was first resuspended in 200μl of resuspension buffer (containing 
RNase A) before being mixed thoroughly, and transferred into the provided 2ml 
collection tubes. 
•This was followed by the addition of 200μl lysis solution and gently mixing by 
inverting the tubes 5-6 times. The resulting mixture was left at room temperature for 5 
minutes before adding 350μl of neutralisation solution. 
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•The tubes were inverted several times again, and centrifuged at 12,000rpm for 10 
minutes. The resulting supernatant was then transferred into a fresh collection tube 
containing a Mini Spin Column, which had resin that would bind plasmid DNA after 
centrifugation at 12,000rpm for 1 minute. 
•The flow through was discarded before the column was washed with 700μl of wash 
solution (containing ethanol) and centrifuging at 12,000rpm for 1 minute. The flow 
through was discarded once more, before the column was dried by another minute of 
centrifugation. 
•The column was then transferred into a fresh collection tube for elution. This was 
carried out by adding 100μl of elution solution and centrifuging at 12,000rpm for 1 
minute. The resulting flow through containing the purified plasmid was collected, and 
around 4μl was mixed with a loading dye before running on a 0.8% agarose gel in 
order to confirm the presence and purification of the plasmid. 
 
2.6.7 Transfection of mammalian cells using electroporation 
•Following plasmid extraction, the empty plasmid, and the plasmid containing the 
ribozyme transgene was used to transfect two colorectal cancer cells (HT-115 and 
HRT-18) 
•The method of transfection used in this study was electroporation using an 
electroporator (Easyjet, Flowgene, Surrey, UK). 
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•Once the cells had reached confluency they were detached from their tissue culture 
flasks, counted, and approximately 1x10
6
 cells were resuspended in 1ml of media. 
•300μl of the cell suspension was then added into an electroporation cuvette 
(Eurgenetech, Southampton, UK), and following the addition of 3-5μl of plasmid, left 
at room temperature for 5 minutes. 
•The cuvette was placed into the electroporator and subjected to an electrical pulse of 
290-310V before immediately being transferred into a fresh tissue culture flask 
containing media. 
 
2.6.8 Establishment of a stable expression mammalian cell line 
•Following transfection and in order to obtain a stable cell line expressing the gene of 
interest, the cultured cells were selected using a specific antibiotics to produce a 
population of cells that contained the required plasmid, and hence the desired 
expression of a molecule. 
•As mentioned before, the pEF plasmid contained a resistance gene against blasticidin 
and this was used as a selection marker for mammalian cells. The transfected cells 
were cultured in selection media containing 5μg/ml blasticidin for around 1-2 weeks. 
Cells without plasmids will be killed by blasticidin. Only those cells containing the 
plasmid would survive. 
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•After selection, the cells were transferred into maintenance media containing 
0.5μg/ml blasticidin. In order to verify that the cells were actually expressing the gene 
of interest, the cells were analyzed by carrying out RT-PCR and Western blotting. 
•Once the cells had been verified to stably express the desired molecule ribozyme 
transgene; they were subjected to various in vitro assays in order to test the effect of 
altering the expression of that molecule on the biological properties of the cells. These 
assays are outlined in section 2.8. 
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Figure 2.8.Flow diagram presents the general process of cloning and the stable 
expression of transfected mammalian cell lines 
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2.7 In vitro cell function assays 
 
2.7.1 In vitro cell growth assay 
•The protocol by Jiang et al. was followed (Jiang et al., 1995). 200μl of media 
containing 3,000 cells was seeded into four 96 well plates. Test agents were added to 
the wells when appropriate. 
•These plates were then incubated at 37oC, with 5% CO2, for a period of 24, 48, 72 
and 120 hours respectively. 
•After incubation, the media was discarded, and the cells fixed with 4% formalin for 
10-20 minutes, before being subsequently stained with 0.5% crystal violet for 10 
minutes. The dye was washed off with water, and the plates left to dry. 
•The dye was then solubilised using 200μl acetic acid, and cell growth was assessed 
by measuring the absorbance at 540nm using a spectrophotometer (BIO-TEK, Elx800, 
UK). The growth rate was calculated as a percentage, using the absorbance taken at 
24 hours as a baseline. 
 
2.7.2 In vitro adhesion assay 
•Wells in a 96 well plate were coated with 100μl of serum free media with 5μg (stock 
concentration 0.05μg /μl) Matrigel (BD Matrigel™ Matrix, Magrigel™ Basement 
Membrane Matrix, Biosciences). The Matrigel was then left to dry for 2 hours at 
55
o
C. 
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•To rehydrate the Matrigel, 200μl of sterile water was added to each well and left for 
45 minutes at room temperature. 
•The media was aspirated and 20,000 cells diluted in 200μl media, were seeded into 
each well and left to adhere at 37
o
C, with 5% CO2 for 40 minutes. 
• After incubation, the media was discarded, and the wells washed with BSS to 
remove any unbound cells. The cells that had remained adhered after washing were 
fixed with 4% formalin for 10-20 minutes, and then stained with 0.5% crystal violet 
for 10 minutes. The dye was washed off and the plates left to dry before capturing 
images under the microscope and cell number counted. Due to the fluid dynamics 
within the small sized wells of a 96 well plate, Matrigel might set unevenly, causing 
cell aggregation around the edges of the well. Therefore, in order to avoid these areas, 
only the cells which had adhered to the centre of the well were counted, making sure 
that the same area of the well was assessed for each sample. 
 
2.7.3 In vitro wounding assay 
• The protocol by Jiang et al. was followed (Jiang et al., 2005). 700μl of media 
containing 200,000-300,000 cells are seeded into a 24 well plate and cells were 
treated with a protein of interest in serum free media if required. 
•These plates were then left to incubate at 37oC, with 5% CO2, for a period of 24 
hours to allow cells to form a confluent monolayer before the monolayer was 
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scratch-wounded using a blunted fine needle. Photos were taken using a microscope 
with camera at 0, 0.25, 1, 2, and 3 hours after wounding. 
• Migration distances were measured using Image-J software (National Institutes of 
Health, USA). 
 
2.7.4 In vitro invasion assay 
•Trans-well inserts with 8 micrometer pore size (FALCON®, pore size 8.0μm, 24 
well format, Greiner Bio one, Germany) were placed into wells of a 24 well plate 
(NUNC™, Greiner Bio one, Germany), using sterile forceps in order to prevent 
contamination. 
•Each insert was subsequently coated with 100μl serum free media with 50μg 
Matrigel (stock concentration 0.5μg /μl), and left to dry for 2 hours at 55oC. 
•The Matrigel was then rehydrated with 200μl sterile water for an hour at room 
temperature for 45 minutes. 
•The water was carefully discarded, and 20,000 cells in 200μl media were seeded into 
each insert. 600μl media was then added to the bottom chamber of each well. The 
cells were incubated for a maximum of 72 hours, with 5% CO2 at 37
o
C. 
•After 72 hours incubation, the invasive cells invaded through Matrigel, and migrated 
through the porous membrane to the other side of the insert. The Matrigel layer and 
the noninvasive cells were then removed from inside of the insert using tissue paper. 
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This step is essential, as Matrigel would also be stained with crystal violet, making it 
difficult to distinguish between the background and invading cells. 
•The invasive cells were then fixed with 4% formalin for 10-20 minutes, and then 
stained with 0.5% crystal violet for 10 minutes. Free crystal violet was washed off, 
the plates left to dry, and the stained cells photographed and counted under a 
microscope. 
 
 
Figure 2.9.Schematic diagrams showing in vitro invasion assay 
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2.8 Electrical cellular impedance sensing (ECIS) 
•Electrical Cellular Impedance Sensing (ECIS) is a novel method used as an 
alternative to the conventional cell function assays mentioned above [119]. Invented 
by Ivar Givaer, the Noble Prize winner for Physics and Charles Keese, ECIS uses a 
biophysical method in monitoring cellular behaviour including cell adhesion, cell 
migration, cell invasion and barrier functions such as tight junctions[119]. It evolved 
from early simple single unit based analysis to what is now multiple well and 
automated versatile assays [120]. 
•The present study used an ECIS Ztheta model. It works on an array of 96 wells, each 
containing one (96W1E) gold plated electrode or ten (96W10E) gold electrodes. 
These electrodes measure the electric current and voltage across this electrode, 
calculating the impedance and resistance. From the impedance changes, effects on 
cell attachment and motility can be examined [120]. Using 96W1E arrays (ECIS™ 
cultureware, Applied Biophysics, Inc., NY, USA), each well was stabilised at room 
temperature for around 20 minutes using 200μl electrode stabilising solution (ECIS™, 
Applied Biophysics, Inc., NY, USA). 
•The solution was then aspirated and replaced with 200μl DMEM/Ham’s F12 media 
containing HEPES buffer (Lonza, Verviers, Belgium) and left until needed. 
•The media was aspirated, and 40,000 cells diluted in 200μl DMEM were seeded into 
each well, and treated with test reagents if required. 
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•The array was then placed into an ECIS™ CO2 incubator (RS biotech 9600, R 
galaxy R+) which was connected to the ECIS™ Ztheta Controller (Applied 
Biophysics, Inc., NY, USA). The software was set up so that resistance to the current 
flow was measured at frequencies ranging from 125 to 64,000Hz. Data was 
normalised using resistance from the first time point. 
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Figure 2.10.A.96W1E arrays (ECIS™ cultureware, Applied Biophysics, Inc., NY, 
USA) 
 
 
 
Figure 2.10.B.The ECIS™ Model Ztheta Controller (Applied Biophysics, Inc., NY, 
USA) 
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2.9. In vivo tumour model 
Athymic nude mice (Strain CD-1) were purchased from Charles River Laboratories 
(Charles River Laboratories International, Inc., Kent, England, UK). Female 4-6 week 
old CD-1 mice were used. All the mice were kept in a filter-topped isolation cages 
and all the procedures were carried out in a class-II cabinet. The study was conducted 
under the Home Office Project license PPL 30/2591 and personal license number (No. 
PIL 30/10005). 
 
After the mice were settled for a week in the designated laboratories, HT-115 cells 
(control or Kiss-1 knockdown cells) were injected subcutaneously at a volume of 
100µl which contained Matrigel at final concentration of 2.5ml/ml. The mice were 
then carefully monitored twice weekly by measuring body weight, tumour size (using 
a digital caliper), and any size effects, according to the regulations of the Home Office 
and UKCCCR Guideline for using experimental animals in cancer research. Any 
severe side effects, significant weight loss (>20% of body weight) and oversized 
tumours (>1cm in any diameter) would trigger a termination of the study.   
 
The volume of tumours was calculated by using the following formula: 
tumour volume (mm
3
)= 0.512× Width
2
×length 
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2.10. Collection of clinical cohort 
This was collected under the Approval by the South East Wales Local Research Ethics 
Committee (ref 05/WSE03/92) with patient's consent. Fresh tissues were obtained 
immediately after surgery. Tumour tissues and normal tissues (>10cm away from the 
tumour margin) were obtained with the pathologist on call and stored immediately in 
a deep freezer (-80
o
C) until use.  
 
The frozen tissues were first sectioned using a Leica CM1900 Cryostat (Leica 
Microsystems Ltd, Bristol, UK) at 8-10µm thickness. A part of sections (>50) were 
divided into three portions were pooled and homogenised to extract RNA for 
molecular bades analysis. 
  
2.11 Data analysis 
The statistical comparisons were made using either a non-parametric Mann- Whitney 
test if the data was not normalized or a Students two tailed t- test if the data was found 
to be normalized and have equal variances. Graphs were constructed using Microsoft 
Excel Software Package.  
The relationship between the expression of Kiss-1 and Kiss-1R and tumour grade, 
TNM staging and nodal status was respectively analyzed using Mann-Whitney U and 
Kruskal-Wallis test. Survival analysis curve were performed using Kaplan-Meier 
survival analysis. Quantitative data were analyzed using the Student’s t-test, and 
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chi-squared test, where appropriate. Differences were considered to be statistically 
significant at p<0.05.  
For the in vivo tumour growth study, both student t test and two way ANOVA tests 
were employed using the SigmaPlot software. 
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Chapter 3 
 
The expression of Kiss-1 and Kiss-1R in tissues, 
cell lines and verification of Kiss-1 and Kiss-1R 
knockdown 
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3.1 Introduction 
Lee and colleagues (1994) introduced the full length of chromosome 6 into the human 
metastatic melanoma cell line C8161 using a microcell-mediated transferring 
technique and then found the introduction of chromosome 6 suppressed metastasis 
without impacting tumourgenicity and invasion [60]. Two years later, the human 
Kiss-1 gene was isolated and identified from the melanoma cells by Lee et al [61-62]. 
Kiss-1 is mapped to chromosome 1q32, which was identified as a human melanoma 
metastasis suppressor gene through the analysis of subtractive hybridization in highly 
metastatic cell lines when compared with non-metastatic cell lines [60]. Kiss-1 
receptor (Kiss-1R), also known as G-protein coupled receptor 54 (GPR54), 
HOT7T175, AXOR12 and Metastin receptor, was first discovered and cloned from rat 
brain by Dennis in 1999 [68]. In humans, it maps to chromosome 19p13.3, contains 5 
exons and 4 introns encoding 398 amino acids, resulting in a 75 kDa protein. Kiss-1R 
shares 81% protein homology with the preceding cloned rat homolog [64, 69].  
Tissue distribution of Kiss-1 and its receptor are often concordant, like placenta and 
the central nervous system in which both genes are highly expressed [48, 61, 69]. 
High levels of Kiss-1R have been observed in the cerebral vortex, cerebellum, 
thalamus and pons-medulla [69]. By contrast, Kiss1 is highly expressed in the 
hypothalamus and pituitary [64]. In addition to the placenta high expression of 
Kiss-1R is also seen in the pancreas, whilst it has low expression in adipose tissue, 
lymph nodes, peripheral blood lymphocytes, pituitary gland and spleen [48, 69]. 
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In 1997, Lee and Welch hypothesized that Kiss-1 might suppress metastasis in other 
tumour types in addition to melanoma. Hence, the human breast cancer cell line 
MDA-MB-435 transfected with full-length Kiss-1 cDNA was implanted into athymic 
nude mice with paired control cells. The results demonstrated that the metastatic 
potential of transfected cells was significantly decreased, but tumourigenicity was not 
inhibited [71]. In light of these observations, Kiss-1 and its receptor were suggested 
as a pair of metastasis suppressors in several cancers. However, it remains largely 
unknown what effect Kiss-1 and Kiss-1R may have in malignancies and the 
molecular mechanisms or pathways underlying their influence on tumour suppression. 
The expression of Kiss-1 and Kiss-1R genes are mainly found in the placenta, but 
Kiss-1 was also detected in colon, pancreas and intestinal tissue [121]. No previous 
studies have specially shown a possible role of Kiss-1 and its receptor in colorectal 
cancer. However, Chen et al., (2012) reported that Kiss-1 expression increased in the 
colorectal cancer cell line SW480 irradiated with 6-MV X-rays for 48 hours, which 
resulted in a decrease in proliferation and an increase in apoptosis [122]. Their 
investigation provides some indication that Kiss-1 may have an inhibitive effect on 
colorectal cancer cells. The present study aimed to establish the role played by Kiss-1 
and Kiss-1R has in colorectal cancer cells. Initially, the mRNA expression of Kiss-1 
and Kiss-1R were screened in four human colorectal cancer cell lines, subsequently to 
knock down the expression level of Kiss-1 and Kiss-1R in those cells, which have 
relatively high expression of Kiss-1 and Kiss-1R.  
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3.2 Materials and methods 
 
3.2.1 Materials 
Primers 
All the primers used were synthesized and provided by Invitrogen (Paisley, UK). 
Primer sequences are shown in Table 3.1 
 
 
Table 3.1.The sequences of the primers Kiss-1/Kiss-1R, Kiss-1/Kiss-1R ribozymes 
and GAPDH. 
 
The details of the touchdown PCR reaction and colony analysis using PCR have been 
described in Chapter 2. 
 
 
Gene Sense primer Antisense primer 
Kiss-1 5’-TGAACTCACTGGTTTCTTGG
-3’ 
5’-CGAAGGAGTTCCAGTT
GTAG-3’ 
Kiss-1R 5’-CTTCATGTGCAAGTTCGTC-
3’ 
5’-CACCAGGAACAGCTGG
AT-3’ 
Kiss-1 rib 
 
 
5’-CTGCAGCTCTCGGGGGGGC
GGGGACAGCGAGGTCCCCCCT
GATGAGTCCGTGAGGA-3’ 
5’-ACTAGTGCCAGCTGCT
ACTGCCA-3’ 
Kiss-1R rib 
 
 
5’-CTGCAGTTCCGCATCGGCT
TGTGGCGGCACTGATGAGTCC
GTGAGGA-3’ 
5’-ACTAGTGCCCCGCCTG
GCGCTGGCTGTTTCGTCC
TCACGGACT-3’ 
GAPDH 5’-GGCTGCTTTTAACTCTGGTA
-3’ 
5’-GACTGTGGTCATGAGT
CCTT-3’ 
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Antibodies 
Polyclonal anti-Kiss-1 antibody (sc-101246, mouse polyclonal IgG2a) and polyclonal 
anti Kiss-1R antibody (sc-48220, goat polyclonal IgG) were obtained from Santa 
Cruz Biotechnology (Santa Cruz, California, USA). 
 
3.2.2 Generation of Kiss-1 and Kiss-1R ribozyme transgenes 
Hammerhead ribozymes targeting Kiss-1 and Kiss-1R were designed using Zuker’s 
mRNA Fold programme (Zuker, 2003) based on the secondary structure of both 
Kiss-1 and Kiss-1R mRNA. The transgenes were synthesised using touchdown PCR 
with the reaction conditions described in Chapter 2. The products were then run on a 
2% agarose gel to verify their presence as well as size, before being cloned into the 
pEF6/His plasmid vector. 
 
3.2.3 TOPO TA cloning and generation of stable transfectants 
The ribozymes obtained from the above procedure were subsequently cloned into the 
pEF6/V5-His-TOPO vector. One microlitre of the vector, 1µl salt solution, 1µl of the 
ribozyme products and 3µl H2O were gently mixed and allowed to react at room 
temperature for 5 minutes. This was followed by transferring the reaction mixture to 
the TOP10 E.Coli, a chemically competent E.Coli strain. After 30 minutes on ice, the 
bacteria were subject to heat shock at 42
o
C for 3 seconds, before being placed on ice 
for 2 minutes. The bacterial mixture was added to SOC media and placed on an 
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orbital shaker for 1 hour, at a speed of 200rpm. The bacterial solution was plated on 
liquid broth (LB)-ampicillin agar plates and allowed to grow overnight. Only the cells 
containing the plasmid were able to grow on the agar, as the pEF plasmid has 
antibiotic resistance genes to ampicillin and blasticidin (figure 3.1). Colonies of 
transformed E.Coli,transgenes of Kiss-1 and Kiss-1R cloned into 
pEF6/V5-His-TOPO plasmids (Invitrogen Inc., Paisley, UK) were analyzed RT-PCR, 
using the T7F primer coupled either with RbBMR and RbTPF primers. After 
amplifying the correct colonies the plasmids were extracted using the Sigma 
GenElute Plasmid MiniPrep Kit (Sigma-Aldrich, USA). 
Control plasmid and the plasmid containing theribozyme transgene was used to 
transfect both the HT115 and HRT18 cell lines respectively. The transfected cells 
were cultured in selection media containing 5μg/ml blasticidin for around 1-2 weeks 
so that only those cells containing the plasmid would survive. Following selection, the 
cells were transferred into maintenance media containing 0.5μg/ml blasticidin, to 
verify the knockdown of Kiss-1 and Kiss-1R by carrying out RT-PCR, Q-PCR and 
Western blot. HT115
wt
, HT115
pEF
, HT115
Kiss-1 kd
 and HT115
Kiss-1R kd
 represent for 
HT115 wild type, HT115 pEF, HT115 Kiss-1 knockdown and HT115 Kiss-1R 
knockdown cells respectively; HRT18
wt
, HRT18
pEF
, HRT18
Kiss-1 kd
 and HRT18
Kiss-1R kd
 
represent for HRT18 wild type, HRT18 pEF, HRT18 Kiss-1 knockdown and HRT18 
Kiss-1R knockdown cells respectively.  
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Figure 3.1.Gel image for the plasmid of Kiss-1 and Kiss-1R. A. After incubation at 
37
o
C overnight, the Kiss-1 ribozyme colonies positive for the plasmid containing the 
gene of interest were grown on the agar. Ten independent colonies were selected and 
numbered for analyzing the gene sequence ligated into the vector in the correct 
orientation. B. The Kiss-1R ribozyme colonies positive for the plasmid were grown 
on the agar. Ten independent colonies were numbered and then selected to verify the 
gene sequence inserted in the correct orientation by PCR reaction. 
 
 
3.2.4 RNA isolation, cDNA synthesis, RT-PCR and Q-PCR 
RNA isolation was carried out using the Tri Reagent kit (Sigma-Aldrich, Inc., Poole, 
Dorset, England, UK), and then converted into cDNA by reverse transcription using 
the iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories, California, USA). cDNA as 
the template was detected by RT-PCR and Q-PCR. The reaction conditions of 
RT-PCR and Q-PCR were described in Chapter 2. The products were run on an 
agarose gel (the concentration depends on the size of product) and stained using 
ethidium bromide solution for visualizing using an Ultra Violet Transilluminator 
(UVP, Cambridge, UK). 
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3.2.5 Protein extraction, SDS-PAGE and Western blot analysis 
Protein was extracted from cells and quantified using the DC Protein Assay kit 
(BIO-RAD, USA). Proteins were separated according to charge using SDS-PAGE and 
blotted onto nitrocellulose sheets. Specific primary (anti-Kiss-1 and Kiss-1R 1:500) 
and HRP-conjugated secondary antibodies (1:1000) were used to probe proteins, and 
bands stained by the chemiluminescence detection kit (Luminata, Millipore) were 
visualized using the Supersignal
TM
 West Dura system (Pierce Biotechnology, USA). 
 
3.3 Results 
 
3.3.1 Colorectal cancer cell lines screening for the expression of Kiss-1 and 
Kiss-1R 
The expression of Kiss-1 and Kiss-1R were examined in four colorectal cancer cell 
lines of human origin including HT115, HRT18, RKO and Caco-2. They were from 
highly invasive human colorectal carcinoma. Figure 3.2 showed the expression of 
Kiss-1 and Kiss-1R in the cell lines. On the whole, both Kiss-1 and Kiss-1R were 
generally expressed in all the four colorectal cancer cells, while the expression levels 
displayed differences in different cell line. Although the mRNA expression of both 
Kiss-1 and Kiss-1R were detected in four colorectal cancer cells, higher levels were 
seen in HT115 and HRT18 cells compared with RKO and Caco-2 cells. From these 
analysis, HT115 and HRT18 cells were chosen for Kiss-1 and Kiss-1R knock down. 
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Figure 3.2.Colorectal cancer cells screening for the expression of Kiss-1 and Kiss-1R. 
mRNA expression of Kiss-1 and Kiss-1R was screened in four colorectal cancer cells 
(HT115, HRT18, RKO and Caco-2) using conventional PCR techniques.  
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3.3.2 Generation of Kiss-1 and Kiss-1R ribozyme transgenes 
For the purpose of silencing both Kiss-1 and Kiss-1R expression in colorectal cancer 
cells, anti-Kiss-1 and anti-Kiss-1R ribozyme transgenes were generated and cloned 
into pEF6/His plasmids respectively, allowing for mammalian cell transfection. In 
order to verify correct orientation of the ribozyme transgenes, two primers (RbTPF 
and RbBMR) were paired with BGHR respectively. If the transgene is correctly 
orientated, the bands of PCR product would be determined from RbTPF+ BGHR 
reaction. In contrast, a wrong sized product would arise for the RbBMR+ BGHR 
reaction. 
From Figure 3.3.B, it is demonstrated that colony 18-1 (Kiss-1) and 19-7 (Kiss-1R) 
had the highest levels of correctly orientated ribozyme transgenes, in the meantime, 
the bands of wrongly orientated ribozyme transgenes were weakest. Colonies 18-1 
and 19-7 were subsequently collected and amplified. The plasmids were extracted 
from the correct colonies and were verified with DNA electrophoresis. Based on the 
difference of migrating speed and the amount of negative charge, open circular DNA, 
linear DNA and covalently closed circular DNA presented three bands respectively 
after electrophoresis from the top down in Figure 3.3.C. As the surface of covalently 
closed circular DNA, which had the strongest band, carried the least negative charge, 
it had the fastest speed from a negative pole to a positive pole. There were no white 
bands observed in the sample holes, it illustrated the high purity of plasmids was 
without proteins. 
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(Figure 3.3) 
129 
 
 
Figure 3.3.Ribozyme transgene synthesis.A.The ribozymes generated using 
touchdown PCR, run on an agarose gel. B. The colonies were analysed using PCR 
after transformation into E.coli cells, to verify correct orientation of the transgene. P 
represented correct orientation (140bp ribozyme sequence plus 173bp sequence 
downstream of the insert site), which used a ribozyme specific primer (RbTPF) and a 
plasmid specific primer (BGHR) in a PCR reaction; N stood for incorrect orientation 
(140bp ribozyme sequence plus 173bp sequence downstream of the insert site), where 
a ribozyme primer (RbBMR) was coupled with a plasmid specific primer (BGHR), in 
a PCR reaction. C. The plasmids of Kiss-1 and Kiss-1R extracted from the correct 
colonies were verified with DNA electrophoresis. Three bands appeared after 
electrophoresis because of the difference of their migrating speed in the process of gel 
electrophoresis, the order from the top – down is: open circular DNA, linear DNA and 
covalently closed circular DNA.  
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3.3.3 Verification of Kiss-1 knockdown in HT115 and HRT18 cells 
To ensure the knockdown of Kiss-1 was successful, we used Q-PCR and Western 
blots to verify the message and protein in the transfected cells. Figure 3.4 and 3.5 
showed that the expression of Kiss-1mRNA was significantly reduced in the 
ribozyme transgene transfected cells (HT115
Kiss-1 kd 
and HRT18
Kiss-1 kd
) compared with 
the levels of expression seen in wild type cells (HT115
wt 
and HRT18
wt
) and control 
transfection with empty plasmid (HT115
pEF
 and HRT18
pEF
). The levels of 
Kiss-1mRNA from three repeats, which was normalized against corresponding 
internal control (GAPDH) using Quantitative real time PCR are described at Figure 
3.4.B and 3.5.B. The expression of Kiss-1 was decreased in HT115
Kiss-1 kd
 cells as 
compared with bothHT115
wt
 and HT115
pEF
 cells (p< 0.05). Figure 3.6 and 3.7 showed 
the expression of Kiss-1 knock down at the protein level in both HT115 and HRT18 
cells using Western blots. The volume of the Kiss-1 protein bands with three repeats 
normalized against corresponding internal control (GAPDH) is demonstrated at figure 
3.6.B and 3.7.B. Similarly, the expression of Kiss-1 was decreased in both HT115
Kiss-1 
kd
and HRT18
Kiss-1 kd
 cells compared with the respective controls (p< 0.05). 
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Figure 3.4.Verification of knockdown of Kiss-1 in HT115 cells. A. RT-PCR 
displayed reduced level of Kiss-1 in mRNA in HT115
Kiss-1 kd
cells compared with 
control cells (HT115
wt
 and HT115
pEF
 cells). B. Quantitative real time PCR showed 
Kiss-1 mRNA volume of three repeats which was normalised against corresponding 
internal control (GAPDH). The expression of Kiss-1decreased significantly in 
HT115
Kiss-1 kd
 cells compared with HT115
wt
 (p= 0.0083) and HT115
pEF
 cells (p= 
0.0033). Asterisk represented p< 0.005. Original data is shown in Table 1 of 
Appendices. 
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Figure 3.5.Verification of knockdown of Kiss-1 in HRT18 cells. A. RT-PCR 
displayed a reduced mRNA expression level of Kiss-1 in HRT18
Kiss-1 kd 
cells 
compared with control cells (HRT18
wt
 and HRT18
pEF
 cells). B. Quantitative real time 
PCR showed Kiss-1 mRNA volume of three repeats which was normalized against 
corresponding internal control (GAPDH). The expression of Kiss-1 decreased 
significantly in HRT18
Kiss-1 kd
 cells compared with HRT18
wt
 (p= 0.000031) and 
HRT18
pEF
 cells (p= 0.0008) respectively. Asterisk represented p< 0.005. Original data 
is shown in Table 2 of Appendices. 
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Figure 3.6.Confirmation of Kiss-1 knockdown in HT115 cells. A. Kiss-1 protein 
bands volume of three repeats which was normalized against corresponding internal 
control (GAPDH). B. The expression of Kiss-1 showed a significant decrease in 
HT115
Kiss-1 kd
 cells compared with both that in HT115
wt 
(p= 0.0083) and HT115
pEF
 
(p= 0.0035) cells. Asterisk stood for p< 0.05. Original data is shown in Table 3 of 
Appendices. 
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Figure 3.7.Confirmation of Kiss-1 knockdown in HRT18 cells. A. Kiss-1 protein 
bands volume of three repeats which was normalized against corresponding internal 
control (GAPDH). B. The expression of Kiss-1 showed a significant decrease in 
HRT18
Kiss-1 kd
 cells compared with both that in HRT18
wt
 (p= 0.0031) and HRT18
pEF
 
(p= 0.00081) cells. Asterisk stood for p< 0.05. Original data is shown in Table 4 of 
Appendices. 
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3.3.4 Verification of Kiss-1R knockdown in HT115 and HRT18 cells 
We further detected the expression of Kiss-1R knockdown compared with control 
groups (wild type and pEF) in both HT115 and HRT18 cells at both mRNA and 
protein levels using Q-PCR and western blots. Figure 3.8 and 3.9 display the 
decreased expression of Kiss-1R mRNA in the ribozyme transgene transfected cells 
(HT115
Kiss-1R kd 
and HRT18
Kiss-1R kd
) compared with the levels of expression seen in 
wild type (HT115
wt
and HRT18
wt
) cells and empty plasmid (HT115
wt
and HRT18
pEF
) 
cells. The levels of Kiss-1R mRNA from three repeats, normalized against 
corresponding internal control (GAPDH) using Quantitative real time PCR is 
demonstrated at figure 3.8.B and 3.9.B. An obviously significantly decreased 
expression of Kiss-1R in HT115
Kiss-1R kd 
and HRT18
Kiss-1R kd
 cells was seen when 
compared with HRT18
wt
 and HRT18
pEF
 cells (p< 0.05). Figure 3.10 and 3.11illustrate 
the expression of Kiss-1R knockdown at protein level using western blots. The levels 
of Kiss-1R from three repeats normalized against corresponding internal control 
(GAPDH),is shown at Figures 3.10.B and 3.11.B. Similarly, the expression of 
Kiss-1R was decreased in HT115
Kiss-1R kd 
and HRT18
Kiss-1R kd
 cells compared with 
control groups respectively (p< 0.05). 
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Figure 3.8.Confirmation of knockdown of Kiss-1R in HT115 cells. A. RT-PCR 
displayed reduced mRNA expression level of Kiss-1R in HT115
Kiss-1R kd
 cell 
compared with control cells (HT115
wt
 and HT115
pEF
 cells). B. Quantitative real time 
PCR showed Kiss-1 mRNA volume of three repeats which was normalised against 
corresponding internal control (GAPDH). The expression of Kiss-1R decreased 
significantly in HT115
Kiss-1R kd
 cells compared with HT115
wt
 (p= 0.00017) and 
HT115
pEF
 cells (p= 0.000044) respectively. Asterisk represented p< 0.005. Original 
data is shown in Table 5 of Appendices. 
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Figure 3.9.Confirmation of knockdown of Kiss-1R in HRT18 cells. A. RT-PCR 
displayed reduced mRNA expression level of Kiss-1R in HRT18
Kiss-1R kd
 cells 
compared with control cells (HRT18
wt
 and HRT18
pEF
 cells). B. Quantitative real time 
PCR showed Kiss-1R mRNA volume of three repeats which was normalized against 
corresponding internal control (GAPDH). The expression of Kiss-1R decreased 
significantly in HRT18
Kiss-1R kd 
cells compared with HRT18
wt
 (p= 0.0016) and 
HRT18
pEF
 cells (p= 0.0038) respectively. Asterisk represented p< 0.005. Original data 
is shown in Table 6 of Appendices. 
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Figure 3.10.Confirmation of Kiss-1R knockdown in HT115 cells. A. Kiss-1R protein 
bands volume of three repeats which were normalized against corresponding internal 
control (GAPDH). B. The expression of Kiss-1R showed a significant decrease in 
HRT18
Kiss-1R kd 
compared with that in HT115
wt
 (p= 0.0013) and HRT18
pEF
 (p= 0.0056) 
cells. Asterisk stood for p< 0.05. Original data is shown in Table 10 of Appendices. 
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Figure 3.11.Confirmation of Kiss-1R knockdown in HRT18 cells. A. Kiss-1R protein 
bands volume {normalized against corresponding internal control (GAPDH)}. B. The 
expression of Kiss-1R showed a significant decrease in HRT18
Kiss-1R kd
 cells 
compared with that in HRT18
wt
 (p= 0.0011) and HRT18
pEF
 (p= 0.001) cells. Asterisk 
stood for p< 0.05. Original data is shown in Table 8 of Appendices. 
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3.4 Discussion 
Kiss-1 has been known as a novel metastasis suppressor due to its inhibitory role in 
lung metastases without affecting tumorigenicity [61]. Tissue distribution of Kiss-1 
and its receptor are often concordant, like placenta, where both of their transcripts are 
high [48, 61, 69]. In further studies on the biological function of Kiss1 in metastasis, 
Ohtakiet al (2001) transferred Kiss-1R into Chinese hamster ovary (CHO) cells and 
then implanted the melanoma cells (B16-BL6) transfected with Kiss-1R into the nude 
mice in order to observe their lung metastases. The results revealed that Kiss-1 
inhibited the migration and invasion of CHO cells and also reduced the ratio of lung 
metastases [48]. There have been a growing number of reports pointing to a 
metastasis suppressor role for Kiss-1 in solid cancers, such as breast cancer, gastric 
cancer, oesophageal carcinoma, pancreatic cancer, ovarian cancer, bladder cancer and 
prostate cancer. A relationship between reduced expression of Kiss-1 and poor clinical 
outcomes has been evident in most malignancies that have so far been investigated. 
However, few studies attempted to define the potential function of Kiss-1 and 
Kiss-1R involved in colorectal cancer and cancer metastasis. In the current study, four 
colorectal cancer cells (HT115, HRT18, RKO and Caco-2) were screened for the 
mRNA expression of Kiss-1 and Kiss-1R and were found positive, particularly in 
HT115 and HRT18 cells. We transfected anti-human Kiss-1 and Kiss-1R hammerhead 
ribozymes into two colorectal tumour cell lines (HT115 and HRT18), which had high 
expression of both Kiss-1 and Kiss-1R, so to create cell models with differential 
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expression of Kiss-1 and Kiss-1R, for further investigation of the biological impact of 
both molecules on colorectal cancer cells. HT115 and HRT18 cell lines with epithelial 
morphology have been established from highly invasive human colorectal carcinomas, 
which express high amounts of the tumor marker carcino-embryonic antigen (CEA). 
The sources of HT115 and HRT18 cells were from colon and rectum tissues 
respectively.  
The expression of Kiss-1 and Kiss-1R knockdown verified at both mRNA and protein 
levels were successful. There were significant difference between the knockdown 
groups and the control groups (wild type and pEF) (p< 0.05). In addition, HT115
pEF
 
and HRT18
pEF
 revealed similar expression of Kiss-1 and Kiss-1R with HT115 WT 
and HRT18 WT respectively at both transcript and protein levels (p> 0.05). For 
improving the efficiency of research and cutting cost, we decided to choose HT115 
pEF and HRT18 pEF as the controls in the subsequent experiments. pEF control 
transfected cells should be a more convincing cell subline than wild type cells as 
controls once the similar expression levels between pEF cells and wild type cells have 
been verified. Subsequently, we used these stabilized transfected cell lines to deduce 
the role played by Kiss-1 and Kiss-1R on how they influence the function of 
colorectal cancer cells through in vitro function assays. These data are shown in the 
next chapter. 
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Chapter 4 
 
 
Influence of targeting Kiss-1 and Kiss-1R on the 
proliferation, adhesion, invasion and migration 
of colorectal cancer cells 
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4.1 Introduction 
Tumour metastasis remains the leading cause of cancer related mortality and 
morbidity, although diagnostic and therapeutic modalities in the treatment of cancer 
patients have been significantly developed. Tumour metastasis depends on the 
characteristics of cancer cells, which make themselves more effective in adapting the 
in vivo environments and in competing for resources with normal cells. These 
characteristics include proliferation, adhesion, invasion and migration. The liver is the 
most frequently visited organ by colorectal cancer cells. Many studies have reported 
that tropism of cancer cells to specific organs is regulated by the complexity of 
genetic alterations, likewise, the maintenance of cell stability lies in the activity of 
tumour suppressor genes, which can inhibit the proliferation of cells. Kiss-1 has been 
suggested to have an inhibitory effect on the migration of pancreatic cancer, ovarian 
cancer and prostate cancer cells and the invasion of breast cancer and prostate cancer 
cells [48, 50, 71, 95]. Kiss-1 has been reported to negatively regulate MMP-9 
expression in ovarian tumour [96]. MMP-9 is known as one of the most important 
proteases related to tumour metastasis and is capable of degrading the primary 
structure of extracellular matrix and basement membrane (collagen, laminin, 
fibronectin). However, the influence of Kiss-1 and Kiss-1R on the function of 
colorectal cancer cells remains unknown. The expression of Kiss-1 and Kiss-1R 
knockdown in the colorectal cancer cell lines (HT115 and HRT18) was described in 
Chapter 3. The stably transfected cells were used in in vitro cell function assays, 
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which included growth, adhesion, invasion and migration assays in order to 
investigate if there were any changes in the function of these transfected cell lines 
through the effect of Kiss-1 and Kiss-1R knock down. 
 
4.2 Materials and methods 
4.2.1 Cell lines 
In this study, HT115 and HRT18 colorectal cancer cells transfected with empty 
plasmid and the plasmids of Kiss-1 and Kiss-1R knockdown were used. The cells 
were maintained in DMEM media with 10% FBS, antibiotics and 0.5μg/ml 
blasticidin. 
 
4.2.2 In vitro cell growth assay 
Cells were seeded into 96-well plates at 2, 500 cells/well, which were cultured using 
normal media (10% foetal calf serum, 0.1% antibiotics). The cells were cultured in 
triplicate for 1, 3 and 5 days. After incubation the cells were fixed in 4% formalin and 
stained by 0.5% crystal violet (w/v). The crystal violet stain was then extracted using 
10% (v/v) acetic acid, and the absorbance was determined using a spectrophotometer 
(Bio-Tek, ELx800) at a wavelength of 540nm. 
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4.2.3 In vitro cell adhesion assay 
A 96-well plate was precoated with5μg Matrigel (Collaborative Research Products, 
Bedford, Massachusetts, USA) and allowed to air dry. Following rehydration using 
serum free media, 40,000 cells were seeded into each well. After 40 minutes of 
incubation, non-adherent cells were washed off using BSS. The adherent cells were 
then fixed with 4% formalin and stained using 0.5% crystal violet. The number of 
adherent cells was counted under a microscope. 
 
4.2.4 In vitro invasion assay 
Transwell inserts (with 8μm pore) were precoated with 50μg Matrigel and air dried. 
Following rehydration, 40,000 cells were seeded into each insert. After incubation for 
three days, cells which had invaded through the matrix and adhered to the other side 
of the insert were fixed in 4% formalin, and stained with 0.5% (weight/volume) 
crystal violet. The number of invaded cells was then counted under a microscope. 
 
4.2.5 In vitro Wounding assay 
Cells were seeded into a 24-well plate at a density of 200,000 per well and allowed to 
form a monolayer of cells. The monolayer of cells was then scratched to create a 
wound. Migration of the cells at wounding edges was monitored over a period up to 
18 hours. Optimas 6.0 motion analysis (Meyer Instruments, Houston, Texas) was 
used to track the leading edge of the cells to measure the distance of the migration. 
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4.2.6 Electric cell-substrate impedance sensing (ECIS) 
The ECIS system (Ztheta, Applied Biophysics Inc., USA) was used to quantify cell 
migration as previously reported (Jiang et al., 2008) and 96W1E arrays were used in 
this study. Cells (HT115 pEF, HT115 Kiss-1 knockdown and HT115 Kiss-1R 
knockdown) were prepared for six groups and seeded at 40,000 cells per well in 200μl 
of DMEM medium alone or medium supplemented with 200nM ERK (FR180204) 
small inhibitor (MERCK, Germany), Kisspeptin-10 (Tocris Bioscience, Bristol, UK) 
and Kisspeptin-234 (Tocris Bioscience, Bristol, UK), which is a 
Kisspeptin-10/Kiss-1R antagonist, which belongs to Kisspeptin-10 analog (Tocris 
Bioscience, Bristol, UK). The details of treatment for each group are as follows: 
group 1 was treated with serum free; group 2 was treated with Kisspeptin-10; group 3 
was treated with Kisspeptin-234; group 4 was treated with ERK inhibitor; group 5 
was treated with ERK inhibitor+ Kisspeptin-10; group 6 was treated with ERK 
inhibitor+ Kisspeptin-234. The resistance was recorded for 8 hours after wounding 
and the data was analyzed using an ECIS-9600 software package. 
 
4.2.7 In vivo tumour model 
Female CD-1 mice aged 4-6 weeks old were used for this study. All the mice were 
kept in filter-topped isolation cages and all the procedures were carried out in a 
class-II cabinet. After mice were settled for a week in the designated laboratories, 
HT115 cells (control or Kiss-1 knockdown cells) were injected subcutaneously at a 
147 
 
volume of 100µl which contained Matrigel at final concentration of 2.5mg/ml The 
mice were then carefully monitored twice weekly by measuring body weight and 
tumour size (using a digital caliper), and looking for any side effects. 
The volume of tumours was calculated by using the following formula: 
tumour volume (mm
3
)= 0.512× (Width×2)×length 
 
4.3 Results 
 
4.3.1 Effect of Kiss-1 and Kiss-1R knockdown on HT115 cancer cell growth 
There was a steady increase in cell growth of both Kiss-1 and Kiss-1R knockdown 
HT115 cells compared with HT115 pEF cell line (Figure 4.1 A). In particular, the 
growth rate of the Kiss-1 knockdown cells (1223.32 ± 356.59) and Kiss-1R 
knockdown cells (1138.22 ± 213.46) increased gradually in comparison with the 
control group (HT115 pEF 829.611 ± 265.92) at the fifth day, however the value did 
not reached the level of statistical significance (p> 0.05). 
 
4.3.2 Effect of Kiss-1 and Kiss-1R knockdown on HRT18 cancer cell growth 
Similarly to that seen with HT115 cell lines, both Kiss-1 and Kiss-1R knockdown 
showed a relatively gentle increase in growth compared with the control group in the 
HRT18 cell lines (Figure 4.1 B). The cell growth was moderately increased in 
HRT18
Kiss1kd 
(728.58± 159.50) and HRT18
Kiss1rkd
 (678.99± 124.27) in comparison 
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with the control group (HRT18 pEF: 570.13 ± 47.40), while the value did not show a 
statistically significant (p> 0.05). 
 
4.3.3 Effect of Kiss-1 and Kiss-1R knockdown on HT115 cancer cell adhesion 
HT115 cells were further investigated for their adhesive properties in an in vitro 
Matrigel adhesion assay. Compared with the control group (HT115 pEF35±7.80), 
both Kiss-1 and Kiss-1R knockdown cells did not demonstrate a significant change 
(32±9.02 and 41.5±12.66 respectively) (Figure 4.2). 
 
4.3.4 Effect of Kiss-1 and Kiss-1R knockdown on HRT18 cancer cell adhesion 
Likewise, HRT18 cells were investigated for their adhesive properties in an in vitro 
Matrigel adhesion assay. Similarly, there was mild fluctuation between the cells with 
Kiss-1 knockdown (28.67±10.91) and Kiss-1R knockdown (43.5±13.58) and the 
HRT18 pEF cells (26±7.89) (Figure 4.3).  
 
4.3.5 Influence of Kiss-1 and Kiss-1R knockdown on HT115 cell invasion 
Figure 4.4 showed that the cells with Kiss-1 knockdown (55.91±2.75) significantly 
increased in invasiveness compared with HT115 pEF cells (27 ± 3.16) (p= 0.015). 
While HT115 Kiss-1R knock down cells did not demonstrate a significant difference 
with the control (Figure 4.4). 
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4.3.6 Influence of Kiss-1 and Kiss-1R knockdown on HRT18 cell invasion 
Similarly, there was an increase of invasion in the Kiss-1 knockdown HRT18 cells 
(59.13± 6.34) compared with HRT18 pEF cells (39.75±6.90) from Figure 4.5 (p= 
0.0077). There was no statistical significance between the HRT18 Kiss-1R 
knockdown and HRT18 pEF cells (p< 0.05). 
 
4.3.7 Effect of Kiss-1 and Kiss-1R knockdown on the motility of HT115 cells 
To analyse the motility of HT115 cells, a scratch wounding assay was employed. 
After 2 hours the cells with Kiss-1 knockdown showed a significant increase in the 
pace of migration compared with the control group with the difference appearing to 
reach maximum (59.16± 6.52) at the fifth hour (Figure 4.6) (p= 0.0094). However the 
difference of the migration of HT115 Kiss-1 knockdown and HT115 pEF cells did not 
show a statistical significance (p> 0.05). 
 
4.3.8 Effect of Kiss-1 and Kiss-1R knockdown on the motility of HRT18 cells 
A similar influence of Kiss-1 knockdown on HRT18 cells was seen which revealed 
significant increase in motility compared with the control group, consistently from 3
td
 
hour to 5
th
 hour. At the end of the test, the cells with kiss-1 knockdown and pEF 
reached 59.18± 6.25 and 40.62± 7.59 respectively. There was a significant difference 
between HRT18 Kiss-1 knockdown and HRT18 pEF cells (p= 0.001289), while 
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HRT18 Kiss-1R rib (43.95±6.44) did not show a significant difference with HRT18 
pEF (Figure 4.7). 
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HT115 pEF 
(mean ± SD) 
N=6 
HT115 Kiss-1 kd 
(mean ± SD) 
N=6 
HT115 Kiss-1R kd 
(mean ± SD) 
N=6 
829.611 ± 265.92 1223.32 ± 356.59 1138.22 ± 213.46 
 
Figure 4.1.A.HT115 cells with knockdown of Kiss-1 and Kiss-1Rconsistently 
increased growth compared with HT115 pEF. After 5 days incubation there was a 
slight increase in the HT115
kiss-1kd
 cells (1223.32 ± 356.59) and HT115
kiss-1rkd
 cells 
(1138.22 ± 213.46) compared with the control HT115
pEF
 (829.611 ± 265.92). Data 
shown is representative of 3 repeats of experiment. Each experiment has 6 
independent repeats. Error bars represent standard deviation. The absorbance of Day 
1 was used as a baseline to normalise the data. Original data is shown in Table 9 of 
Appendices. 
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HRT18 pEF 
(mean ± SD) 
N=6 
HRT18 Kiss-1 kd 
(mean ± SD) 
N=6 
HRT18 Kiss-1R kd 
(mean ± SD) 
N=6 
570.13 ± 47.40 728.58 ± 159.50 678.99 ± 124.27 
 
Figure 4.1.B. HRT18 cells with Knockdown of Kiss-1 and Kiss-1R increased growth 
compared with HRT18pEF. After 5 days incubation there was a slight increase in the 
HRT18
kiss-1kd
cells and HRT18
kiss-1rkd
 cells compared with the control HRT18
pEF
. Data 
shown is representative of 3 repeats of experiment. Each experiment has 6 
independent repeats. Error bars represent standard deviation. The absorbance of Day 
1 was used as a baseline to normalise the data. Original data is shown in Table 10 of 
Appendices. 
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HT115 pEF 
(mean ± SD) 
N=6 
HT115 Kiss-1 kd 
(mean ± SD) 
N=6 
HT115 Kiss-1R kd 
(mean ± SD) 
N=6 
35±7.80 32±9.02 41.5±12.66 
 
Figure 4.2.Knockdown of Kiss-1 and Kiss-1R in HT115 cells did not display 
significantly different adhesive ability compared with the control group. Three 
Representative images of cells following staining are displayed in the top. The cells 
on an artificial Matrigel basement membrane, showed a slight decrease in 
HT115
kiss-1kd 
cells compared with the control HT115
pEF
 after 40 minutes incubation. 
While there was a gentle increase in HT115
kiss-1rkd 
cells compared with the control 
HT115
pEF
 cells. Data shown is representative of 3 repeats of experiment. Each 
experiment has 6 independent repeats. Error bars represent standard deviation. 
Original data is shown in Table 11 of Appendices. 
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HRT18 pEF 
(mean ± SD) 
N=6 
HRT18 Kiss-1 kd 
(mean ± SD) 
N=6 
HRT18 Kiss-1R kd 
(mean ± SD) 
N=6 
26±7.89 28.67±10.91 43.5±13.58 
 
Figure 4.3.Knockdown of Kiss-1 and Kiss-1R in HRT18 cells did not display 
significantly different adhesive ability compared with the control group. Three 
representative images of cells following staining are displayed in the top. The cells on 
an artificial Matrigel basement membrane, showed a gentle increase in HRT18
kiss-1kd 
and HRT18
kiss-1rkd 
cells compared with the control HRT18
pEF
 after 40 minutes 
incubation. Data shown is representative of 3 repeats of experiment. Each experiment 
has 6 independent repeats. Error bars represent standard deviation. Original data is 
shown in Table 12 of Appendices. 
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HT115 pEF 
(mean ± SD) 
N=4 
HT115 Kiss-1 kd 
(mean ± SD) 
N=4 
HT115 Kiss-1R kd 
(mean ± SD) 
N=4 
44.25±5.38 55.91±2.75 46±10.36 
 
Figure 4.4.The influence of Kiss-1 and Kiss-1R knockdown on the invasive 
capability of HT115 cells. Three representative images of cells following staining are 
displayed in the top. There was a marked increase of cell invasion in HT115
Kiss-1kd 
compared with that of the control (HT115
pEF
) after 3 day incubation of the cells on an 
artificial Matrigel basement membrane. Data shown is representative of 3 repeats of 
experiment. Each experiment has 4 independent repeats. Error bars represent standard 
deviation.*represents p< 0.05 analyzed by T-test (HT115
Kiss-1kd  
vs HT115
pEF
: p= 
0.015). Original data is shown in Table 13 of Appendices. 
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HRT18 pEF 
(mean ± SD) 
N=4 
HRT18 Kiss-1 kd 
(mean ± SD) 
N=4 
HRT18 Kiss-1R kd 
(mean ± SD) 
N=4 
39.75±6.90 59.13± 6.34 34±7.03 
 
Figure 4.5.The effects of Kiss-1 and Kiss-1R knockdown on the invasive capability 
of HRT18 cells. Three representative images of cells following staining are shown in 
the top. There was a significant increase of cell invasion in HRT18
Kiss-1kd
cells 
compared with the control HRT18
pEF
 after 3 day incubation of the cells on an 
artificial Matrigel basement membrane. Data shown is representative of 3 repeats of 
experiment. Each experiment has 4 independent repeats. Error bars represent standard 
deviation.*stands for p< 0.05, analysed by T-test (HRT18
Kiss-1kd 
vs HTRT18
pEF
: p= 
0.0077). Original data is shown in Table 14 of Appendices. 
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HT115 pEF 
(mean ±SD) 
HT115Kiss-1 kd 
(mean ± SD) 
HT115 Kiss-1R kd 
(mean ± SD) 
41.70± 3.98 59.16± 10.54 46.87±9.89 
 
Figure 4.6.Knockdown of Kiss-1 had a discernible effect on the migration of HT115 
cells. After 2 hours the significant difference in cell motility of HT115
kiss-1kd 
was 
visualized compared with the control HT115
pEF
. Data shown is representative of 3 
repeats of experiment. Error bars represent standard deviation.*represents p< 0.05, 
analyzed by T-test (HT115
Kiss-1kd 
vs HT115
pEF
: p= 0.0094). Original data is shown in 
Table 15 of Appendices. 
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HRT18 pEF 
(mean ± SD) 
N=6 
HRT18 Kiss-1 kd 
(mean ± SD) 
N=6 
HRT18 Kiss-1R kd 
(mean ± SD) 
N=6 
40.62±7.59 59.18±6.52 43.95±6.44 
 
Figure 4.7.Knockdown of Kiss-1 had a marked effect on the migration of HRT18 
cells. There was a consistent difference in cell motility of HRT18
kiss-1kd 
cells 
compared with the controlHRT18
pEF 
from 3
rd 
hour to 5
th
 hour. Data shown is 
representative of 3 repeats of experiment. Error bars represent standard deviation.* 
stands for p< 0.05, ***p< 0.001 analyzed by T-test (HRT18
Kiss-1kd 
vs HRT18
pEF 
p= 
0.001289). Original data is shown in Table 16 of Appendices. 
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4.3.9 Effect of Kiss-1 and Kiss-1R knockdown on the motility of cancer cells, 
ECIS based analysis 
Figure 4.8 demonstrates that HT115 Kiss-1 knockdown cells treated with 
Kisspeptin-10 had a significant decrease in motility compared with the control (no 
treatment) (p= 0.0205), while there was no significant difference between control and 
the Kiss-1R knockdown cells. In contrast, neither Kiss-1 knockdown or Kiss-1R 
knockdown cells treated with Kisspeptin-234 showed a difference in comparison with 
the control groups (no treatment) (p> 0.05) (Figure 4.9). From Figure 4.10, it can be 
easily seen that the adherence of Kiss-1 knockdown cells treated with ERK inhibitor 
significantly decreased compared with that of the control group (no treatment) after 
wounding (p= 0.0397). There was a slight decrease in the Kiss-1R knockdown cells 
treated with ERK inhibitor compared with the untreated cells, but the difference did 
not reach the significant level (p> 0.05). A similar situation was also observed in the 
comparison between the control group (no treatment) and the cells treated with ERK 
inhibitor+ Kisspeptin-234 (Figure 4.12). What is more, by contrast to the groups 
treated with ERK inhibitor and ERK inhibitor+ Kisspeptin-234, there were more 
striking links between the Kiss-1 knockdown cells treated with ERK inhibitor+ 
Kisspeptin-10 and its control (no treatment) (p= 0.0164) (Figure 4.11). 
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Figure 4.8.A and B.The effect of Kiss-1 and Kiss-1R knockdown on the migration 
ability of HT115 cells treated with Kisspeptin-10 compared with control group (serum 
no treatment). A. ECIS traces (mean of 4 sets) of cell migration of cells in two groups 
of experiments, namely, serum free and Kisspeptin-10, during an 8 hour experiment, 
following electric wounding. B. Overall changes of resistance on the eighth hour *p< 
0.05vs the respective control group at the specific time point. Original data is shown 
in Table 17 of Appendices. 
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Figure 4.8.C.The effect of Kiss-1 knockdown on the migration ability of HT115 cells 
treated with Kisspeptin-10 compared with control group (no treatment). Left: HT115 
kiss-1 knockdown cells control; right: the same cells treated with kisspeptin-10. The 
decreased migration of cells treated with Kisspeptin-10 compared with the control (no 
treatment) using ECIS was shown as 3D model. Shown are changes of normalized 
resistance measured at different frequencies over a period up to 8 hours. 
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Figure 4.9.The effect of Kiss-1 and Kiss-1R knockdown on the migration ability of 
HT115 cells treated with Kisspeptin-234 compared with control group (no treatment). 
A. Cells in two different experimental settings (no treatment and Kisspeptin-234) 
during 8 hours after wounding. B. Overall changes of resistance on the eighth hour. 
Original data is shown in Table 18 of Appendices. 
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Figure 4.10.A and B.The effect of Kiss-1 and Kiss-1R knockdown on the migration 
ability of HT115 cells treated with ERK inhibitor compared with control group (no 
treatment). A. The mean trace of the cells in two groups of experiments (no treatment 
and ERK inhibitor) during 8 hours after wounding. B. Overall changes of resistance 
on the eighth hour. *p< 0.05 vs the respective control group at the specific time point. 
Original data is shown in Table 19 of Appendices. 
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Figure 4.10.C.The effect of Kiss-1 knockdown on the migration ability of HT115 
cells treated with ERK inhibitor compared with control group (no treatment), shown 
in 3D. Shown are changes of normalized resistance measured at different frequencies 
over a period up to 8 hours. 
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Figure 4.11.A and B.The effect of Kiss-1 and Kiss-1R knockdown on the migration 
ability of HT115 cells treated with ERK inhibitor and Kisspeptin-10 compared with 
control group (no treatment). A. Cell responses after wounding (no treatment and 
ERK inhibitor+ Kisspeptin-10) during 8 hours after wounding. B. Overall changes of 
resistance on the eighth hour *p< 0.05 vs the respective control group at the specific 
time point. Original data is shown in Table 20 of Appendices.  
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Figure 4.11.C.The effect of Kiss-1 knockdown on the migration ability of HT115 
cells treated with ERK inhibitor+ Kisspeptin-10 compared with control group (no 
treatment), shown in 3D. Shown are changes of normalized resistance measured at 
different frequencies over a period up to 8 hours. 
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Figure 4.12.A and B.The effect of Kiss-1 and Kiss-1R knockdown on the migration 
ability of HT115 cells treated with ERK inhibitor+ Kisspeptin-234 compared with 
control group (no treatment). A. Cells responses in different experimental settings, 
namely serum free and ERK inhibitor+ Kisspeptin-234, over an 8 hours period after 
wounding. B. Overall changes of resistance on the eighth hour *p< 0.05 vs the 
respective control group at the specific time point. Original data is shown in Table 21 
of Appendices.  
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Figure 4.12.C.The effect of Kiss-1 knockdown on the migration ability of HT115 
cells treated with ERK inhibitor+ Kisspeptin-234 compared with control group (no 
treatment), as shown in a 3D model. Shown are changes of normalized resistance 
measured at different frequencies over a period up to 8 hours. 
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4.3.10 Knockdown of Kiss-1 reduced tumour growth in vivo 
From Figure 4.13, it is observed that the tumour growth of the group of Kiss-1 
knockdown increased significantly compared with the control group during the 7 
week period. On the eighth day, both the Kiss-1 knockdown group and the control 
group have measurable tumours with no statistical difference between the two groups 
(p> 0.05) after that the tumour size of both groups gradually decreased. The possible 
reason was that the Matrigel, which was used to suspend the cells, formed nodules at 
the initial stage after injection and also insufficient number of tumour cells injected. 
However, significant differences were observed between the Kiss-1 knockdown group 
and the control group at 22
nd 
(p= 0.034882), 29
th 
(p=0.009967) and 36
th
 (p= 0.039235) 
days respectively. Using Two-was ANOVA analysis (Tukey corrections) with time 
and group as variables, there is a significant different between the control and Kiss-1 
knockdown groups (P=0.002) (Figure4.13). 
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Figure 4.13.In vivo tumour growth of HT115 cells in CD-1 athymic nude mice. * 
p<0.05 vs the respective control group at the specific time point. The two groups had 
a significant difference over the 7 weeks period by using two-way ANOVA (Tukey 
model) test (p=0.002) 
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4.4 Discussion 
For the last two decades, more than 30 putative metastasis suppressors have been 
recognized [123]. These molecules inhibit widely multiple steps of the metastatic 
cascade, which include adhesion, invasion, angiogenesis and colonization of ectopic 
tissues. Most of the molecules do not significantly affect the growth of cancer cells, 
thus marking them different from the classical oncogenes. The kiss-1 gene was first 
suggested as a metastasis suppressor in human melanoma [61]. Nash et al. reported 
that Kiss-1 re-expression inhibit multiple organ metastasis combined with Kiss-1 
receptor (Kiss-1R) [124]. Studies with human melanomas, breast cancer and 
pancreatic cancer xenografts demonstrated that Kiss-1 reduced proliferation of 
orthotopic tumours to other organs in all of the tested models [61, 71, 124-125]. 
Kiss-1 kept disseminated tumour cells in a dormant state so as to block the 
development of macroscopic metastases [71, 124-126]. Once the dissemination of 
cancer cells, which occurs before macroscopic detection clinically, is intervened, its 
value will contribute to the cancer therapy. However, the function of Kiss-1 as a 
metastasis suppressor in some cancers, including colorectal cancer is not clear. For 
this purpose, we used transfected HT115 and HRT18 cells with Kiss-1 and Kiss-1R 
knockdown and empty plasmid (pEF) to deduce the influence of Kiss-1 and its 
receptor on the function of colorectal cancer cells. Through the comparison between 
the control group and the knockdown groups, we wanted to verify if Kiss-1 and 
Kiss-1R may transform the function of colorectal cancer cells. The in vitro function 
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assays included growth, adhesion, invasion and migration assays, we repeated each 
assays more than three times to avoid artificial errors and ensure stability and 
accuracy of the results. The general trend of all repeats manifested consistency. There 
was no statistically significant effect of Kiss-1 and Kiss-1R knockdown on the growth 
of both HT115 and HRT18 cells (p>0.05), even if the growth of cells with Kiss-1 and 
Kiss-1R knockdown increased compared with both HT115 and HRT18 pEF cells 
(Kiss-1 kd in HT115: p= 0.0609; Kiss-1R kd in HT115: p= 0.057; Kiss-1 kd in 
HRT18: p= 0.059; Kiss-1R kd in HRT18: p= 0.089). Similarly, the effect of Kiss-1 
and its receptor on the adhesion of HT115 and HRT18 cells did not show a significant 
difference compared with controls (p> 0.05). However the contrast observations were 
made with invasion assays, namely there were significant links between Kiss-1 
knockdown cells and the controls in both HT115 and HRT18 cell lines but not with 
Kiss-1R knockdown cells.  
With regard to the influence of Kiss-1on the motility of colorectal cancer cells, 
migration assays have shown that Kiss-1 negatively regulated the motility of both 
HT115 and HRT18 cells. The inhibitory influence of Kiss-1 was more significant on 
HRT18 cells than on HT115 cells at the 5
th 
hour. There was no obvious difference 
between the knockdown groups and the control group during the first 2 hours. After 
that the cells with Kiss-1 knockdown revealed a visible increase compared with the 
pEF cells. P value in figure 4.5 (p= 0.0077) and 4.6 (p= 0.0094) demonstrated the 
links between knockdown groups and the control at 5
th
 hour, while there was no 
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significant difference between the Kiss-1R knockdown cells and the controls (HT115 
pEF and HRT18 pEF). 
Through the analysis of ECIS assays, we focused on the investigation of the 
involvement of the ERK pathway and Kisspeptin-10 in Kiss-1 and Kiss-1R on cell 
migration. As shown in figure 4.8 and 4.10, the Kiss-1 knockdown cells treated with 
Kisspeptin-10 and ERK inhibitor respectively showed a significant decrease of 
migration ability compared with the control groups. It validated again the previous 
conclusion of the inhibitory effect of Kiss-1 on the migration ability of colorectal 
cancer cells using wounding assays through the treatment of Kisspeptin-10. What is 
more, it pointed out the inhibitory influence of Kiss-1 on cell migration via the ERK 
pathway. Furthermore, Figure 4.11 illustrated that the combined action of ERK 
inhibitor and Kisspeptin-10 caused more significant decrease of adhered cells in the 
Kiss-1 knockdown cells compared with the control through two tracks: the inhibition 
of the ERK signaling pathway and the increased activity of Kiss-1. 
The study has further demonstrated, using an in vivo tumour model, that knocking 
down Kiss-1 from HT115 cells resulted in a marked increase in tumour growth as 
shown in figure 4.13. The present study was limited due to various restraints 
including the experimental conditions and number of cells injected, as there was little 
information in the literature on using this cell line in animal studies. This resulted in 
the steady decline of tumour size in both control and Kiss-1 knockdown groups. 
Future studies would need to re-explore the optimal conditions for using this cell line 
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with the particular experimental settings. The cell number of MDA-MB-435s 
transfected by full-length Kiss-1 cDNA used in the in vivo study at 1997 by D.R. 
Welsh should be a great reference for our future studies. In addition, Kisspeptin-10 
should be suggested as a treatment to determine if it would have a negative effect on 
the tumour growth of the in vivo tumour model. However, the significant difference 
between the two groups is nonetheless highly supportive of the potential tumour 
suppressor role of Kiss-1. 
Overall, it is easily seen that Kiss-1 had a significant inhibition on the migration and 
invasion of HT115 and HRT18 cells, while it did not show a strong inhibitory effect 
on the growth and adhesion in colorectal cancer cells. It prompted the conclusion that 
Kiss-1 may have a negative regulatory effect on the motility of colorectal cancer cells, 
while Kiss-1R did not seemingly exhibit as strong an inhibition on the migration and 
invasion of colorectal cancer cells as Kiss-1 (p< 0.05). In the following chapter, we 
will further analyze how Kiss-1 affects the colorectal cancer cells in the signaling 
pathway. Kiss-1 has been reported to activate a variety of signals (e.g. phospholipase 
C, protein kinase C, ERK1/2, intracellular Ca
2+
 mobilization) through Kiss-1R [126]. 
On the basis of the study of in vitro function assays, which displayed the significant 
inhibitory effect on the motility and invasion of colorectal cancer cells, the interaction 
between Kiss-1 and MMPs were considered in the MAPK signaling pathway, 
especially MMP-9 and MMP-2. MMPs, as the most important proteases related with 
tumour metastasis, can degrade extracellular matrix and basement membrane. Yan et 
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al, [127] proved that there was a marked reduction of in vitro invasion through 
Matrigel
®
-coated porous filters by HT-1080 cells which had reduced transcription and 
activity of MMP-9 following the over-expression of Kiss-1 [73]. This report provides 
grounds of argument to support the next study of the influence of Kiss-1 on MMPs 
through MAPK signal pathway in colorectal cancer cells. 
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Chapter 5 
 
The influence of Kiss-1 on the enzyme activities 
of MMP-9 and MMP-2  
177 
 
5.1 Introduction 
Metastasis is the most life-threatening complication of solid tumours [128]. Surgical 
intervention would be easy to get rogue lesions and micro-metastases in distant sites 
if it did not achieve complete resection of the primary neoplasm. This is particularly 
apparent in melanoma, in which 90% of the patients who died of melanoma were 
found to have lung metastasis at the time of autopsies [129]. What is more, the 
incidence rate of melanoma has increased 15 fold during the last 50 years, which has 
made its contribution to morbidity and mortality a public health concern. Therefore, a 
clear understanding of tumour metastasis and the role played by metastasis suppressor 
genes in regulating this cascade are important[129]. Kiss-1 was suggested as a novel 
tumour suppressor genes and provides us with a vital target for investigation in 
melanoma [61]. This has been further demonstrated by data presented in Chapter-5 of 
this thesis, in which Kiss-1 demonstrated a tumour suppressive role in colorectal 
cancer. However, the mechanism of the metastasis suppressor function of Kiss-1 
remains poorly understood. Yan et al. reported that Kiss-1 can diminish P65 and P50 
NF-KB proteins which can combine with the promoter of MMPs, so as to reduce the 
synthesis of MMPs and inhibit the effects on the mobility and invasion of cancer cells 
[48, 70, 73]. Another study demonstrated that the activation of Kiss-1R by 
Kisspeptin-10 can abolish the activation of protein kinase B [116] by the tyrosine 
kinase receptors for epidermal growth and lymphoid cell lines. Furthermore, the 
signaling of Kiss-1R was found to be the main trigger of apoptosis in epithelial and 
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lymphoid cell lines [130]. Interestingly, this phenomenon depended on the activation 
of the ERK pathway rather than the inhibition of Akt [130]. This data may establish 
the novel experimental basis for a paracrine mode of action by which Kisspeptins 
inhibit the metastatic potential of cancer cells. 
The previous chapter showed a significant effect of Kiss-1 and its receptor 
knockdown on the motility of colorectal cancer cells. Here, in light of previous study, 
we investigated if Kiss-1R was phosphorylated at the phospho-tyrosine 
phosphorylation site when combined with Kisspeptin-10 in colorectal cancer cells in 
the light of previous studies and if Kiss-1 inhibits MMP-9 and MMP-2 through ERK 
signaling pathway as a potential mechanism of action to account for the suppression 
of colorectal cancer cells motility. 
 
5.2 Materials and methods 
5.2.1 Cell lines 
HT115 and HRT18 cell lines were routinely cultured in DMEM-F12 medium as 
described in Chapter 2. 
 
5.2.2 Generation of Kiss-1 and Kiss-1R ribozyme transgenes 
Hammerhead ribozymes targeting Kiss-1 and Kiss-1R were designed based on the 
secondary structure of Kiss-1 and Kiss-1R mRNA respectively and synthesized 
following the method described in Chapter 2. 
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5.2.3 Generation of Kiss-1 and Kiss-1R knockdown in colorectal cancer cell lines 
The plasmids were transfected into colorectal cells through by the electroporation at 
310V. Subsequently, the cells were placed into 5 μg/ml blasticidin selection for a 
sufficient period to kill cells which did not contain the plasmid. Empty plasmid 
vectors were used to transfect the cells as control. The verification of Kiss-1 and 
Kiss-1R knockdown in the transfected cells was done using RT-PCR, Q-PCR and 
Western blotting as described in Chapter 3. 
 
5.2.4 Immunoprecipitation 
In our study, immunoprecipitation (IP) was used for testing if Kiss-1R can be 
phosphorylated at the tyrosine phosphorylation site in colorectal cancer cells. The 
process involves adding a specific antibody (Kiss-1R in this case) recognising a 
protein of interest within a cell lysate. This is then mixed with sepharose or agarose 
bonded staphylococcal protein A, protein G, or both, in order to collect the ensuing 
protein-antibody complexes. These complexes are then centrifuged to induce 
precipitation, run on an SDS-PAGE gel, and evaluated using immune probing. The 
details of the process have been outlined in Chapter 2. 
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5.2.5 Gelatin zymography assay 
1x10
6
 cells were counted and seeded to a tissue culture flask and incubated overnight. 
After incubation, the samples were washed once with 1x BSS followed by a wash 
with serum-free DMEM and then either incubated in serum-free DMEM control or 
treated medium for 4 hours. Following the 4 hours treatment, the samples were 
prepared in non-reducing sample buffer and the medium was collected. Protein 
samples were separated using SDS-PAGE on gels containing 10% gelatin 
(Sigma-Aldrich Inc, USA).After SDS-PAGE, gels were renatured by washing with 
buffer twice (15 minutes for each wash) at room temperature, and then soaked in 
developing buffer at 37
o
C for 36- 40 hours incubation. Following incubation, the gels 
were stained with 0.5 % Coomassie blue in distilled de-ionized water for 1 hour and 
washed in destain buffer for approximate 1 hour based on the staining strength of gel. 
The presence of clear bands where MMP2 and MMP9 were located and gelatin was 
degraded, indicated proteins activity. 
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5.3 Results 
5.3.1 Tyrosine phosphorylation were increased by Kiss-1R knockdown 
To investigate the influence and functional status of Kiss-1R and the effects of 
Kisspeptin-10, a Kiss-1 receptor agonist, on colorectal cancer cells on tyrosine 
phosphorylation, Immunoprecipitation (IP) was carried out to examine tyrosine 
phosphorylation level of Kiss-1R in HT115 pEF cells treated with Kisspeptin-10 
(Figure 5.1.A). The cells were divided into four groups, which respectively accepted 
different treatment: no treatment (control), Kisspeptin-10, Kisspeptin-234 and 
positive control (sodium orthovanadate and hydrogen peroxide). Kisspeptin-234 is 
Kisspeptin-10/Kiss-1R antagonist, which belongs to Kisspeptin-10 analogue. Results 
demonstrated that the tyrosine phosphorylation of Kiss-1R in the cells treated with 
Kisspeptin-10 was strongly activated compared with both the cells without treatment 
and the cells treated with Kisspeptin-234 (p< 0.001), in the meantime, there was no 
significant difference between those cells treated with Kisspeptin-234 and control 
cells (p= 0.4035). The detailed data is showed in Table 5.1. For obtaining actual and 
reliable research results, the experiment was repeated three times and mean value 
taken. 
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Figure 5.1.Effect on tyrosine phosphorylation of Kiss-1R in HT115 pEF. 
A. Immunoprecipitation and Western blot displayed bands in HT115 pEF cells, which 
were treated with no treatment (control), Kisspeptin-10, Kisspeptin-234 and positive 
control for each group. Anti-Kiss-1R was used for the immunoprecipitation and 
primary antibody in the Western blot and probing was PY20. 
B. The comparison among four different treatments, showed the representative 
histogram of the difference in intensity of bands in HT115 pEF. The intensity of band 
of cell treated with Kispeptin-10 was significantly increased compared with the 
control. Experiment was repeated three times and mean value taken. Error bars 
represent SD. Asterisk represents p< 0.05. Relative intensity of bands was analyzed 
using by Image-J software. Original data is shown in Table 22 of Appendices. 
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Table 5.1.The intensity of bands in HT115 pEF 
Control 
Mean+SD 
N=3 
+Kisspeptin-10 
Mean+SD 
N=3 
+Kisspeptin-234 
Mean+SD 
N=3 
Positive control 
Mean+SD 
N=3 
250356.3+ 
30308.83 
356095+ 
31705.2 
269073+ 
34635.64 
331635.7+ 
112206.7 
Control vs + Kisspeptin-10, P= 0.01396; + Kisspeptin-234 vs + Kisspeptin-10, P = 0.03259 
 
5. 3.2 ERK inhibition impact on MMP-9 activity in Kiss-1 knockdown and 
control cells following treated with Kisspeptin-10 and Kisspeptin-234. 
 
In chapter 4, we established that Kiss-1 inhibited the migration and invasion of 
colorectal cancer cells (HT115 and HRT18). A previous study has reported that the 
overexpression of Kiss-1 could reduce transcription and activity of MMP-9 and in 
doing so suppress the invasion of HT-1080 cells [73]. In addition, thyroid cancer cells 
transfected with Kiss-1R showed a strong and sustained phosphorylation of ERK1/2 
after treatment with Kiss-1 [74]. Here, we further explored the influence of Kiss-1 
knockdown together with treatment with Kisspeptin-10 and 234 on MMP-9 and 
MMP-2 activity, together with the inhibition of ERK pathway in the HT115 cell line. 
The cells were divided into three treatment groups namely no treatment (control 
group), Kisspeptin-10 and Kisspeptin-234 respectively. For each group, two pairs of 
HT115 pEF and HT115 Kiss-1 knockdown cells were treated without or with ERK 
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inhibitor, namely control and + ERK inhibitor respectively. Figure 5.2 displays the 
results from zymography experiments and shows that expression of Kiss-1 and 
treatment of the cells with the inhibitors had a greater impact on the enzyme activity 
of MMP-9 than on that of MMP-2. Hence, the difference in MMP-9 expression in 
HT115 cells was chosen to analyse further. The results showed that the intensity of 
MMP-9 bands in the cells treated with the ERK inhibitor was decreased compared 
with the control in all three groups (no treatment, Kisspeptin-10 and Kisspeptin-234) 
(figure 5.3 and 5.4). Figure 5.3 showed that the difference of the enzyme activity of 
MMP-9 in HT115 pEF cells of all three groups. The enzyme activity of MMP-9 in 
HT115 pEF cells treated with ERK inhibitor was significantly inhibited compared 
with that of controls in all three groups (cells+ ERK inhibitor vs control in the group 
of no treatment: p= 0.006577; cells+ ERK inhibitor vs control in the group of 
Kisspeptin-10: p= 0.001839; cells+ ERK inhibitor vs control in the group of 
Kisspeptin-234: p= 0.005935). Figure 5.4 demonstrated that that the difference of the 
enzyme activity of MMP-9 in HT115 Kiss-1 knockdown cells of all three groups. 
Similarly with HT115 pEF cells, the enzyme activity of MMP-9 in HT115 Kiss-1 
knockdown cells treated with ERK inhibitor brought about a strong inhibition in 
comparison with the controls in the groups of no treatment (p= 0.00017) and 
Kisspetin-10 (0.001544). Furthermore, the results pointed out that both HT115 pEF 
and HT115 Kiss-1 knockdown cells treated with Kisspeptin-10 showed a decreased 
expression of MMP-9 in comparison with the cells treated with serum free and 
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Kisspeptin-234 from Figure 5.3 and 5.4. The experiments were repeated three times 
and mean value taken. 
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(Figure 5.2, Legend please see next page) 
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Figure 5.2.The enzyme activity of MMP-9 and MMP-2 in HT115 pEF and HT115 
Kiss-1 knockdown (kd) cells, following treatment (no treatment, Kisspeptin-10 and 
Kisspeptin-234). A. The enzyme activity of MMP-9 and MMP-2 in the control group 
and the group treated with ERK inhibitor. B. The expression of MMP-9 and MMP-2 
in HT115 pEF and HT115 Kiss-1 knockdown (kd) cells, which were treated with 
Kisspeptin 10, in the presence of ERK inhibitor. C. The enzyme activity of MMP-9 
and MMP-2 in the group treated with Kisspeptin-234, in the presence ERK inhibitor.  
 
Table 5.2.The intensity of MMP-9 bands in HT115 pEF and HT115 Kiss-1 
knockdown (kd) cells with no treatment 
Treatment Control ERK inhibitor 
Cell lines HT115 
pEF 
HT115 
Kiss-1 kd 
HT115 
pEF 
HT115 
Kiss-1 kd 
Intensity of bands 
(mean+ SD, n= 3) 
5058.33±1
43.16 
5516.33±8
2.25 
4597±47.
16 
4790± 
42.52 
 
Table 5.3.The intensity of MMP-9 bands in HT115 pEF and HT115 Kiss-1 
knockdown (kd) cells treated with Kisspeptin-10 
Treatment Control ERK inhibitor 
Cell lines HT115 
pEF 
HT115 
Kiss-1 kd 
HT115 
pEF 
HT115 
Kiss-1 kd 
Intensity of bands 
(mean+SD, n= 3) 
4935± 
58.65 
4944± 
63.07 
4570± 
60.01 
4632± 
30.99 
 
 
Table 5.4.The intensity of MMP-9 bands in HT115 pEF and HT115 Kiss-1 
knockdown (kd) cells treated with Kisspeptin-234 
Treatment Control ERK inhibitor 
Cell lines HT115 
pEF 
HT115 
Kiss-1 kd 
HT115 
pEF 
HT115 
Kiss-1 kd 
Intensity of bands 
(mean+ SD, n= 3) 
5181± 
120.75 
5361.33± 
237.769 
4701±10
8.04 
5027± 
116.66 
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Figure 5.3.Effects of Kiss-1 and ERK inhibitor on MMP activities. The histograms 
demonstrated that the difference of MMP-9 enzyme activity in three groups of HT115 
pEF cells (no treatment, Kisspeptin-10 and Kisspeptin-234).Plus sign (+) represents 
for corresponding treatment. For each group, the enzyme activity of MMP-9 in pEF 
cell treated with ERK inhibitor all showed the significant decrease compared with the 
control. Asterisks stand for p< 0.05. Experiment was repeated three times and mean 
value taken. Relative intensity of bands was analyzed using by Image-J software. 
Original data is shown in Table 23 of Appendices. 
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Figure 5.4.The bar graphs show the difference of MMP-9 enzyme activity in HT115 
Kiss-1 knockdown cells. The cells were separated into three groups on the basis of 
three different treatments (no treatment, Kisspeptin-10 andKisspeptin-234). Plus sign 
(+) represents for corresponding treatment. The significant decrease of the enzyme 
activity of MMP-9 in Cells treated with ERK inhibitor compared with the controls 
was observed in both no treatment and Kisspeptin-10 groups. Asterisks stand for p< 
0.05. Experiment was repeated three times and mean value taken. Relative intensity 
of bands was analyzed using by Image-J software. Original data is shown in Table 23 
of Appendices. 
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5.4 Discussion 
Previous studies have reported the inhibitory impact of Kiss-1 on MMP-9 and the 
increased ERK phosphorylation caused by ARO cells treated with Kiss-1 [73-74]. 
Masato and colleagues reported that Kiss-1R bound with Kisspeptin derived from the 
product of Kiss-1 stimulated PIP2 hydrolysis, Ca
2+
 mobilization, arachidonic acid 
rease and ERK1/2 tyrosine phosphorylation in Chinese hamster ovary K1 cells [64]. 
Our current study aimed to test if treatment of HT115 cells with Kisspeptin-10 may 
cause phosphorylation of the Kiss-1 receptor. It was also aimed to examine the impact 
of Kisspeptin-10 on the on MMP-9 and MMP-2 in the context of Kiss-1 knockdown. 
The third aim was to test if ERK signal pathway plays a role in Kiss-1 mediated effect 
on MMP-9 and MMP-2. Knocking down Kiss-1 in HT115 cells (Figure-5.2) resulted 
in an increase in MMP-9 activities. This change of MMP-9 activities was 
significantly blocked when ERK pathway was blocked by an ERK inhibitor. 
Furthermore, It can be seen that the activated Kiss-1 receptor from cells treated with 
Kisspeptin-10 was significantly stronger than that for the cells treated with serum free 
and Kispeptin-234 (p< 0.001) through the analysis of Immunoprecipitation in HT115 
cells. This suggests that Kisspeptin-10, a Kiss-1 agonist is able to activate the Kiss-1 
receptor in HT115 cells. As expected, Kisspeptin-234, a Kisspeptin-10/Kiss-1R 
antagonist has no significant effect on the receptor activation (p> 0.05).  
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The present study indicates that Kiss-1 may suppress motility of colorectal cancer 
cells through inhibiting the expression of MMP-9 and that this effect is likely to be 
via the ERK signaling pathway. 
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Chapter 6 
 
Expression of Kiss-1 and Kiss-1R in Human 
colorectal cancer tissues and the association 
with clinicopathological characteristics 
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6.1 Introduction 
Colorectal cancer as the second most common diagnosed cancer, it is believed to 
occur globally at a rate of approximate 1,200,000 new cases every year, accounting 
for approximately 10% of all incident cancers, with mortality rates due to colorectal 
cancer estimated at about 609,000 [3]. Local recurrence and metastases occur in about 
50% of colorectal cancer patients after radical operation. For the purpose of 
predicting the prognosis of patients with colorectal cancer and recording the anatomic 
extent of colorectal cancer, several classification system  have been established and 
modified (e.g. Dukes classification, TNM classification and T staging classification). 
The discovery of suitable biomarkers, which have correlation with tumour stage, 
invasion or recurrence, to aid in identifying colorectal cancer with high metastatic 
potential is key and would allow patients with colorectal cancer to receive effective 
chemo-radiotherapy soon after surgery. 
The Kiss-1 gene has been reported to be a novel metastasis suppressor gene in human 
melanoma and breast cancer cells [61, 71]. Kiss-1 encodes a 54-amino acid peptide, 
which is the endogenous ligand of an orphan G-protein-coupled receptor (Kiss-1R). 
After binding with Kiss-1R, Kiss-1 gene product acted with a metastasis suppressor 
function, activity to inhibit chemotaxis, invasion and metastasis of cells [48]. The 
influence of Kiss-1 and Kiss-1R on the function of colorectal cancer cells through the 
analysis of in vitro function assays has been introduced in Chapter 4. However, the 
clinical importance of the expression of Kiss-1 and its receptor remains unknown in 
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colorectal cancer. There is no available data about the association of Kiss-1 and 
Kiss-1R with tumour or patients clinicopathological characteristics in human 
colorectal cancer. In the present study, we analyzed the quantitative expression levels 
of Kiss-1 and Kiss-1R mRNAs and protein in colorectal cancer tissues and 
para-tumorous tissues in relation to tumour histopathological grade, stage and nodal 
status using the real-time Q -PCR. We also correlate the level of expression with the 
prognosis and clinical outcome of the patients. On the basis of the analysis above, we 
evaluated the efficiency of Kiss-1 and Kiss-1R as biological markers for the 
malignant potential of colorectal cancer. 
 
6.2 Materials and methods 
Colorectal tissues 
Colorectal cancer tissues (n=94) and normal background tissues (n=80) were 
collected immediately after surgery and stored in a deep freeze (-80℃) until use. 
Patients were routinely followed after surgery and the median follow up period was 
120 months for this study. The histopathological details, tumour grading (modified 
Bloom and Richardson’s grading system), Duke staging, tumour staging (TNM) and 
the prognostic index for the patients is shown in table 6.1.  
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Real-time quantitative polymerase chain reaction (Q-PCR) 
Real-time quantitative PCR, using the Amplifluor™ technique, was used for verifying 
the level of mRNA expression of Kiss-1 from the prepared cDNA samples mentioned 
above. All colorectal cDNA samples were simultaneously examined for Kiss-1 
expression along with an applicable set of plasmid standards. Q-PCR primers for 
Kiss-1and Kiss-1R were designed using Beacon Design software (PREMIER Biosoft, 
Palo Alto, CA). Sequences of primers used in the current study are provided in 
Chapter 2. Real-time PCR conditions were given in Chapter-2. 
 
Data analysis 
The relationship between Kiss-1 and Kiss-1R expression and tumour grade, TNM 
staging and nodal status was analyzed using Mann-Whitney U and Kruskal-Wallis 
tests. Survival analysis curve were performed using Kaplan-Meier survival analysis. 
Differences were considered to be statistically significant at p<0.05.  
 
6.3 Results 
Detailed patient information is outlined in table 6.1.The clinical cohort of Kiss-1 and 
Kiss-1R has been shown in Table 6.2 (A and B) below. 
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Table 6.1.Detailed information of patients with colorectal cancer
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Table 6.2.A.The correlation of the expression of Kiss-1 and clinical parameters. Red 
colouration is used to indicate statistical significance (p value< 0.05). The p value 
[131] in the statistical difference between tumour stage 2 and tumour stage 3 and 3&4 
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Table 6.2.B. The correlation of the expression of Kiss-1R and clinical parameters. 
Red colouration is used to indicate statistical significance (p value< 0.05). The p 
value [131] stands for the statistical difference between tumour stage 2 and tumour 
stage 3, 4 and 3&4. 
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6.3.1 Expression of Kiss-1 in colorectal cancer tissues and normal background 
tissues 
We analysed the expression of Kiss-1 in both colorectal cancer tissues and adjacent 
tissues using real time quantitative RT-PCR (expressed as median Kiss-1 transcript 
levels/50 ng mRNA). As shown in Table6.2.A tumour tissues had lower level of 
Kiss-1 compared with normal tissues, however the difference was not statistically 
significant. 
 
6.3.2 Expression of Kiss-1 and its relation to Dukes classification 
Duke B, C and B&C carcinoma had decreased level of Kiss-1 expression compared 
with Duke A carcinoma. This difference was found to be statistically significance 
(Figure 6.1). 
 
Statistic Duke A Duke B Duke C Duke B&C 
q1 848 104 190 163 
min 90 <0.00001 <0.00001 <0.00001 
median 5539 780 611 643 
max 31329 27762 24974 27762 
q3 24856 2272 1221 1468 
Figure 6.1.The relationship between Kiss-1 transcript levels and Dukes staging. The 
expression of Kiss-1 in duke B, C and B&C all showed a significant decrease 
compared with that in duke A 
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6.3.3 Expression of Kiss-1 and its correlation with Tumour stage 
As shown in Figure 6.3, a gradual reduction of the level of kiss-1 was displayed from 
Tumour stage Ⅱto Ⅳ and also Tumour stage Ⅲ&Ⅳ, however, none of these 
differences was found to be statistically significant. Interestingly, there was statistical 
significance between Kiss-1 level in Tumour stage Ⅱ and stage Ⅳ and Ⅲ&Ⅳ 
(Figure 6.2). 
 
Statistic T Ⅱ T Ⅲ T Ⅳ T Ⅲ&Ⅳ 
q1 789 71 215 126 
min 90 <0.00001 <0.00001 <0.00001 
median 1721 639 592 635 
max 31329 27762 5242 27762 
q3 10369 1332 1600 1419 
 
Figure 6.2.The relationship between Kiss-1 transcript level and Tumour staging. 
There were significant links between tumour stage Ⅱ and stage Ⅲ and Ⅲ&Ⅳ 
respectively. 
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6.3.4 Expression of Kiss-1 and its relationship to Lymph node involvement 
Kiss-1 expression was found to be reduced with the deepening of lymph node 
involvement (from Node 0 to Node 2). Statistically reduced levels of Kiss-1 were 
observed in Node 2 compared with Node 0 (Figure 6.3). Node 0 stands for no node 
involvement; Node 1 stands for 1 to 3 lymph nodes close to the bowel found to 
contain cancer cells; Node 3 stands for more than 3 lymph nodes found to contain 
cancer cells and further than 3cm away from the main tumour in the bowel or the 
presence of cancer cells in lymph nodes connected to the main blood vessels around 
the bowel. 
 
Statistic Node 0 Node 1 Node 2 
q1 213 67 200 
min <0.00001 <0.00001 43 
median 872 715 609 
max 31329 24974 1463 
q3 2874 1428 643 
 
Figure 6.3.The correlation of Kiss-1 levels in Lymph node involvement node 0 and 
node 2. 
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6.3.5 Expression of Kiss-1 and its correlation with TNM staging 
The expression level of Kiss-1 decreased as TNM stage progressed, and statistical 
analysis revealed significant links between TNM stage Ⅰ and stage Ⅲ, ⅢC, Ⅱ&Ⅲ, 
Ⅲ&Ⅳ and Ⅱ&Ⅲ&Ⅳ, which is outlined in Figure 6.4. 
 
Statistic TⅠ T Ⅱ T Ⅲ T Ⅳ T Ⅱ&Ⅲ T Ⅲ&Ⅳ T Ⅱ&Ⅲ&Ⅳ 
q1 814 122 84 249 122 84 249 
min 90 <0.00001 <0.00001 187 <0.00001 <0.00001 <0.00001 
median 2081 756 611 610 756 611 610 
max 31329 27762 24974 5746 27762 24974 27762 
q3 20038 2473 1079 2489 2473 1079 2489 
 
Statistic TⅠ T ⅢA T ⅢB T ⅢC 
q1 814 N/A N/A 113 
min 90 882 <0.00001 43 
median 2081 1178 738 463 
max 31329 1473 24974 1463 
q3 20038 N/A N/A 635 
Figure 6.4.The correlation between Kiss-1 transcript levels and TNM stage. The 
expression of Kiss-1 in TNM stage Ⅲ (p= 0.009), stage ⅢC (p= 0.003), stage Ⅱ&Ⅲ 
(p= 0.000.016), stage Ⅲ&Ⅳ (p= 0.009) and stage Ⅱ&Ⅲ&Ⅳ (p= 0.015) all showed 
the significant decreases in comparison with that in stage Ⅰ. Colorectal cancer TNM 
stage Ⅲ has been divided into ⅢA (T1 –T2, N1/N1c, M0 or T1, N2a, M0), ⅢB 
(T3-T4a, N1/N1c, M0 or T2-T3, N2a, M0 or T1-T2, N2b, M0) and ⅢC (T4a, N2a, 
Mo or T3-T4a, N2b, M0 or T4b, N1-N2, M0) by AJCC in 2010. Asterisks 
represented for p< 0.05 
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6.3.6 The expression of Kiss-1R in tumour tissues and normal background 
tissues 
The expression of Kiss-1R transcript was examined in the specimens of 81 colorectal 
adenocarcinoma patients using by real-time quantitative PCR (expressed as median 
Kiss-1R transcript levels/50 ng mRNA and all the data has been normalized by 
GAPDH). A significantly decreased mRNA expression level of Kiss-1R was 
observed in tumour tissues compared with the normal background tissues (Table 6.3) 
and in paired tumour and normal background tissues (Table 6.4). 
 
Table 6.3.The correlation of Kiss-1R expression in tumour tissues compared with 
normal background tissues; transcript normalized by GAPDH (shown as Kiss-1R: 
GAPDH ratio). P< 0.0001. 
Statistic Normal Tumour 
q1 1 <0.000001 
min 90 <0.000001 
median 30 <0.000001 
max 1704709 447209 
q3 2406 <0.000001 
 
Table 6.4.The relationship of Kiss-1R expression in paired tumour tissues and in 
paired normal background tissues; transcript normalized by GAPDH (shown as 
Kiss-1R: GAPDH ratio). P< 0.0001. 
Statistic 
Paired 
normal 
Paired 
tumour 
q1 <0.000001 <0.000001 
min <0.000001 <0.000001 
median 23 <0.000001 
max 809996 133.36 
q3 522 0.02 
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6.3.7 The correlation of Kiss-1R expression with clinical outcome 
Compared with levels in disease free patients, an enhanced expression of Kiss-1R was 
associated with patient morbidity over the follow up period (Figure 6.5). A significant 
difference was observed in the expression levels between alive patients and those who 
had died (Table 6.5). Interestingly, Kiss-1R expression in those patients undergoing 
chemo-radio therapy was conspicuously high in comparison with that in patients 
without therapy (Table 6.6). 
 
 
Statistic Disfree Incidence 
q1 <0.000001 <0.000001 
min <0.000001 <0.000001 
median 0.00019 0.01 
max 0.22669 41.73 
q3 0.00523 0.12 
Figure 6.5.The correlation of Kiss-1R expression in new morbidity crowd compared 
with the patients who remained disease free; transcript normalized by GAPDH 
(shown as Kiss-1R: GAPDH ratio). 
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Table 6.5.The correlation of Kiss-1R expression in the alive patients and those who 
died; transcript normalized by GAPDH (shown as Kiss-1R: GAPDH ratio). P=0.0158 
Statistic Alive Dead 
q1 <0.000001 <0.000001 
min <0.000001 <0.000001 
median 0.00028 <0.000001 
max 0.22669 41.73 
q3 0.00724 0.13 
 
 
Table 6.6.The correlation of Kiss-1R expression in the patients without therapy and 
the patients with chem-radio therapy; transcript normalized by GAPDH (shown as 
Kiss-1R: GAPDH ratio). P= 0.0115 
Statistic Nontreat Chemo-radio 
q1 <0.000001 0.012 
min <0.000001 <0.000001 
median 0.0002 0.0796 
max 0.1719 6.354 
q3 0.006 0.1607 
 
6.3.8 Correlation between Kiss-1 expression and prognosis 
Patients were divided into groups using Dukes classification as a general guide. If the 
levels of Kiss-1 and Kiss-1R transcripts in tumour samples are higher than the tumour 
samples with Duke B, the samples will be considered as having a high level described 
as Figure 6.6.A and B and Figure 6.7.A and B. Kaplan-Meier survival analysis 
demonstrated that patients with a low expression level of Kiss-1 had lower overall 
survival, being 120.340 months (95%C.I. 97.287- 143.392 months), compared with 
136.275 months (95%C.I. 111.031- 161.520 months) of patients with high expression 
of Kiss-1 (Figure 6.6.A). In regards to disease free survival, a poor survival rate was 
observed in the group with low expression levels of Kiss-1 in comparison with the 
high expression levels (Figure 6.6.B). However, all of the data above did not 
demonstrated statistical significance (p> 0.05). 
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Figure 6.6.A.The Kaplan-Meier survival model of correlation between Kiss-1 
transcript levels and overall survival. Patients with low levels of Kiss-1 had a 
relatively poor disease free survival (median=120.340 months, 95% C.I. 97.287- 
143.392 months) compared with those with higher levels (median= 136.275 months, 
95%C.I. 111.031- 161.520 months) (p> 0.05). 
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Figure 6.6.B.The Kaplan-Meier survival model of correlation between Kiss-1 
transcript levels and the disease free survival. 
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6.3.9 Increased Kiss-1R is correlated with poor prognosis 
By contrast to Kiss-1, the expression pattern of Kiss-1R revealed the opposed 
relationship with prognosis in both overall survival and disease free survival. Patients 
with high levels of Kiss-1R {median: 85.798 (95%C.I. 49.989- 121.606)} had a 
significantly shorter overall survival in comparison with those with low levels 
{median: 142.987 (95%C.I. 124.261- 161.712)} (p= 0.011) (Figure 6.7.A). Figure 
6.7.B showed the high expression of Kiss-1R transcripts was also associated with 
poor prognosis in disease free survival. The patients with lower expression of Kiss-1R 
had longer disease free survival {median: 133.176 (95%C.I. 111.675- 154.676)} 
compared with those with high expression levels in {median: 88.347 (95%C.I. 
50.108- 126.587)} (p= 0.033). 
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Figure 6.7.A. Kaplan- Meier survival analysis displaying relationship between the 
transcript levels of Kiss-1R and overall survival. Patients with high levels of Kiss-1R 
had a remarkably shorter overall survival (median= 85.798 months, 95%C.I. 49.989- 
121.606) compared with those with lower levels (median= 142.987 months, 95% C.I. 
124.261- 161.712) (p= 0.011). 
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Figure 6.7.B.Kaplan- Meier survival analysis displaying the relationship between the 
transcript levels of Kiss-1R and overall survival. Patients with high levels of Kiss-1R 
had a remarkably shorter overall survival (median= 88.347 months, 95%C.I. 50.108- 
126.587) compared with those with lower levels (median= 133.176 months, 95%C.I. 
111.675- 154.676) (p= 0.033).  
 
6.3.10 Multivariate analysis of Kiss-1 and Kiss-1R as prognostic factors. 
Through multivariate analysis, we attempted to find out if Kiss-1 and Kiss-1Rare 
independent prognostic factors. Table 6.7 showed the correlation of colorectal related 
death and T staging and Kiss-1R respectively had statistical significance. TNM 
staging and Kiss-1R are also independent factors for colorectal cancer related 
incidence (table 6.8).  
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Table 6.7.Multifactors against colorectal cancer related death 
 
Table 6.8.Multifactors against colorectal cancer incidence (death, recurrence and 
metastasis) 
 
 
Dependent 
variables 
Type III 
Sum of 
square 
df Mean 
Square 
F Sig. 
Invasion .547 2 .273 1.155 .322 
Location .485 2 .243 .187 .830 
Dukes .604 2 .302 .687 .507 
Tstage 3.377 2 1.688 3.938 .025 
TNM 16.216 2 8.108 1.990 .146 
Node 2.004 2 1.002 1.507 .230 
Differentiation .222 2 .111 .514 .601 
Kiss-1 .422 2 .211 .844 .435 
Kiss-1R 2.142 2 1.071 6.302 .003 
Dependent 
variables 
Type III 
Sum of 
square 
df Mean 
Square 
F Sig. 
Invasion .731 3 .244 1.010 .396 
Location 3.249 3 1.083 .856 .470 
Dukes 1.829 3 .610 1.415 .249 
Tstage 3.102 3 1.034 2.258 .092 
TNM 36.942 3 12.314 3.216 .030 
Node 5.074 3 1.691 2.669 .057 
Differentiation .768 3 .256 1.181 .326 
Kiss-1 .523 3 .174 .683 .566 
Kiss-1R 2.126 3 .709 4.003 .012 
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6.4 Discussion 
Since being suggested as a novel metastasis suppressor in human melanoma and 
breast cancer cells [61, 71], Kiss-1 has been detected in various cancers through the 
analysis of real-time Quantitative PCR . Reduced expression of Kiss-1 was observed 
in gastric cancer, oesophageal carcinoma, pancreatic cancer, ovarian cancer, bladder 
cancer and prostate cancer [80, 83, 90]. These studies suggest that the Kiss-1 gene 
may act as a metastasis suppressor in those cancers. What is more, it also has been 
reported that Kiss-1 expression correlated with several clinical and histopathological 
parameters. For example, Kiss-1 was suggested as an independent predictor of patient 
survival in comparison with the traditional prognostic predictors of gastric cancer, as 
its expression had a relationship with frequent metastases and tumour recurrence [80]. 
Schmid and colleagues, on the other hand, have also reported that Kiss-1 may be a 
prognosis factor in hepatocellular carcinoma (HCCs), as its increased expression was 
related to poor prognosis [87]. 
However, the expression of Kiss-1 and its receptor (Kiss-1R) and their correlation to 
the clinical outcome in colorectal cancer remains unknown. For this purpose, we 
investigated Kiss-1 and Kiss-1R expression in 171 (normal background= 80; tumour= 
94) samples of which 136 were paired samples (n=68 pairs) of patients with 
colorectal adenocarcinoma using real-time PCR. There was no significant links 
between the expression of Kiss-1 in normal background tissues compared with 
tumour tissues, while its expression was correlated significantly with Dukes and TNM 
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staging, tumour stage and lymph node involvement. Kiss-1 expression was 
down-regulated in all the advanced stages mentioned. The relatively small sample 
size likely accounted for the lack of statistical significance between Kiss-1 in adjacent 
tissues and tumour tissues. In contrast to Kiss-1, there was statistical significance 
between Kiss-1R expression in normal background and tumour tissues, in which 
Kiss-1R expression was significantly decreased in tumour tissues compared with 
adjacent normal tissues (p< 0.0001). By compared with Kiss-1, Kiss-1R did not show 
any correlation with clinical classification of colorectal cancer (p> 0.05), while loss of 
Kiss-1R expression was significantly associated with death and no chemo-radio 
therapy) (p< 0.05). By contrast, the increased expression of Kiss-1R had positive 
correlation with colorectal incidence (p= 0.0207). These results suggested that 
Kiss-1R may be a poor prognostic factor. Using multivariate analysis, we discovered 
that Kiss-1R had strong correlation with any colorectal death and poor clinical 
outcome. These prompted that Kiss-1R, T staging and TNM staging could be 
independent prognostic factors. Kiss-1R was found to be more sensitive than other 
dependent variables. These results indicate that Kiss-1 and Kiss-1R may play the role 
as a tumour suppressor in colorectal cancer. In the meantime, the decreased 
expression of Kiss-1 was relevant to Duke staging, TNM staging and possibly acts as 
a poor prognosis factor. 
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Chapter 7  
 
General discussion 
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Metastasis, as a complex multistep process, includes impairment of cell-cell adhesion 
in neoplastic epithelium, invasion of adjacent tissues and dissemination of cancer 
cells through the manner of lymphatic and haematogenous metastasis [132-133]. To 
block the metastatic process at an early stage has become a hot subject in cancer 
research [134]. Hence, we are interested in identifying metastasis suppressor genes, 
which may have the potential to control the dissemination of cancer cells. Kiss-1 gene, 
initially described as a metastasis suppressor in melanoma cancer [61], encodes a 
number of peptides (e.g. Kisspeptin-10, Kisspeptin-13, Kisspeptin-14 and 
Kisspeptin-54). These peptides are endogenous ligands of Kiss-R, which is a G 
protein-coupled receptor, referred as hOT7T175, AXOR12 or GPR54. The Kiss-1 
gene has been suggested as a suppressor of metastasis in a variety of cancers through 
the regulation of cellular migration and invasion [48].  
 
Influence of Kiss-1 and Kiss-1R on the functions (proliferation, adhesion, 
invasion and migration) of colorectal cancer cells 
The data obtained from the present study suggests that Kiss-1 significantly inhibits 
the motility and invasion of HT115 and HRT18 colorectal cancer cells, but has no 
effects on the proliferation and adhesion of HT115 and HRT18 cells. These results are 
consistent with the previous studies in breast cancer, ovarian cancer and prostate 
cancer [50, 71, 95]. Interestingly, the similar increase of cell migration in Kiss-1R 
knockdown cells compared with the controls was not observed in both HT115 and 
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HRT18 cells. From this one hypothesis suggested that the inhibitory effect of Kiss-1 
on colorectal cancer cells may not completely combine with Kiss-1R but other 
unkown receptors. The motility of Kiss-1R knockdown cells would increase as same 
as the Kiss-1 knockdown cells, if Kiss-1 indeed had the inhibitory influence on cell 
migration through the combination with Kiss-1R, as Kiss-1 would not regulate the 
cell migration in Kiss-1R knockdown cells. While the result that slight difference of 
cell migration between the Kiss-1R knockdown cells and the control cells supported 
this hypothesis. 
 
The inhibition of cell migration via treating with Kisspeptin-10 and ERK 
inhibitor 
Several studies have suggested that the mechanism by which Kiss-1 inhibits 
metastasis may involve the extracellular-regulated kinase 1/2 (ERK1/2) 
phosphorylation and decreased matrix metalloproteinase-2 (MMP-2) expression [74, 
90, 135]. In addition, Yan and et al. reported that Kisspeptin-10/Kiss-1R activation 
can dephosphorylate nuclear factor kappa B (NF-Kappa B), so that cause it to 
dissociate from MMP-9 promoter. This process ultimately results in a decrease of 
MMP-9 expression in the placenta [73]. However, relevant research was needed to 
delineate the signaling pathways in the colorectal cancer cells. As a contribution to 
this endeavour, we have examined the effects of Kisspeptin-10 and ERK inhibitor on 
the migration ability of HT115 pEF, HT115 Kiss-1 knockdown and HT115 Kiss-1R 
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knockdown cells using ECIS assays (The details have been described in Chapter 
4).Kisspeptin-10, a short peptide of 10 amino acids, is proteolytically processed from 
Kiss-1. Kisspeptin-10 is ten times as active as Kiss-1 [136]. The results demonstrate 
the migration ability of HT115 pEF and Kiss-1 knockdown cells treated with 
Kisspeptin-10 decreased strongly compared with the control groups (p< 0.05). This 
result is consistent with the previous in vitro function assays and provides further 
evidence that Kiss-1 indeed inhibits the migration of colorectal cancer cells. The 
decreased migration of cells treated with ERK inhibitor compared with the controls 
pointed out that the regulation of Kiss-1/Kiss-1R system on colorectal cancer cells 
may be via ERK signalling pathway.  
 
The inhibitory effect of Kiss-1 on tumour growth in in vivo animal model 
We detected the influence of Kiss-1 knockdown on tumour growth in an in vivo 
tumour model. It was observed the tumour growth of Kiss-1 knockdown cells 
increased remarkably in comparison with the control group during the 7 week period, 
especially at 22
th 
(p= 0.034882), 29
th
 (p= 0.009967) and 36
th
 (p= 0.039235) days. This 
result indicates a potential therapeutic value of Kiss-1 and its analogue 
(Kisspeptin-10). However, the present in vivo model and in vivo results are far from 
satisfactory. Firstly, the size of the tumours seen in the present study were rather small 
and secondly, tumours in both control and Kiss-1 knockdown groups tend to get 
smaller after two weeks of implantation. The main reason for these results is that 
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HT115 has been rarely used in in vivo studies and we have not been able to find 
literature support for the experimental conditions. At the time of these experiments, 
the available cells were rather limited, due to time constrains. In future studies, it will 
be necessary to conduct an experiment by using a much larger cell number for 
injection.    
 
Kiss-1/Kiss-1R negatively regulated cell invasion/motility by inhibiting MMP-9 
via the ERK signaling pathway. 
Kiss-1 significantly inhibits the motility and invasion of HT115 cells. It is clear that 
this action is at least partly mediated by regulating the activity of MMP9. The study 
further indicates that this effect on MMP-9 is via the ERK pathway rather than the 
JNK pathway. In summary, it is suggested that Kiss-1 inhibits ERK activation via 
Kiss-1R and consequently reduces the enzymatic activity of MMP-9 caused by the 
degradation of NF-κB, which contributes to the suppression of tumour metastasis 
(Figure 7.1). 
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Figure 7.1.Potential interacting pathways and molecules involved in the functions of 
Kiss-1 and Kiss-1R in colorectal cancer cells.  
 
Aberrant expression of Kiss-1/Kiss-1R in colorectal cancer 
Next, our study focused on analyzing the quantitative expression levels of Kiss-1 and 
Kiss-1R mRNAs and protein using real-time Q-PCR. The expression of Kiss-1 was 
correlated significantly with Dukes classification, TNM staging, tumour stage and 
lymph node involvement. Interestingly, these stages are classified by the level of 
tumour invasion and metastasis. Hence, the conclusion from clinical cohort was 
consistent with the previous study: Kiss-1 has a significant and negative correlation 
with tumour metastasis and invasion. Loss of Kiss-1R expression was significantly 
associated with disease free compared with the incidence group, while the increased 
expression of Kiss-1R may have positive correlation with alive compared with the 
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death groups (0.0158). Moreover, high expression of Kiss-1R transcripts was 
associated with poor prognosis in both overall survival (p= 0.011) and disease free 
survival (p=0.033) compared with low expression of Kiss-1R clinically. Aberrant 
expression of Kiss-1 and Kiss-1R expression is definitely a point for consideration. 
One hypothesis is that there may be another unknown receptor involved in Kiss-1 
regulation of colorectal cancer cells or there may be another ligand with Kiss-1R. 
Navenot et al. reported that the Kiss-1/Kiss-1R also influenced signaling events by 
interacting with the chemokine receptor (CXCR4) and the gonadotrophin-releasing 
hormone receptor [137]. 
Perhaps the most intriguing property of Kiss-1 is how it could be exploited clinically. 
In the future we are interested in investigating the influence of Kisspeptin-10 on 
tumour growth and metastasis based on our previous studies in an in vivo tumour 
model. What is more, Ziegler et al. reported that anti-proliferative function of 
Kisspeptin-10 was regulated by the expression levels of Kiss-1R [138]. There was no 
effect on proliferation observed in the breast cancer cells expressing Kiss-1R 
endogenously, while Kisspeptin-10 had a significant inhibition on proliferation of 
transfected neuronal cells over-expressing Kiss-1R [138]. Hence, to detect the 
influence of Kisspeptin-10 on colorectal cancer through changing Kiss-1R’s 
expression levels will be the subjects of follow-up studies.  
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In conclusion, the present thesis has presented evidence that Kiss-1 is a putative 
tumour suppressor molecule in human colorectal cancer. This is seen by its inhibitory 
effect on the migration and invasion of the cells, on actions achieved by 
downregulating the activities of MMP9, via a ERK dependent pathway. The 
preliminary data from in vivo tumour model and studies on a clinical cohort of 
colorectal cancer patients supports this argument. 
 
Future directions: 
The present study has further demonstrated the pivotal role of Kiss-1 and Kiss-1 
receptor in human colorectal cancer. However, the study has also raised more 
questions and points to new directions for future research. 
 
1. Future research need to base upon more large clinical samples, so that to 
investigate the expression of Kiss-1 and Kiss-1R in tumour tissue compared with 
normal tissue at the protein level using IHC. 
2. The role of Kiss-1 the downstream of Kiss-1 receptor. Although the present study 
has shown that Kiss-1 regulates the MMP-9, the exact mechanism by which Kiss-1 
leads to this regulation is not clear. It will be useful in the future to investigate 
transcriptional regulation and possible post-translational regulation for MMP-9 in this 
context. 
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3. Other potential receptors for Kiss-1 and the contribution of these potential 
receptors to the tumour suppressive role of Kiss-1. The complex nature of cell 
response to Kiss-1 has indicated that there may be more receptors for Kiss-1 involved. 
This has been demonstrated in some recent studies. To clarify this aspect is highly 
useful in determining the role of the molecule in the regulation in colorectal cancer 
and other tumour types. 
4. The potential therapeutic implications of the Kiss-1 agonists in cancer. In most 
cancer types, Kiss-1 has been shown to act as a tumour suppressor. It will be highly 
useful to investigate if specific activation of Kiss-1 may have therapeutic implications. 
Although the present study was aimed at this aspect, the time restraint and availability 
of Kiss-1 and Kiss-1 agonist made this evaluation impossible. It will be a highly 
practical study to pursue. 
5. Investigation of the mutation of Kiss-1 receptor mutation in human cancers. This 
would allow an understanding into the genetic and biological impact of the receptor 
complex in a clinical context, either for therapeutic or prognostic considerations. 
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Appendices 
 
 
Table 1. 
 1(normalized 
by GAPDH) 
2(normalized 
by GAPDH) 
3(normalized 
by GAPDH) 
Average 
(normalized 
by pEF) 
SD 
HT115 WT 0.95654 0.98432 1.1876 0.976179481 0.12615 
HT115 pEF 1.0655 0.9961 1.1432 1 0.073589 
HT115 Kiss-1 kd 0.4033 0.5697 0.4508 0.444271093 0.085715 
 
 
 
Table 2. 
 1(normalized 
by GAPDH) 
2(normalized 
by GAPDH) 
3(normalized 
by GAPDH) 
Average 
(normalized 
by pEF) 
SD 
HRT18WT 1.46432 1.47564 1.29425 1.048954566 0.101616 
HRT18 pEF 1.4327 1.3981 1.2058 1 0.122243 
HRT18 
Kiss-1 kd 0.5094 0.5812 0.5709 0.41160878 0.038823 
 
 
Table 3. 
 1(normalized 
by GAPDH 
2(normalized 
by GAPDH) 
3(normalized 
by GAPDH) 
Average  SD 
HT115 WT 1.204 1.295 1.054 1.184333 0.121698 
HT115 pEF 1.254 1.343 1.19873 1.265243 0.072789 
HT115 
Kiss-1 kd 0.7945 0.52423 0.4832 0.600643 0.169134 
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Table 4. 
 1(normalized 
by GAPDH 
2(normalized 
by GAPDH) 
3(normalized 
by GAPDH) 
Average  SD 
HRT18 WT 1.1342 1.36432 1.1042 1.200907 0.142313 
HRT18 pEF 1.142342 1.34242 1.194325 1.226362 0.103815 
HRT18 
Kiss-1 kd 0.665747 0.65453 0.694645 0.671641 0.020697 
 
 
 
Table 5. 
 1(normalized 
by GAPDH) 
2(normalized 
by GAPDH) 
3(normalized 
by GAPDH) 
Average 
(normalized 
by pEF) 
SD 
HT115 WT 1.089534 1.0342 1.09534 0.861498153 0.033748 
HT115 pEF 1.3432 1.1954 1.198 1 0.169184 
Ht115 
Kiss-1R kd 0.4965 0.50543 0.5643 0.419159129 0.036838 
 
 
 
 
Table 6. 
 1(normalized 
by GAPDH) 
2(normalized 
by GAPDH) 
3(normalized 
by GAPDH) 
Average 
(normalized 
by pEF) 
SD 
HRT18 WT 1.66345 1.49534 1.454 0.977824649 0.110935 
HRT18 pEF 1.7833 1.5351 1.399 1 0.194856 
HRT18 
Kiss-1R kd 0.531 0.7915 0.8012 0.450184424 0.153277 
 
 
 
Table 7. 
 1(normalized 
by GAPDH) 
2(normalized 
by GAPDH) 
3(normalized 
by GAPDH) 
Average  SD 
HT115 WT 1.2942 1.2542 1.10432 1.217573 0.100099 
HT115 pEF 1.43534 1.343245 1.24356 1.340715 0.095915 
HT115 
Kiss-1R kd 0.605345 0.7023 0.72455 0.677398 0.063384 
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Table 8. 
 1(normalized 
by GAPDH) 
2(normalized 
by GAPDH) 
3(normalized 
by GAPDH) 
Average  SD 
HRT18 WT 1.51423 1.334325 1.294325 1.38096 0.117135 
HRT18 pEF 1.3425 1.543563 1.32423 1.403431 0.121701 
hRT18 
Kiss-1R kd 0.68543 0.742342 0.799433 0.742402 0.057001 
 
 
 
Table 9. 
  1 2 3 4 5 6 Average SD 
pEF DAY1 100 100 100 100 100 100 100 0 
 
DAY3 
190.5
353 
297.534
6 
306.654
4 
401.532
5 
299.664
6 
295.645
64 
298.59449
91 
66.8564
9 
DAY5 
400.2
53 
890.342
65 
865.545
3 
820.536
4 
12
30.453 
770.535
3 
829.61088
7 
265.922
6 
Kiss-1 
kd DAY1 100 100 100 100 100 100 100 0 
 
DAY3 
440.4
254 
423.543
543 
483.514
5 
505.455
2 510.545 419.534 
463.83629
1 
41.0739
3 
DAY5 
700.5
435 
1656.43
242 
1350.56
5 
1500.34
5 
1193.54
5 
938.545
1 
1223.3294
19 
356.594
8 
Kiss-1
R kd DAY1 100 100 100 100 100 100 100 0 
 
DAY3 
546.1
423 
502.543
254 
489.432
5 
546.655
5 
410.543
5 
597.543
25 
515.47672
27 
64.0374
2 
 
DAY5 
1101.4
32 
849.425
34 
1193.54
3 
1437.31
4 
1282.14
5 
965.453
6 
1138.2189
86 
213.464
9 
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Table 10. 
  1 2 3 4 5 6 Average SD 
pEF 
DAY1 100 100 100 100 100 100 100 0 
 
DAY3 
472.423
4 
349.545
34 
466.23
43 
337.53
46 
328.432
5 
350.542
54 
384.118
793 
66.5
348 
DAY5 
515.425
2 
626.543
63 
573.43
52 
595.42
35 
510.545
4 
599.424
54 
570.132
9342 
47.4
0103 
Kiss-1 kd DAY1 100 100 100 100 100 100 100 0 
 
DAY3 
449.534
5 
575.543
53 
519.45
35 
536.53
45 
648.425
3 
427.452
54 
526.157
3213 
81.4
3068 
DAY5 504.313 
728.423
42 
818.34
52 
955.42
35 
601.423
4 
763.534
5 
728.577
1809 
159.
5005 
Kiss-1R 
kd DAY1 100 100 100 100 100 100 100 0 
 
DAY3 
485.432
5 463 
504.53
4 
454.53
45 
468.534
5 576.545 
492.168
8417 
44.9
8514 
 
DAY5 
805.535
3 
718.252
45 
593.53
45 
504.52
35 
819.543
5 
632.536
3 
678.987
605 
124.
2656 
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Table 11. 
       Average STDEV 
pEF 43 39 24 38 26 39 34.83333 7.833688 
Kiss-1 kd 29 18 38 26 41 39 31.83333 9.020347 
Kiss-1R kd 40 20 39 49 43 58 41.5 12.66096 
 
 
 
Table 12. 
       Average STDEV 
pEF 35 23 21 19 33 31 27 6.811754546 
Kiss-1 kd 34 20 19 18 39 42 28.66667 10.91176735 
Kiss-1R kd 39 41 20 50 58 53 43.5 13.57571361 
 
 
 
 
Table 13. 
HT115 FIELD 1 FIELD 2 FIELD 3 FIELD 4 AVERAGE SD 
pEF 41 46 39 51 44.25 5.377422 
Kiss-1 kd 57 53 54 59 55.91 2.753785 
Kiss-1R kd 47 36 41 60 46 10.36018 
 
 
 
 
Table 14. 
HRT18 FIELD 1 FIELD 2 FIELD 3 FIELD 4 AVERAGE SD 
pEF 47 38 31 43 39.75 6.898067 
Kiss-1 kd 51 66 60 56 59.13 6.344289 
Kiss-1R kd 35 33 43 25 34 7.033691 
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Table 15. 
  1 2 3 4 5 6 Average SD 
pEF 0HR 0 0 0 0 0 0 0 0 
 
1HR 
8.
53453 
10.5
4353 
9.76
577 
9.45
353 
8.53
532 
10.5
3655 
9.5615
3677 
2.396
813 
2HR 
16
.44534 
17.5
6456 
15.6
4564 
19.5
3453 
19.5
345 
17.5
6437 
17.714
8232 
3.140
3727 
3HR 
17
.54353 
18.6
363 
20.5
435 
19.5
3453 
18.0
908 
20.5
3463 
19.813
8817 
2.167
9479 
4HR 
39
.53453 
35.4
3534 
40.5
3453 
37.5
3453 
33.0
808 
36.5
336 
35.775
5557 
4.605
8485 
5HR 
43
.43253 
39.5
4365 
38.5
363 
41.5
3636 
42.5
3453 
42.6
4574 
41.704
8535 
3.982
1873 
 
Kiss-1 
kd 0HR 0 0 0 0 0 0 0 0 
 
1HR 
9.
532453 
13.4
2534 
13.6
3564 
7.76
4744 
12.0
8758 
9.64
5645 
13.848
57 
5.633
8058 
2HR 
23
.53534 
26.4
2453 
21.5
3453 
24.5
3453 
22.5
4353 
23.6
4576 
23.703
04 
3.190
8387 
3HR 
43
.53454 
49.5
3645 
45.4
2344 
52.5
3453 
47.4
3535 
48.4
3543 
47.483
29 
5.959
071 
4HR 
45
.53453 
66.4
2343 
57.5
3454 
53.5
4353 
54.5
3453 
57.5
3453 
55.684
19 
10.54
7208 
5HR 
56
.43423 
57.5
4353 
56.5
4353 
70.5
4353 
54.4
4233 
61.4
3243 
59.156
6 
10.54
691 
 
Kiss-1R 
kd 0HR 0 0 0 0 0 0 0 0 
 
1HR 
8.
432432 
11.4
3254 
14.4
232 
13.5
3454 
9.43
2423 
13.5
453 
12.63
341 
5.219
7437 
2HR 
18
.31435 
15.5
4356 
14.5
3454 
17.4
3254 
15.5
4353 
16.4
5435 
16.80
381 
2.965
1286 
3HR 
21
.53454 
25.5
4354 
22.5
4353 
27.5
3635 
22.6
3464 
23.5
4354 
23.22
269 
3.532
9808 
4HR 
42
.43254 
33.5
2525 
34.5
4325 
40.4
5325 
45.5
3453 
47.5
4544 
39.67
238 
10.60
9333 
5HR 
45
.54353 
43.5
4353 
46.5
3636 
53.5
4354 
39.5
3465 
49.5
3453 
46.87
269 
9.893
303 
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Table 16. 
  1 2 3 4 5 6 Average SD 
pEF 0HR 0 0 0 0 0 0 0 0 
 
1HR 
5.432
4 
9.54
3544 
6.56
4577 
8.5435
35 
7.56
4565 
6.94
7657 
14.43
271 
1.462
6762 
2HR 
20.54
325 
15.6
4577 
16.6
4577 
14.543
57 
21.5
6465 
22.6
4565 
18.59
811 
3.403
9321 
3HR 
25.43
436 
20.5
6456 
23.4
3254 
26.543
53 
31.4
3254 
28.5
5365 
27.99
353 
3.815
3532 
4HR 
40.56
544 
42.6
4577 
32.6
4766 
47.654
77 
37.4
5365 
43.7
689 
39.78
936 
5.233
0136 
5HR 
35.63
463 
39.5
3654 
45.7
5677 
35.432
53 
48.7
5676 
49.6
4575 
40.62
716 
7.595
2498 
 
Kiss-1 
kd 0HR 0 0 0 0 0 0 0 0 
 
1HR 
12.64
565 
18.5
6646 
13.6
4646 
16.647
8 
15.6
5646 
13.6
4574 
16.80
143 
2.766
07 
2HR 
29.64
577 
24.6
4577 
20.6
7578 
26.675
68 
25.7
6586 
28.6
5465 
26.67
725 
3.428
6749 
3HR 
48.56
465 
40.7
6586 
50.6
5766 
47.675
87 
47.7
6987 
44.6
4749 
46.34
69 
6.524
6739 
4HR 
55.56
488 
55.5
645 
57.7
5859 
49.657
56 
59.7
5688 
56.8
7098 
55.52
89 
6.957
276 
5HR 
54.45
647 
57.5
6457 
54.7
6577 
62.086
79 
57.5
3656 
61.6
5465 
59.17
747 
6.517
6819 
 
Kiss-1R 
kd 0HR 0 0 0 0 0 0 0 0 
 
1HR 
12.64
5647 
16.6
5765 
13.5
6456 
17.645
75 
15.6
5458 
15.4
5254 
15.77
012 
2.814
7381 
2HR 
21.43
535 
28.3
4654 
24.6
4674 
27.645
7647 
29.6
4575 
22.4
6356 
24.30
759 
3.590
7615 
3HR 
33.75
786 
27.5
3646 
35.7
6757 
32.676
77 
29.6
7659 
30.5
6476 
30.49
667 
6.445
8184 
4HR 
29.56
475 
27.4
5437 
37.5
6475 
39.564
58 
31.7
6757 
33.6
5757 
33.76
226 
6.979
7378 
5HR 
43.64
565 
47.6
4575 
44.5
3646 
50.454
35 
41.6
4565 
46.7
5675 
43.94
743 
6.438
4178 
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Table 17. 
 pEF  Kiss-1 kd  Kiss-1R kd  
Time(hrs) Average SD Average SD Average SD 
1 0 0 0 0 0 0 
2 18.49 8.07129482 75.25 37.69569888 43.14285714 26.85776468 
3 42.6765 6.6935524 119.0375 46.23869553 70 33.62662635 
4 53.01375 10.627645 168.6125 57.49803568 102.1 35.62293269 
5 87.653 7.88537439 209.675 73.03380333 130.3857143 42.9903256 
6 91.6485 15.7367823 230.15 81.38290449 149.2142857 48.12419449 
7 104.66075 7.89553551 260.5125 89.98014761 154.2857143 48.22182869 
8 110.9575 13.6390298 276.4 89.80784248 159.9142857 36.60266059 
 
 pEF  Kiss-1 kd  Kiss-1R 
kd 
 
Time(hrs) Average SD Average SD Average SD 
1 0 0 0 0 0 0 
2 2.3 2.924608236 48.93333333 30.91429012 22.425 20.47655163 
3 13.95 6.733250825 85.7 45.20387152 40.7 34.09574754 
4 33.05 18.27283959 128.1 56.31894294 65.025 42.81435702 
5 43.2 18.89144427 167.7333333 70.2156915 86.65 51.06469753 
6 54.525 25.09028697 183.9333333 56.75000734 93.025 50.1428875 
7 59.075 21.79837532 203.8 60.61330987 98.225 57.14690864 
8 63.55 27.00253075 208.4666667 77.33319684 105.95 55.10919464 
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Table 18. 
 pEF  Kiss-1 kd  Kiss-1R kd  
Time(hrs) Average SD Average SD Average SD 
1 0 0 0 0 0 0 
2 18.49 8.07129482 75.25 37.69569888 43.14285714 26.85776468 
3 42.6765 6.6935524 119.0375 46.23869553 70 33.62662635 
4 53.01375 10.627645 168.6125 57.49803568 102.1 35.62293269 
5 87.653 7.88537439 209.675 73.03380333 130.3857143 42.9903256 
6 91.6485 15.7367823 230.15 81.38290449 149.2142857 48.12419449 
7 104.66075 7.89553551 260.5125 89.98014761 154.2857143 48.22182869 
8 110.9575 13.6390298 276.4 89.80784248 159.9142857 36.60266059 
 
 pEF  Kiss-1 kd  Kiss-1R kd  
Time(hrs) Average SD Average SD Averag
e 
SD 
1 0 0 0 0 0 0 
2 19.79646 2.117614242 91.7 18.55927441 36.225 17.63091508 
3 43.7117825 9.864968611 127.8 29.51078899 54.625 13.56376914 
4 48.924075 6.755564468 155.55 45.21950169 81.875 26.22370111 
5 80.29365 12.1117425 200.88 8.059156283 111.04765 30.19606735 
6 86.1195 7.128527009 253.8485 30.771077 125.7507 26.4968366 
7 94.09805 11.61444408 268.4725 39.08461622 131.0257875 25.66771927 
8 101.7600075 11.86046328 300.575 43.20288378 145.52415 44.24373398 
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Table 19. 
 pEF  Kiss-1 kd  Kiss-1R kd  
Time(hrs) Average SD Average SD Average SD 
1 0 0 0 0 0 0 
2 18.49 8.07129482 75.25 37.69569888 43.14285714 26.85776468 
3 42.6765 6.6935524 119.0375 46.23869553 70 33.62662635 
4 53.01375 10.627645 168.6125 57.49803568 102.1 35.62293269 
5 87.653 7.88537439 209.675 73.03380333 130.3857143 42.9903256 
6 91.6485 15.7367823 230.15 81.38290449 149.2142857 48.12419449 
7 104.66075 7.89553551 260.5125 89.98014761 154.2857143 48.22182869 
8 110.9575 13.6390298 276.4 89.80784248 159.9142857 36.60266059 
 
 pEF  Kiss-1 kd  Kiss-1R kd  
Time(hrs) Average SD Average SD Average SD 
1 0 0 0 0 0 0 
2 18.795 2.195093012 59.93333333 18.7526887 50.2 36.26219335 
3 38.856325 18.82532999 105.3 34.14659573 50.925 36.98345351 
4 56.64 13.24466119 152.4666667 48.01635138 71.525 34.04539861 
5 70.644175 14.71468974 202.6333333 79.07251946 91.025 37.66079969 
6 83.118375 9.957250352 216.0333333 95.0757768 105.225 37.73162908 
7 94.0191925 12.7960285 247.4666667 104.2611625 113.925 43.57624544 
8 98.68246325 9.059680542 256.2666667 112.5380973 111.15 40.62745377 
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Table 20. 
 pEF  Kiss-1 kd  Kiss-1R kd  
Time(hrs) Average SD Average SD Average SD 
1 0 0 0 0 0 0 
2 18.49 
8.0712948
2 
75.25 
37.695698
88 
43.1428
5714 
26.8577
6468 
3 42.6765 6.6935524 
119.03
75 
46.238695
53 
70 
33.6266
2635 
4 53.01375 10.627645 
168.61
25 
57.498035
68 
102.1 
35.6229
3269 
5 87.653 
7.8853743
9 
209.67
5 
73.033803
33 
130.385
7143 
42.9903
256 
6 91.6485 
15.736782
3 
230.15 
81.382904
49 
149.214
2857 
48.1241
9449 
7 104.66075 
7.8955355
1 
260.51
25 
89.980147
61 
154.285
7143 
48.2218
2869 
8 110.9575 
13.639029
8 
276.4 
89.807842
48 
159.914
2857 
36.6026
6059 
 
 pEF  Kiss-1 kd  Kiss-1R kd  
Time(hrs) Average SD Averag
e 
SD Averag
e 
SD 
1 0 0 0 0 0 0 
2 
5.1533333
33 
5.1432544
82 
45.25 
9.5098194
87 
25.6068
75 
17.2022
543 
3 
8.2820666
67 
7.1007443
65 
86.65 
15.222899
42 
55.1125 
34.8900
2976 
4 
36.985333
33 
24.161450
94 
130.1 
28.210045
49 
96.008 
41.2095
3922 
5 
44.291666
67 
26.675284
85 
174.15 
70.753492
26 
106.039
25 
43.4711
5072 
6 
46.996632
5 
7.2831000
38 
208.72
5 
109.41070
56 
134.066
25 
23.2662
1311 
7 57.75225 
7.2772587
5 
214.87
44 
37.530523
56 
140.727
5 
23.4235
2432 
8 64.968 
5.4788115
5 
220.47
75 
30.604790
87 
146.283
5 
24.1711
4436 
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Table 21. 
 pEF  Kiss-1 kd  Kiss-1R kd  
Time(hrs) Average SD Average SD Average SD 
1 0 0 0 0 0 0 
2 18.49 8.07129482 75.25 37.69569888 43.14285714 26.85776468 
3 42.6765 6.6935524 119.0375 46.23869553 70 33.62662635 
4 53.01375 10.627645 168.6125 57.49803568 102.1 35.62293269 
5 87.653 7.88537439 209.675 73.03380333 130.3857143 42.9903256 
6 91.6485 15.7367823 230.15 81.38290449 149.2142857 48.12419449 
7 104.66075 7.89553551 260.5125 89.98014761 154.2857143 48.22182869 
8 110.9575 13.6390298 276.4 89.80784248 159.9142857 36.60266059 
 
 pEF  Kiss-1 kd  Kiss-1R kd  
Time(hrs) Average SD Average SD Average SD 
1 0 0 0 0 0 0 
2 8.525 10.6828133 72.45 14.32119641 37.43625 9.169237859 
3 24.9 22.94704048 119.225 25.53081471 64.839 13.72197695 
4 41.6 30.50497227 163.525 30.25396668 91.5687 32.52052788 
5 61.2 40.9341748 197.725 56.83655595 106.4957075 36.30109155 
6 71.4 48.51315973 226.875 41.96954253 118.7645 44.15770038 
7 81.55 62.13520205 228.5575 39.83797884 121.82125 24.34660085 
8 83.77 26.19229516 243.39 40.89756064 135.77425 63.56995972 
 
Table 22. 
 1 2 3 Average SD 
No treatment 253617 218549 278903 250356.3 30308.83 
Kisspeptin-10 390971 348299 329015 356095 31705.2 
Kisspeptin-234 230861 277956 298402 269073 34635.64 
postive control 354362 209805 430739 331635.3 112206.7 
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Table 23. 
No treatment 
  1 2 3 Average SD 
Control pEF 5125 4894 5156 5058.333 143.1584 
Kiss-1 kd 5509 5438 5602 5516.333 82.24557 
ERK 
inhibitor 
pEF 4659 4595 4567 4607 47.1593 
Kiss-1 kd 4807 4742 4822 4790.333 42.5245 
Kisspeptin-10 
  1 2 3 Average SD 
Control pEF 5003 4904 4899 4935.333 58.65435 
Kiss-1 kd 
4941 4883 5009 
4944.3
33 
63.066
1 
ERK 
inhibitor 
pEF 4620 4609 4511 4580 60.00833 
Kiss-1 kd 4599 4660 4639 4632.667 30.98925 
Kisspeptin-234 
  1 2 3 Average SD 
Control pEF 5172 5065 5306 5181 120.7518 
Kiss-1 kd 5489 5508 5087 5361.333 237.7695 
ERK 
inhibitor 
pEF 4602 4705 4798 4701.667 98.04251 
Kiss-1 kd 5098 4893 5092 5027.667 116.6633 
 
Table 24. 
Kiss-1 
 1 2 3 4 5 6 7 Average SD 
Normal  76740 80231 81566 80395 77138 73134 78200.67 3136.773 76740 
Tumour 11048 10485 11879 12789 10528 13976 11784.17 1387.843 11048 
Kiss-1R 
 1 2 3 4 5 6 7 Average SD 
Normal  37626 45891 38141 32789 39742 36791 38496.67 4303.448 37626 
Tumour 1903 5901 4031 5697 3956 4391 4313.167 1446.261 1903 
 
